DDI-DrugBank.d477.s0	Hypertensive JJ B-adj.all	crises NNS B-noun.person	have VBP 0	resulted VBN B-verb.cognition	when WRB 0	sympathomimetic_amines NNS B-noun.communication	have VBP 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	within14 CD 0	days NNS B-noun.substance	following VBG 0	use NN 0	of IN 0	monoamine_oxidase_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d290.s2	vasopressors NNS B-noun.person	, , 0	such JJ 0	as IN 0	dopamine NN 0	and CC 0	isoproterenol NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d324.s4	Imipramine NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	Sonata NNP B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	and CC 0	imipramine JJ B-adj.all	75 CD 0	mg RB 0	produced VBN B-verb.creation	additive JJ 0	effects NNS B-noun.phenomenon	on IN 0	decreased VBN B-verb.change	alertness RB B-adv.all	and CC 0	impaired VBN B-verb.communication	psychomotor NN B-noun.person	performance NN B-noun.person	for IN 0	2 CD 0	to TO 0	4 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d289.s11	Steady NNP B-noun.person	- : 0	state NN B-adj.all	bosentan NN B-noun.person	plasma NN B-noun.person	concentrations NNS I-noun.person	were VBD B-verb.stative	3- PRP 0	to TO 0	4-fold JJ B-verb.possession	higher JJR B-adj.all	than IN 0	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	cyclosporine_A. NNP B-noun.group	. . 0
DDI-DrugBank.d558.s19	Of IN 0	the DT 0	229 CD 0	patients NNS B-noun.person	who WP 0	had VBD B-verb.social	potassium_depleting_diuretics NNS B-noun.person	added VBD B-verb.communication	to TO 0	their PRP$ 0	concomitant JJ B-adj.all	medications NNS B-noun.person	in IN 0	the DT 0	DIAMOND NNP B-noun.group	trials NNS B-noun.communication	, , 0	the DT 0	patients NNS B-noun.person	on IN 0	TIKOSYN NNP B-noun.group	had VBD 0	a DT 0	non NN B-noun.person	- : 0	significantly RB B-adv.all	reduced VBN B-verb.change	relative JJ B-adj.all	risk NN B-noun.person	for IN 0	death NN B-noun.time	of IN 0	0.68 CD 0	( ( 0	95 CD 0	% NN 0	CI $ 0	0.376 CD 0	, , 0	1.230 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d321.s0	Dexamethasone NNP B-noun.person	, , 0	Steady NNP B-noun.person	- : 0	state NN B-adj.all	trough NN B-noun.act	concentrations NNS B-noun.attribute	of IN 0	albendazole_sulfoxide NNP B-noun.person	were VBD B-verb.stative	about IN 0	56 CD 0	% NN 0	higher JJR B-adj.all	when WRB 0	8 CD B-adj.all	mg NN B-noun.quantity	dexamethasone NN 0	was VBD 0	coadministered VBN B-verb.contact	with IN 0	each DT 0	dose NN B-noun.quantity	of IN 0	albendazole NN B-noun.person	( ( 0	15 CD 0	mg FW 0	/ FW 0	kg FW 0	/ FW 0	day NN 0	) ) 0	in IN 0	eight CD 0	neurocysticercosis NN 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d289.s12	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	bosentan NN B-noun.food	and CC 0	cyclosporine_A NNP B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d407.s1	An DT 0	immune JJ B-adj.all	response NN B-noun.communication	to TO 0	Campath NNP B-noun.location	may MD 0	interfere VB B-verb.stative	with IN 0	subsequent JJ B-adj.all	diagnostic NN B-noun.person	serum NN B-noun.artifact	tests NNS I-noun.artifact	that WDT 0	utilize VBP B-verb.stative	antibodies NNS I-verb.stative	. . 0
DDI-DrugBank.d429.s4	Ampicillin NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	chloroquine NN 0	significantly RB B-adv.all	reduced VBD B-verb.change	the DT 0	bioavailability NN B-noun.cognition	of IN 0	ampicillin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d331.s10	- : 0	Digoxin NN B-noun.person	, , 0	Interaction NNP B-noun.person	studies NNS B-noun.artifact	in IN 0	humans NNS B-noun.animal	have VBP 0	shown VBN B-verb.perception	no DT 0	effect NN B-noun.cognition	on IN 0	digoxin NN B-noun.substance	blood NN B-noun.location	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d77.s14	cimetidine NN B-noun.act	) ) 0	and CC 0	many JJ 0	that WDT 0	are VBP B-verb.stative	substrates NNS B-noun.person	for IN 0	P450 JJ 0	2D6 NN 0	( ( 0	many JJ 0	other JJ 0	antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	and CC 0	the DT 0	Type_1C_antiarrhythmics NNS B-noun.group	propafenone NN B-noun.person	and CC 0	flecainide NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d89.s2	Due JJ 0	to TO 0	its PRP$ 0	nephrotoxicity NN B-noun.motive	, , 0	gentamicin NN 0	may MD 0	cause VB B-verb.communication	abnormal JJ B-adj.all	renal JJ B-adj.all	uptake NN B-noun.location	to TO 0	be VB 0	seen VBN B-verb.perception	on IN 0	99mTc SYM 0	- : 0	MDP NNP B-noun.group	bone NN 0	scintigraphy NN 0	. . 0	. . 0
DDI-DrugBank.d216.s15	Drugs NNS B-noun.person	With IN 0	A DT 0	Narrow NNP B-noun.person	Therapeutic NNP I-noun.person	Index NNP I-noun.person	Digoxin NNP I-noun.person	A NNP 0	single JJ 0	dose NN 0	of IN 0	eszopiclone NN B-noun.communication	3 CD B-adj.all	mg NN B-noun.quantity	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	measured VBN B-verb.cognition	at IN 0	steady JJ B-adj.all	state NN B-noun.state	following VBG 0	dosing NN B-noun.act	of IN 0	0.5 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	for IN 0	one CD 0	day NN B-noun.person	and CC 0	0.25 CD 0	mg PRP$ 0	daily JJ B-noun.person	for IN 0	the DT 0	next JJ B-noun.communication	6 CD B-adj.all	days NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d98.s10	However RB 0	, , 0	in IN 0	vivo JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.act	of IN 0	ketoconazole NN B-noun.shape	with IN 0	vitamin_D NNS B-noun.plant	have VBP 0	not RB 0	been VBN 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d372.s0	Cytadren NNP B-noun.person	accelerates VBZ B-verb.communication	the DT 0	metabolism NN B-noun.attribute	of IN 0	dexamethasone NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d330.s5	Oral NNP B-noun.group	neomycin_sulfate NNP I-noun.group	may MD 0	enhance VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	coumarin NN B-noun.food	in IN 0	anticoagulants NNS B-noun.animal	by IN 0	decreasing VBG B-verb.change	vitamin NN 0	K NNP 0	availability NN 0	. . 0	. . 0
DDI-DrugBank.d143.s60	Hemodynamic NNP B-noun.person	and CC 0	electrophysiologic JJ B-noun.person	interactions NNS I-noun.person	have VBP 0	also RB B-adv.all	been VBN 0	observed VBN B-verb.perception	after IN 0	concomitant JJ B-adj.all	administration NN B-noun.person	with IN 0	propranolol NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	and CC 0	verapamil NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d238.s16	While IN 0	all PDT 0	the DT 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	e.g. NNP B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	and CC 0	fluvoxamine NN B-noun.person	, , 0	inhibit VBP B-verb.stative	P450 JJ 0	2D6 NN 0	, , 0	they PRP 0	may MD 0	vary VB B-verb.stative	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d320.s5	macrolide_antibiotics NNS B-noun.person	e.g. JJ I-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d338.s5	Estazolam NN B-noun.person	, , 0	Interaction NNP B-noun.person	with IN 0	Drugs NNP B-noun.person	that IN 0	Inhibit NNP B-noun.person	Metabolism NNP I-noun.person	via IN 0	Cytochrome NNP B-noun.person	P450 NNP I-noun.person	3A . 0	( ( 0	CYP3A NNP 0	) ) 0	, , 0	The DT 0	metabolism NN B-noun.attribute	of IN 0	estazolam NN 0	to TO 0	the DT 0	major JJ B-adj.all	circulating VBG B-verb.change	metabolite JJ B-adj.all	4-hydroxy JJ B-noun.group	- : 0	estazolam NN B-noun.communication	and CC 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	other JJ 0	triazolobenzodiazepines NNS 0	is VBZ 0	catalyzed VBN B-verb.communication	by IN 0	CYP3A. NNP B-noun.person	. . 0
DDI-DrugBank.d386.s23	If IN 0	desipramine_hydrochloride NN 0	is VBZ B-verb.stative	to TO 0	be VB 0	combined VBN B-verb.change	with IN 0	other JJ B-adj.all	psychotropic_agents NNS B-noun.object	such JJ 0	as IN 0	tranquilizers NNS B-noun.person	or CC 0	sedative JJ B-adj.all	/ JJ 0	hypnotics NNS B-noun.person	, , 0	careful JJ B-adj.all	consideration NN B-noun.act	should MD 0	be VB 0	given VBN B-verb.possession	to TO 0	the DT 0	pharmacology NN B-noun.time	of IN 0	the DT 0	agents NNS B-noun.person	employed VBN B-verb.consumption	since IN 0	the DT 0	sedative JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	desipramine NN B-noun.location	and CC 0	benzodiazepines NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	chlordiazepoxide NN B-noun.cognition	or CC 0	diazepam NN B-noun.attribute	) ) 0	are VBP B-verb.stative	additive JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d524.s0	Albuterol NNP B-noun.person	, , 0	Antihistamines NNPS B-noun.person	, , 0	antidiabetic_drugs NNS B-noun.object	, , 0	diuretics NNS B-noun.person	, , 0	digitalis NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d143.s22	Cardiovasculars NNS B-noun.person	, , 0	Cardiac_glycosides NNS B-noun.group	, , 0	In IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	digoxin NN B-noun.person	therapy NN B-noun.person	, , 0	administration NN B-noun.person	of IN 0	oral JJ B-adj.all	amiodarone NN 0	regularly RB B-adv.all	results VBZ B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	serum NN 0	digoxin NN 0	concentration NN B-noun.event	that WDT 0	may MD 0	reach VB B-verb.stative	toxic JJ B-adj.all	levels NNS B-noun.state	with IN 0	resultant JJ B-adj.all	clinical JJ B-adj.all	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d368.s11	Acetazolamide NNP B-noun.person	may MD 0	prevent VB B-verb.stative	the DT 0	urinary JJ B-adj.all	antiseptic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	methenamine NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d78.s9	Warfarin NNP B-noun.person	, , 0	In IN 0	subjects NNS B-noun.artifact	receiving VBG B-verb.perception	warfarin NN B-noun.act	, , 0	no DT 0	significant JJ B-adj.all	change NN B-noun.relation	in IN 0	clotting VBG B-verb.contact	time NN B-noun.person	was VBD 0	observed VBN B-verb.perception	when WRB 0	grepafloxacin NN B-noun.person	was VBD 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d499.s3	Antacids NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	magnesium_hydroxide JJ B-noun.other	and CC 0	aluminum_hydroxide RB 0	does VBZ 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	rate NN B-noun.time	or CC 0	extent NN B-noun.attribute	of IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	ketoprofen NN B-noun.person	administered VBN B-verb.possession	as IN 0	Orudis NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d412.s10	If IN 0	labetalol_HCl NN 0	is VBZ 0	used VBN B-verb.consumption	with IN 0	nitroglycerin NN B-noun.person	in IN 0	patients NNS B-noun.person	with IN 0	angina NN 0	pectoris NNS 0	, , 0	additional JJ B-adj.all	antihypertensive JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d120.s2	apomorphine NN B-noun.person	; : 0	prior JJ B-adj.all	ingestion NN B-noun.act	of IN 0	diphenidol NN B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	emetic JJ B-adj.all	response NN B-noun.communication	to TO 0	apomorphine VB B-verb.social	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	poisoning NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d77.s16	The DT 0	extent NN B-noun.attribute	to TO 0	which WDT 0	SSRI NNP B-noun.group	- : 0	TCA NNP B-noun.group	interactions NNS B-noun.possession	may MD 0	pose VB B-verb.possession	clinical JJ B-adj.all	problems NNS B-noun.communication	will MD 0	depend VB B-verb.cognition	on IN 0	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	, , 0	and CC 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	SSRI NNP B-noun.group	involved VBD B-verb.stative	. . 0	. . 0
DDI-DrugBank.d172.s14	However RB 0	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.person	with IN 0	CELEBREX NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increased VBN B-adj.all	rate NN B-noun.time	of IN 0	GI NNP 0	ulceration NN B-noun.communication	or CC 0	other JJ B-adj.all	complications NNS B-noun.person	, , 0	compared VBN B-verb.cognition	to TO 0	use VB B-verb.consumption	of IN 0	CELEBREX NNP B-noun.group	alone RB 0	. . 0	. . 0
DDI-DrugBank.d241.s0	Additional JJ B-adj.all	reductions NNS B-noun.motive	in IN 0	blood NN B-adj.all	pressure NN B-noun.act	may MD 0	occur VB B-verb.cognition	when WRB 0	FLOLAN NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	with IN 0	diuretics NNS B-noun.person	, , 0	antihypertensive_agents NNS B-noun.location	, , 0	or CC 0	other JJ B-adj.all	vasodilators NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d350.s12	In IN 0	addition NN 0	, , 0	results NNS B-noun.communication	from IN 0	regression NN B-noun.act	analyses NNS B-noun.act	of IN 0	patient JJ B-adj.all	pharmacokinetic JJ B-adj.all	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	other JJ 0	inducers NNS B-noun.person	of IN 0	drug NN B-noun.phenomenon	clearance NN B-noun.attribute	( ( 0	efavirenz NN B-noun.person	, , 0	nevirapine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	dexamethasone NN B-noun.person	, , 0	or CC 0	carbamazepine NN B-noun.location	) ) 0	with IN 0	CANCIDAS NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	clinically RB B-adv.all	meaningful JJ B-adj.all	reductions NNS B-noun.artifact	in IN 0	caspofungin NN B-noun.animal	concentrations NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d123.s14	Phenytoin NN B-noun.person	, , 0	Altered NNP B-noun.person	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	phenytoin NN B-noun.substance	( ( 0	increased VBN B-verb.change	and CC 0	decreased VBD B-verb.change	) ) 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	ciprofloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d217.s11	Multivitamins NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	products NNS B-noun.artifact	containing VBG B-verb.stative	iron NN B-noun.person	or CC 0	zinc NN B-noun.artifact	, , 0	antacids NNS B-noun.attribute	or CC 0	sucralfate NN B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	, , 0	or CC 0	within IN 0	2 CD B-adj.all	hours NNS B-noun.person	of IN 0	, , 0	the DT 0	administration NN B-noun.time	of IN 0	norfloxacin NN B-noun.food	, , 0	because IN 0	they PRP 0	may MD 0	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.artifact	resulting VBG B-verb.stative	in IN 0	lower JJR B-adj.all	serum NN B-noun.person	and CC 0	urine NN B-noun.body	levels NNS B-noun.attribute	of IN 0	norfloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d290.s4	and CC 0	diuretics NNS B-noun.person	, , 0	such JJ 0	as IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d549.s2	Since IN 0	iloprost NN B-noun.act	inhibits VBZ B-verb.stative	platelet NN I-verb.stative	function NN B-noun.act	, , 0	there EX 0	is VBZ B-verb.stative	a DT 0	potential NN B-noun.person	for IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding NN B-noun.act	, , 0	particularly RB B-adv.all	in IN 0	patients NNS B-noun.person	maintained VBD B-verb.stative	on IN 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d291.s3	- : 0	The DT 0	action NN B-noun.state	of IN 0	sulphonylureas NNS B-noun.location	and CC 0	insulin NN B-noun.person	may MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	Bezalip NNP B-noun.person	or CC 0	Bezalip_retard RB 0	. . 0	. . 0
DDI-DrugBank.d112.s1	The DT 0	conversion NN B-noun.cognition	of IN 0	6-deoxy_penciclovir NNP B-noun.person	to TO 0	penciclovir NN B-noun.person	is VBZ 0	catalyzed VBN B-verb.communication	by IN 0	aldehyde JJ B-adj.all	oxidase NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d316.s18	When WRB 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	felodipine NN B-noun.person	, , 0	the DT 0	tacrolimus NN 0	blood NN B-noun.location	concentration NN B-noun.person	should MD 0	be VB 0	followed VBN B-verb.possession	and CC 0	the DT 0	tacrolimus NN B-noun.artifact	dose NN I-noun.artifact	may MD 0	need VB 0	to TO 0	be VB 0	adjusted VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d364.s18	A DT 0	clinical JJ B-adj.all	interaction NN B-noun.act	study NN B-noun.artifact	was VBD 0	also RB B-adv.all	conducted VBN B-verb.communication	with IN 0	alosetron RB 0	and CC 0	the DT 0	CYP3A4 NNP B-noun.other	substrate JJ B-adj.all	cisapride NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d324.s26	There EX 0	is VBZ B-verb.stative	no DT 0	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	zaleplon NN B-noun.person	and CC 0	diphenhydramine NN B-noun.person	following VBG B-verb.stative	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	50 CD B-adj.all	mg NN B-noun.quantity	, , 0	respectively RB B-adv.all	) ) 0	of IN 0	each DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d507.s0	The DT 0	potential NN B-noun.person	for IN 0	increased VBN B-verb.change	sedation NN I-verb.change	when WRB 0	guanfacine NN B-noun.person	is VBZ 0	given VBN B-verb.possession	with IN 0	other JJ 0	CNS NNP B-noun.group	- : 0	depressant_drug NN B-noun.group	should MD 0	be VB 0	appreciated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d124.s15	Antihistamines NNS 0	, , 0	astemizole NN B-noun.location	, , 0	terfenadine NN B-noun.person	_ : 0	CONTRAINDICATED VBN B-verb.cognition	due JJ 0	to TO 0	potential JJ B-adj.all	for IN 0	serious JJ B-adj.all	and/or NN B-noun.attribute	life NN I-noun.attribute	- : 0	threatening JJ B-verb.communication	cardiac JJ B-adj.all	arrhythmias NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d372.s1	therefore RB B-adv.all	, , 0	if IN 0	glucocorticoid JJ B-adj.all	replacement NN B-noun.person	is VBZ 0	needed VBN B-verb.consumption	, , 0	hydrocortisone NN 0	should MD 0	be VB 0	prescribed VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d84.s3	To TO 0	investigate VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	antimicrobial JJ B-adj.all	combinations NNS B-noun.person	of IN 0	GL NNP 0	with IN 0	four CD 0	kinds NNS B-noun.cognition	of IN 0	antibiotics NNS B-noun.person	( ( 0	ampicillin NN B-noun.person	, , 0	cefazolin NN B-noun.body	, , 0	oxytetracycline NN B-noun.person	and CC 0	chloramphenicol NN B-noun.act	) ) 0	, , 0	the DT 0	fractional JJ B-adj.all	inhibitory JJ B-adj.all	concentration NN B-noun.event	index NN B-noun.substance	( ( 0	FICI NNP 0	) ) 0	was VBD 0	determined VBN B-verb.communication	by IN 0	checkerboard NN B-noun.possession	assay NN B-noun.possession	for IN 0	each DT 0	strain NN B-noun.communication	. . 0	. . 0
DDI-MedLine.d67.s5	Diazepam NNP B-noun.person	at IN 0	doses NNS B-noun.act	of IN 0	0.25 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	and CC 0	2.5 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	injected VBN B-verb.change	with IN 0	morphine NN B-noun.person	was VBD 0	found VBN B-verb.cognition	to TO 0	decrease VB B-verb.communication	the DT 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d28.s7	The DT 0	thiazolidinediones NNS 0	( ( 0	rosiglitazone NN B-noun.person	and CC 0	pioglitazone NN 0	) ) 0	, , 0	a DT 0	new JJ B-adj.all	class NN B-noun.attribute	of IN 0	oral JJ B-adj.all	antidiabetic_agents NNS B-noun.location	, , 0	are VBP B-verb.stative	" JJ B-adj.all	insulin NN B-noun.plant	sensitizers NNS B-noun.person	" : 0	. . 0
DDI-DrugBank.d544.s3	Total JJ B-adj.all	body NN 0	clearance NN B-noun.attribute	of IN 0	Simulect NNP B-noun.location	was VBD 0	reduced VBN B-verb.change	by IN 0	an DT 0	average JJ B-noun.communication	22 CD B-adj.all	% NN 0	and CC 0	51 CD 0	% NN 0	when WRB 0	azathioprine NN B-noun.person	and CC 0	mycophenolate_mofetil NNP B-noun.person	, , 0	respectively RB B-adv.all	, , 0	were VBD 0	added VBN B-verb.change	to TO 0	a DT 0	regimen NNS B-noun.person	consisting VBG B-verb.stative	of IN I-verb.stative	cyclosporine NN B-noun.state	, , 0	USP NNP B-noun.group	( ( 0	MODIFIED VBN B-verb.change	) ) 0	and CC 0	corticosteroids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d521.s2	- : 0	a DT 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drug NN B-noun.cognition	( ( 0	NSAID NNP B-noun.group	) ) 0	such JJ 0	as IN 0	ibuprofen NNS B-noun.person	( ( 0	Motrin NNP B-noun.person	, , 0	Advil NNP B-noun.person	, , 0	Nuprin NNP B-noun.person	, , 0	others NNS 0	) ) 0	, , 0	ketoprofen NN B-noun.person	( ( 0	Orudis NNP B-noun.person	, , 0	Orudis_KT NNP B-noun.location	, , 0	Oruvail NNP B-noun.group	) ) 0	, , 0	diclofenac NN B-noun.person	( ( 0	Voltaren NNP B-noun.person	, , 0	Cataflam NNP B-noun.location	) ) 0	, , 0	etodolac NN 0	( ( 0	Lodine NNP B-noun.location	) ) 0	, , 0	indomethacin NN 0	( ( 0	Indocin NNP 0	) ) 0	, , 0	nabumetone NN 0	( ( 0	Relafen NNP B-noun.other	) ) 0	, , 0	oxaprozin NN B-noun.person	( ( 0	Daypro NNP B-noun.person	) ) 0	, , 0	and CC 0	naproxen NN B-noun.person	( ( 0	Anaprox NNP B-noun.person	, , 0	Naprosyn NNP B-noun.person	, , 0	Aleve NNP B-noun.person	) ) 0	, , 0	. . 0
DDI-DrugBank.d237.s14	Cisapride NNP B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	prolong VB B-verb.stative	the DT 0	QT NNP 0	interval NN 0	, , 0	certain JJ B-adj.all	antiarrhythmics NNS B-noun.person	, , 0	including VBG B-verb.change	those DT 0	of IN 0	Class NNP B-noun.other	IA NNP I-noun.other	( ( 0	such JJ 0	as IN 0	quinidine JJ B-adj.all	and CC 0	procainamide NN B-noun.attribute	) ) 0	and CC 0	Class NNP B-noun.person	III NNP I-noun.person	( ( 0	such JJ 0	as IN 0	sotalol NN 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d316.s1	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.person	( ( 0	eg UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	grapefruit NN B-adj.all	juice NN B-noun.person	, , 0	cimetidine NN B-noun.location	) ) 0	with IN 0	felodipine NN B-noun.person	may MD 0	lead VB B-verb.cognition	to TO 0	several- CD 0	fold NN B-noun.object	increases NNS I-noun.object	in IN 0	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	felodipine NN B-noun.person	, , 0	either RB 0	due JJ 0	to TO 0	an DT 0	increase NN B-noun.act	in IN 0	bioavailability NN B-noun.cognition	or CC 0	due JJ 0	to TO 0	a DT 0	decrease NN B-noun.event	in IN 0	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d44.s6	Etofibrate NNP B-noun.person	elicited VBD B-verb.competition	62 CD 0	% NN 0	enhancement NN B-noun.attribute	of IN 0	post NN B-noun.act	- : 0	heparin RB 0	lipolytic JJ B-adj.all	activity NN B-noun.state	and CC 0	100 CD 0	% NN 0	increase NN B-noun.event	of IN 0	3H SYM 0	- : 0	triglyceride RB 0	fractional JJ B-adj.all	clearance NN B-noun.event	rate NN B-noun.time	compared VBN B-verb.change	with IN 0	placebo NN 0	treatment NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d431.s8	Therefore RB 0	, , 0	proton_pump_inhibitors NNS B-noun.person	should MD 0	be VB 0	taken VBN B-verb.possession	at IN 0	least JJS 0	30 CD B-adj.all	minutes NNS B-noun.time	prior RB 0	to TO 0	sucralfate VB B-verb.communication	. . 0	. . 0
DDI-DrugBank.d415.s0	Coumarin NNP B-noun.person	- : 0	Type_Anticoagulants NNS B-noun.person	, , 0	Several JJ B-adj.all	short JJ B-noun.body	- : 0	term NN B-noun.person	controlled VBD B-verb.social	studies NNS B-noun.person	failed VBD B-verb.social	to TO 0	wshow VB B-verb.communication	that DT 0	ibuprofen VBP 0	significantly RB B-adv.all	affected JJ B-adj.all	prothrombin NN B-noun.person	times NNS B-noun.event	or CC 0	a DT 0	variety NN B-noun.cognition	of IN 0	other JJ 0	clotting NN B-verb.contact	factors NNS B-noun.person	when WRB 0	administered VBN B-verb.communication	to TO 0	individuals NNS B-noun.person	on IN 0	coumarin NN B-noun.person	- : 0	type_anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d277.s12	Phenobarbital NNP B-noun.person	( ( 0	Primidone NNP 0	) ) 0	, , 0	Population NNP B-noun.other	pharmacokinetic JJ B-adj.all	analyses NNS B-noun.act	indicate VBP B-verb.cognition	that IN 0	tiagabine JJ B-adj.all	clearance NN B-noun.attribute	is VBZ B-verb.stative	60 CD B-adj.all	% NN 0	greater JJR B-adj.all	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	phenobarbital JJ I-verb.social	( ( 0	primidone NN 0	) ) 0	with IN 0	or CC 0	without IN 0	other JJ 0	enzyme NN B-noun.person	- : 0	inducing VBG B-verb.communication	AEDs NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d9.s3	For IN 0	the DT 0	calcium NN B-noun.person	- : 0	entry_blocking_agents NNS B-noun.person	now RB B-adv.all	available JJ B-adj.all	in IN 0	the DT 0	United NNP B-noun.group	States NNPS I-noun.group	( ( 0	verapamil RB B-adv.all	, , 0	nifedipine NN B-noun.person	and CC 0	diltiazem NN B-noun.artifact	) ) 0	, , 0	these DT 0	data NNS B-noun.cognition	appeared VBD B-verb.change	well RB 0	after IN 0	clinical JJ B-adj.all	patterns NNS B-noun.person	of IN 0	use NN B-noun.person	evolved VBD B-verb.change	. . 0	. . 0
DDI-DrugBank.d328.s26	Anticoagulant JJ B-adj.all	therapy NN B-noun.group	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	particularly RB B-adv.all	during IN 0	the DT 0	first JJ B-adj.all	few JJ B-noun.animal	weeks NNS B-noun.time	, , 0	after IN 0	initiating VBG B-verb.social	therapy NN I-verb.social	with IN 0	BEXTRA NNP B-noun.group	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	warfarin NN B-noun.act	or CC 0	similar JJ B-adj.all	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d46.s15	- : 0	Lithium NN B-noun.person	, , 0	Generally RB B-adv.all	should MD 0	not RB 0	be VB 0	given VBN B-verb.possession	with IN 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s23	In IN 0	four CD 0	subjects NNS B-noun.person	with IN 0	epilepsy NN B-noun.person	ingesting VBG B-verb.social	valproate NN B-noun.attribute	, , 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	trough NN B-noun.person	( ( 0	Cmin NNP 0	) ) 0	valproate VBP B-verb.stative	plasma NN B-noun.substance	concentration NN B-noun.event	was VBD B-verb.stative	63 CD 0	16 CD B-adj.all	micrograms NNS B-noun.quantity	/ . 0	mL. NNP B-noun.person	. . 0
DDI-DrugBank.d531.s38	Increasing VBG B-verb.change	the DT 0	indinavir NN 0	dose NN 0	to TO 0	1000 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.time	does VBZ 0	not RB B-adv.all	compensate VB B-verb.communication	for IN 0	the DT 0	increased VBN B-verb.change	indinavir NN 0	metabolism NN 0	due JJ 0	to TO 0	SUSTIVA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d493.s1	The DT 0	data NNS B-noun.cognition	do VBP 0	not RB B-adv.all	suggest VB B-verb.communication	the DT 0	need NN B-noun.object	for IN 0	dose NN B-noun.act	adjustment NN B-noun.act	of IN 0	either DT 0	HUMIRA NNP B-noun.group	or CC 0	MTX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d198.s17	In IN 0	the DT 0	warfarin NN B-noun.act	study NN B-noun.artifact	, , 0	vardenafil NN B-noun.person	had VBD B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	other JJ 0	pharmacodynamic JJ B-adj.pert	parameters NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d491.s1	The DT 0	duration NN 0	of IN 0	the DT 0	period NN B-noun.time	following VBG 0	treatment NN B-noun.communication	with IN 0	AMEVIVE NNP B-noun.group	_ , 0	before IN 0	one CD 0	should MD 0	consider VB B-verb.communication	starting VBG B-verb.change	other JJ 0	immunosuppressive JJ B-adj.all	therapy NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d440.s3	H2_Blockers NNS B-noun.person	and CC 0	Proton_Pump_Inhibitors NNS B-noun.person	( ( 0	PPIs NNP 0	) ) 0	. . 0
DDI-DrugBank.d441.s3	Commonly RB B-adv.all	used VBN B-verb.consumption	drugs NNS I-verb.consumption	such JJ 0	as IN 0	phenylpropanolamine NN B-noun.person	and CC 0	pseudoephedrine NN B-noun.person	have VBP 0	been VBN 0	specifically RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d64.s93	Drug NN 0	/ '' 0	Laboratory NNP B-noun.other	Test NNP I-noun.other	Interferences NNP I-noun.other	, , 0	Dicumarol NNP B-noun.person	and CC 0	indanedione_anticoagulants NNS B-noun.person	, , 0	including VBG B-verb.stative	anisindione NN 0	, , 0	or CC 0	their PRP$ 0	metabolites NNS B-noun.location	may MD 0	color VB B-verb.communication	alkaline JJ B-adj.pert	urine NN B-noun.substance	red JJ I-noun.substance	- : 0	orange NN B-noun.attribute	, , 0	which WDT 0	may MD 0	interfere VB B-verb.stative	with IN 0	spectrophotometrically RB B-adv.all	determined VBN B-verb.cognition	urinary JJ B-adj.all	laboratory NN B-noun.artifact	tests NNS I-noun.artifact	. . 0	. . 0
DDI-MedLine.d122.s3	The DT 0	initiation NN B-noun.act	of IN 0	alcohol NN B-noun.animal	or CC 0	nicotine JJ B-adj.all	use NN 0	may MD 0	be VB 0	precipitated VBN B-verb.creation	by IN 0	similar JJ B-adj.all	personality NN B-noun.person	characteristics NNS B-noun.person	in IN 0	the DT 0	user NN B-noun.person	, , 0	such JJ 0	as IN 0	impulsivity NN B-noun.event	and CC 0	sensation NN B-noun.person	seeking VBG B-verb.contact	. . 0	. . 0
DDI-DrugBank.d253.s3	Antidepressants NNS B-noun.person	( ( 0	tricyclic JJ 0	) ) 0	, , 0	atropine JJ B-adj.all	or CC 0	other JJ B-adj.all	anticholinergic_agents NNS B-noun.location	, , 0	or CC 0	digitalis_glycosides NNS B-noun.substance	, , 0	concurrent JJ B-adj.all	use NN 0	with IN 0	arbutamine NN B-noun.person	may MD 0	produce VB B-verb.cognition	additive JJ B-adj.all	inotropic NN B-noun.attribute	and/or CC 0	chronotropic NN B-adj.pert	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d124.s12	Drugs NNS B-noun.other	That WDT I-noun.other	Should MD I-noun.other	Not RB I-noun.other	Be VB I-noun.other	Coadministered NNP I-noun.other	With IN I-noun.other	INVIRASE NNP I-noun.other	/ POS 0	Ritonavir NNP B-noun.person	. . 0
DDI-DrugBank.d81.s14	Fentanyl NNP B-noun.person	Anesthesia NNP I-noun.person	, , 0	Severe JJ 0	hypotension NN 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	during IN 0	fentanyl NN 0	anesthesia NN 0	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	a DT 0	beta_blocker JJR B-adj.all	and CC 0	a DT 0	calcium_channel_blocker NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d283.s3	HMG SYM 0	- : 0	CoA_reductase_inhibitors NNS B-noun.person	, , 0	The DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	TRICOR NNP B-noun.group	and CC 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	should MD 0	be VB 0	avoided VBN B-verb.social	unless IN 0	the DT 0	benefit NN B-noun.attribute	of IN 0	further JJ B-adj.all	alterations NNS B-noun.act	in IN 0	lipid NN B-noun.body	levels NNS B-noun.attribute	is VBZ B-verb.stative	likely JJ B-adj.all	to TO 0	outweigh VB B-verb.communication	the DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	this DT 0	drug NN 0	combination NN 0	. . 0	. . 0
DDI-DrugBank.d450.s0	Potassium NN B-noun.person	- : 0	depleting_diuretics NNS B-noun.person	are VBP B-verb.stative	a DT 0	major JJ B-adj.all	contributing JJ B-adj.pert	factor NN B-noun.person	to TO 0	digitalis VB B-verb.consumption	toxicity NN I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d98.s5	Some DT 0	reports NNS B-noun.artifact	have VBP 0	shown VBN B-verb.cognition	that IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	thiazides NNS 0	with IN 0	vitamin_D NNP B-noun.person	causes VBZ B-verb.creation	hypercalcemia NN I-verb.creation	. . 0	. . 0
DDI-DrugBank.d198.s23	These DT 0	effects NNS B-noun.phenomenon	were VBD B-verb.stative	not RB B-adv.all	observed VBN B-verb.perception	when WRB 0	Vardenafil NNP B-noun.communication	20 CD 0	mg DT 0	was VBD 0	taken VBN B-verb.consumption	24 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	the DT 0	NTG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d277.s2	valproate NN B-noun.attribute	and CC 0	gabapentin NN B-noun.act	are VBP B-verb.stative	not RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d456.s0	Co SYM 0	- : 0	treatment NN B-noun.plant	with IN 0	the DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	ketoconazole NN B-noun.possession	increases NNS B-noun.quantity	erlotinib VBP B-verb.stative	AUC NNP 0	by IN 0	2/3 CD 0	. . 0	. . 0
DDI-DrugBank.d135.s7	Ketoconazole NNP B-noun.person	, , 0	In IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	receiving VBG B-verb.communication	ketoconazole NN I-verb.communication	, , 0	a DT 0	CYP3A4 JJ B-noun.person	inhibitor NN I-noun.person	, , 0	at IN 0	200 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	for IN 0	7 CD B-adj.all	days NNS B-noun.act	, , 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	( ( 0	AUC NNP 0	) ) 0	to TO 0	lapatinib NN B-noun.person	was VBD 0	increased VBN B-verb.change	to TO 0	approximately RB B-verb.change	3.6-fold JJ 0	of IN 0	control NN B-noun.act	and CC 0	half NN B-noun.person	- : 0	life NN B-noun.person	increased VBD B-verb.change	to TO 0	1.7-fold CD 0	of IN 0	control NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d48.s4	In IN 0	patients NNS B-noun.person	in IN 0	whom WP 0	CYP3A4 JJ 0	inducers NNS B-noun.person	( ( 0	eg UH 0	, , 0	dexamethasone NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	rifampicin NN B-noun.person	, , 0	phenobarbital NN B-noun.body	) ) 0	are VBP 0	indicated VBN B-verb.communication	, , 0	alternative JJ B-adj.all	agents NNS B-noun.person	with IN 0	less RBR B-adv.all	enzyme JJ B-adj.all	induction NN B-noun.person	potential NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d412.s7	During IN 0	controlled JJ B-adj.all	hypotensive JJ B-adj.all	anesthesia NN B-noun.person	using VBG B-verb.consumption	labetalol_HCl NN B-noun.food	in IN 0	association NN 0	with IN 0	halothane NN B-noun.person	, , 0	high JJ B-adj.all	concentrations NNS B-noun.attribute	( ( 0	3 CD B-adj.all	% NN 0	or CC 0	above VB 0	) ) 0	of IN 0	halothane NN B-noun.person	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	because IN 0	the DT 0	degree NN B-noun.communication	of IN 0	hypotension NN B-noun.act	will MD 0	be VB 0	increased VBN B-verb.change	and CC 0	because IN 0	of IN 0	the DT 0	possibility NN B-noun.state	of IN 0	a DT 0	large JJ B-adj.all	reduction NN B-noun.process	in IN 0	cardiac JJ B-adj.all	output NN B-noun.person	and CC 0	an DT 0	increase NN B-noun.act	in IN 0	central JJ B-adj.all	venous JJ B-adj.all	pressure NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d253.s1	Beta SYM 0	- : 0	adrenergic_blocking_agents NNS B-noun.group	should MD 0	be VB 0	withdrawn VBN B-verb.contact	at IN 0	least JJS 0	48 CD 0	hours NNS 0	before IN 0	conducting VBG B-verb.social	an DT 0	arbutamine NN B-noun.person	- : 0	mediated VBD B-verb.cognition	stress NN 0	test NN 0	. . 0	. . 0
DDI-DrugBank.d40.s4	The DT 0	pharmacokinetics NNS B-noun.person	and CC 0	protein NN B-noun.substance	binding NN B-verb.contact	of IN 0	fosphenytoin NN B-noun.food	, , 0	phenytoin NN B-noun.person	, , 0	and CC 0	diazepam NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	when WRB 0	diazepam NN B-noun.person	and CC 0	Cerebyx NNP B-noun.person	were VBD B-verb.stative	concurrently RB B-adv.all	administered VBN B-verb.possession	in IN 0	single JJ B-adj.all	submaximal JJ B-adj.all	doses NNS B-noun.event	. . 0	. . 0
DDI-DrugBank.d76.s21	Evidence NN B-noun.person	supporting VBG B-verb.communication	the DT 0	conclusion NN B-noun.communication	that IN 0	it PRP 0	is VBZ B-verb.stative	inadvisable JJ B-adj.all	to TO 0	co SYM 0	- : 0	administer NN B-noun.person	fluvoxamine NN B-noun.person	and CC 0	diazepam NN B-noun.person	is VBZ 0	derived VBN B-verb.cognition	from IN 0	a DT 0	study NN B-noun.artifact	in IN 0	which WDT 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	taking VBG B-verb.social	150 CD 0	mg IN 0	/ JJ 0	day NN 0	of IN 0	fluvoxamine NN B-noun.phenomenon	were VBD 0	administered VBN B-verb.perception	a DT 0	single JJ B-adj.all	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	10 CD B-adj.all	mg NN B-noun.quantity	of IN 0	diazepam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d240.s2	Ethopropazine NN B-noun.person	can MD 0	interact VB B-verb.change	with IN 0	chlorpromazine NN B-noun.act	, , 0	increasing VBG B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	chlorpromazine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d139.s0	Broad JJ B-noun.person	- : 0	Spectrum_Antibiotics NNS B-noun.person	- : 0	Broad JJ B-noun.other	- : 0	spectrum_antibiotics NNS B-noun.group	may MD 0	sterilize VB B-verb.change	the DT 0	bowel NN B-noun.artifact	and CC 0	decrease VB B-verb.change	the DT 0	vitamin_K JJ B-noun.phenomenon	contribution NN I-noun.phenomenon	to TO 0	the DT 0	body NN B-noun.object	by IN 0	the DT 0	intestinal JJ B-adj.all	microflora NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d29.s4	Post SYM 0	- : 0	marketing NN B-verb.communication	reports NNS B-noun.communication	of IN 0	changes NNS B-noun.phenomenon	in IN 0	prothrombin NN B-noun.substance	measures NNS B-noun.attribute	have VBP 0	been VBN 0	received VBN B-verb.possession	among IN 0	patients NNS B-noun.person	on IN 0	concomitant JJ B-adj.all	warfarin NN B-noun.communication	and CC 0	esomeprazole NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d552.s1	Nabilone NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	have VB B-verb.social	an DT 0	additive JJ B-adj.all	CNS NNP B-noun.group	depressant JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	either DT 0	diazepam NN B-noun.person	, , 0	secobarbitone_sodium NN B-noun.location	, , 0	alcohol NN B-noun.person	or CC 0	codeine NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d568.s14	Racemic JJ B-adj.all	citalopram NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	mean JJ B-adj.all	AUC NNP B-noun.group	or CC 0	Cmax NNP B-noun.person	of IN 0	pimozide NN 0	. . 0	. . 0
DDI-DrugBank.d140.s12	Warfarin NNP B-noun.person	, , 0	Atorvastatin NNP B-noun.person	had VBD B-verb.social	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	prothrombin NN B-adj.all	time NN B-noun.time	when WRB 0	administered VBN B-verb.communication	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.change	chronic JJ B-adj.all	warfarin NN B-noun.relation	treatment NN I-noun.relation	. . 0	. . 0
DDI-DrugBank.d549.s5	Acetylsalicylic_acid NN B-noun.artifact	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	clearance NN B-noun.person	( ( 0	pharmacokinetics NNS B-noun.event	) ) 0	of IN 0	iloprost NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d422.s6	When WRB 0	intravenous JJ B-adj.all	morphine NN B-noun.motive	and CC 0	BREVIBLOC NNP B-noun.person	were VBD B-verb.stative	concomitantly RB B-adv.all	administered VBN B-verb.possession	in IN 0	normal JJ B-adj.all	subjects NNS B-noun.person	, , 0	no DT 0	effect NN B-noun.cognition	on IN 0	morphine JJR B-adj.all	blood NN B-noun.location	levels NNS B-noun.state	was VBD 0	seen VBN B-verb.perception	, , 0	but CC 0	BREVIBLOC NNP B-noun.other	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	blood NN B-noun.body	levels NNS B-noun.state	were VBD 0	increased VBN B-verb.change	by IN 0	46 CD 0	% NN 0	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d404.s14	Calcium NNP B-noun.person	Supplements NNPS I-noun.person	, , 0	Uncontrolled JJ B-noun.person	intake NN I-noun.person	of IN 0	additional JJ B-adj.all	calcium NN B-noun.act	- : 0	containing VBG B-verb.stative	preparations NNS B-noun.substance	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-MedLine.d68.s0	[ IN 0	The DT 0	effect NN B-noun.cognition	of IN 0	cimetidine NN B-noun.person	on IN 0	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	verografin NN B-noun.food	and CC 0	iodamide NN B-noun.person	in IN 0	dogs NNS B-noun.animal	] . 0	_ : 0	The DT 0	intravenous JJ B-adj.all	injection NN B-noun.event	of IN 0	cimetidine NN B-noun.act	in IN 0	a DT 0	dose NN B-noun.quantity	of IN 0	20 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	enhanced VBN B-verb.change	verografine NN B-noun.artifact	and CC 0	iodamide JJ B-adj.all	excretion NN B-noun.act	in IN 0	chronic JJ B-adj.pert	canine NN B-noun.state	experiments NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d362.s4	In IN 0	another DT 0	drug NN B-noun.artifact	interaction NN B-noun.act	study NN B-noun.artifact	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	orally RB B-adv.all	inhaled JJ B-adj.all	ciclesonide NN B-noun.location	and CC 0	oral JJ B-noun.body	ketoconazole NN I-noun.body	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	, , 0	increased VBD B-verb.change	the DT 0	exposure NN B-noun.cognition	( ( 0	AUC NNP 0	) ) 0	of IN 0	des NNS B-noun.person	- : 0	ciclesonide NN B-noun.act	by IN 0	approximately RB B-adj.all	3.6-fold JJ I-adj.all	at IN 0	steady JJ B-adj.all	state NN B-noun.state	, , 0	while IN 0	levels NNS B-noun.attribute	of IN 0	ciclesonide NN B-noun.location	remained VBD B-verb.stative	unchanged JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d569.s2	There EX 0	is VBZ B-verb.stative	no DT 0	experience NN B-noun.cognition	with IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Angiomax NNP B-noun.person	and CC 0	plasma NN B-noun.plant	expanders NNS 0	such JJ 0	as IN 0	dextran NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s7	- : 0	Carmustine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	BiCNU NNP 0	) ) 0	or CC 0	. . 0
DDI-DrugBank.d364.s10	Coadministration NN B-noun.person	of IN 0	alosetron RB 0	and CC 0	strong JJ B-noun.person	CYP3A4 CD I-noun.person	inhibitors NNS I-noun.person	, , 0	such JJ 0	as IN 0	clarithromycin NN B-noun.person	, , 0	telithromycin NN B-noun.person	, , 0	protease_inhibitors NNS B-noun.person	, , 0	voriconazole NN B-noun.person	, , 0	and CC 0	itraconazole NN B-noun.group	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.change	but CC 0	should MD 0	be VB 0	undertaken VBN B-verb.cognition	with IN 0	caution NN B-noun.act	because IN 0	of IN 0	similar JJ B-adj.all	potential JJ B-adj.all	drug NN B-noun.person	interactions NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d427.s11	and CC 0	Videx NNP B-noun.person	, , 0	( ( 0	Didanosine NNP B-noun.person	) ) 0	, , 0	chewable JJ B-adj.all	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	the DT 0	pediatric JJ B-adj.pert	powder NN B-noun.state	for IN 0	oral JJ B-adj.all	solution NN B-noun.cognition	may MD 0	substantially RB B-verb.possession	interfere VB 0	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	quinolones NNS B-noun.communication	, , 0	resulting VBG B-verb.stative	in IN 0	systemic JJ B-adj.all	levels NNS B-noun.state	considerably RB B-adv.all	lower JJR B-adj.all	than IN 0	desired VBN B-verb.emotion	. . 0	. . 0
DDI-DrugBank.d77.s21	It PRP 0	is VBZ B-verb.stative	desirable JJ B-adj.all	to TO 0	monitor VB B-verb.creation	TCA NNP B-noun.group	plasma NN B-noun.plant	levels NNS B-noun.body	whenever WRB 0	a DT 0	TCA NNP B-noun.group	is VBZ 0	going VBG 0	to TO 0	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	another DT 0	drug NN B-noun.person	known VBN B-verb.cognition	to TO 0	be VB B-verb.stative	an DT 0	inhibitor NN B-noun.person	of IN 0	P450 JJ B-noun.artifact	2D6 NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d199.s2	Cimetidine NNP B-noun.person	, , 0	Cimetidine NNP B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	fosfomycin NN 0	when WRB 0	coadministered VBN B-verb.communication	with IN 0	MONUROL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d434.s15	In IN 0	order NN 0	to TO 0	maintain VB B-verb.consumption	phenytoin NN B-noun.food	levels NNS B-noun.attribute	, , 0	limit VBP B-verb.change	adverse JJ B-adj.all	experiences NNS B-noun.event	, , 0	and CC 0	achieve VB B-verb.social	the DT 0	felbamate NN B-noun.person	dose NN B-noun.quantity	of IN 0	3600 CD 0	mg RB 0	/ JJ 0	day NN 0	, , 0	a DT 0	phenytoin NN B-noun.person	dose NN B-noun.event	reduction NN B-noun.process	of IN 0	approximately RB B-adv.all	40 CD B-adj.all	% NN 0	was VBD B-verb.stative	necessary JJ B-adj.all	for IN 0	eight CD 0	of IN 0	these DT 0	10 CD B-adj.all	subjects NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d358.s3	Pletal JJ 0	does VBZ 0	not RB B-adv.all	, , 0	however RB 0	, , 0	appear VBP B-verb.cognition	to TO 0	cause VB 0	increased VBN B-verb.change	blood NN B-noun.body	levels NNS B-noun.attribute	of IN 0	drugs NNS B-noun.artifact	metabolized VBN B-verb.change	by IN 0	CYP3A4 NNP B-noun.person	, , 0	as IN 0	it PRP 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	lovastatin NN B-noun.feeling	, , 0	a DT 0	drug NN B-noun.person	with IN 0	metabolism NN B-noun.artifact	very RB B-adv.all	sensitive JJ B-adj.all	to TO 0	C.P.A. VB B-verb.motion	inhibition NN I-verb.motion	. . 0	. . 0
DDI-DrugBank.d13.s0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	Flupenthixol NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	some DT 0	drugs NNS B-noun.artifact	, , 0	like IN 0	Monoamine_oxidase_inhibitors NNS B-noun.person	( ( 0	MAOI NNP B-noun.group	) ) 0	, , 0	MAOI NNP B-noun.group	could MD 0	theoretically RB B-adv.all	affect VB B-verb.change	flupenthixol JJ B-adj.all	pharmacodynamics NNS B-noun.person	; : 0	Arecoline NNP B-noun.location	; : 0	Eproxindine NNP B-noun.person	; : 0	Ethanol NNP B-noun.person	, , 0	Flupenthixol NNP B-noun.person	and CC 0	Ethanol NNP B-noun.person	cause VBP B-verb.creation	additive JJ B-adj.all	CNS NNP B-noun.group	depression NN B-noun.feeling	; : 0	Tricyclic_antidepressants NNS B-noun.person	, , 0	Flupenthixol NNP B-noun.person	increases VBZ B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	Tricyclic_antidepressants NNS B-noun.plant	. . 0
DDI-DrugBank.d94.s4	Agents NNS B-noun.person	that WDT 0	are VBP B-verb.stative	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.attribute	that WDT 0	have VBP 0	been VBN 0	found VBN B-verb.possession	, , 0	or CC 0	are VBP 0	expected VBN B-verb.cognition	, , 0	to TO 0	increase VB B-verb.change	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	EQUETROTM NNP B-noun.group	are VBP B-verb.stative	the DT 0	following NN 0	, , 0	Acetazolamide NNP B-noun.person	, , 0	azole_antifungals NNS B-noun.person	, , 0	cimetidine NN B-noun.person	, , 0	clarithromycin(1 NN 0	) ) 0	, , 0	dalfopristin NN B-noun.person	, , 0	danazol NN B-noun.person	, , 0	delavirdine NN B-noun.person	, , 0	diltiazem NN B-noun.person	, , 0	erythromycin(1 NNP B-noun.location	) ) 0	, , 0	fluoxetine NN B-noun.person	, , 0	fluvoxamine NN B-noun.person	, , 0	grapefruit NN B-adj.all	juice NN B-noun.person	, , 0	isoniazid NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	loratadine NN 0	, , 0	nefazodone NN 0	, , 0	niacinamide RB 0	, , 0	nicotinamide NN B-noun.person	, , 0	protease_inhibitors NNS B-noun.person	, , 0	propoxyphene NN B-noun.person	, , 0	quinine NN B-noun.location	, , 0	quinupristin NN B-noun.communication	, , 0	troleandomycin NN B-noun.person	, , 0	valproate(1 NNP B-noun.location	) ) 0	, , 0	verapamil RB B-adv.all	, , 0	zileuton NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d40.s0	No DT 0	drugs NNS B-noun.person	are VBP 0	known VBN B-verb.cognition	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	conversion NN B-noun.cognition	of IN 0	fosphenytoin NN 0	to TO 0	phenytoin VB B-verb.motion	. . 0	. . 0
DDI-DrugBank.d5.s13	Although IN 0	bupropion NN 0	is VBZ B-verb.stative	not RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isoenzyme NN B-noun.attribute	, , 0	bupropion NN B-noun.person	and CC 0	hydroxybupropion NN B-noun.act	are VBP B-verb.stative	inhibitors NNS B-noun.person	of IN 0	the DT 0	CYP2D6 JJ B-adj.all	isoenzyme NN I-adj.all	in IN 0	vitro NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d397.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	erythromycin NN B-noun.food	and CC 0	digoxin NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	result VB B-verb.stative	in IN 0	elevated JJ B-adj.all	digoxin NN B-noun.person	serum NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d73.s3	Beta_blockers NNS B-noun.animal	may MD 0	exacerbate VB B-verb.communication	the DT 0	rebound NN 0	hypertension NN 0	which WDT 0	can MD 0	follow VB B-verb.possession	the DT 0	withdrawal NN B-noun.act	of IN 0	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d413.s9	Uricosuric_Agents NNS B-noun.artifact	, , 0	Since IN 0	the DT 0	excretion NN B-noun.act	of IN 0	oxipurinol NN B-noun.person	is VBZ B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	of IN 0	urate NN B-noun.location	, , 0	uricosuric_agents NNS B-noun.location	, , 0	which WDT 0	increase VBP B-verb.change	the DT 0	excretion NN B-noun.act	of IN 0	urate NN B-noun.location	, , 0	are VBP 0	also RB B-adv.all	likely JJ B-adj.all	to TO 0	increase VB B-verb.change	the DT 0	excretion NN B-noun.act	of IN 0	oxipurinol NN B-noun.food	and CC 0	thus RB B-adv.all	lower JJR B-adj.all	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	of IN 0	xanthine JJ B-adj.all	oxidase NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d330.s2	Oral JJ B-adj.all	neomycin NN B-noun.motive	inhibits VBZ B-verb.stative	the DT 0	gastrointestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	penicillin_V NNP B-noun.person	, , 0	oral JJ B-adj.all	vitamin_B-12 NN B-noun.location	, , 0	methotrexate NN B-noun.person	and CC 0	5-fluorouracil NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d358.s2	Population NNP B-noun.person	pharmacokinetic JJ B-adj.all	studies NNS B-noun.person	showed VBD B-verb.communication	higher JJR B-adj.all	concentrations NNS B-noun.attribute	of IN 0	cilostazol NN B-noun.act	among IN 0	patients NNS B-noun.person	concurrently RB B-adv.all	treated VBN B-verb.change	with IN 0	diltiazem NN B-noun.food	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	C.P.A NNP B-noun.person	.. . 0	. . 0
DDI-DrugBank.d48.s1	Concomitant JJ B-adj.all	use NN 0	of IN 0	SPRYCEL NNP B-noun.group	and CC 0	drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	CYP3A4 NNP I-verb.stative	( ( 0	eg UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	atazanavir NN B-noun.person	, , 0	indinavir NN B-noun.person	, , 0	nefazodone NN 0	, , 0	nelfinavir NN B-noun.person	, , 0	saquinavir NN B-noun.person	, , 0	telithromycin NN B-noun.artifact	) ) 0	may MD 0	increase VB B-verb.change	exposure NN B-noun.communication	to TO 0	dasatinib VB B-verb.change	and CC 0	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d179.s10	- : 0	Daunorubicin NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Cerubidine NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d123.s8	Multivalent NNP B-noun.person	Cation NNP I-noun.person	- : 0	Containing NNP B-noun.person	Products NNPS I-noun.person	, , 0	Concurrent NNP B-noun.person	administration NN I-noun.person	of IN 0	a DT 0	quinolone NN B-noun.communication	, , 0	including VBG B-verb.change	ciprofloxacin NN B-noun.food	, , 0	with IN 0	multivalent JJ B-adj.all	cation NN B-noun.person	- : 0	containing VBG B-verb.stative	products NNS B-noun.substance	such JJ 0	as IN 0	magnesium NN B-noun.person	or CC 0	aluminum NN B-noun.artifact	antacids NNS I-noun.artifact	, , 0	sucralfate NN B-noun.person	, , 0	VIDEX NNP B-noun.group	chewable NN B-noun.communication	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	pediatric JJ B-adj.pert	powder NN B-noun.person	, , 0	or CC 0	products NNS B-noun.artifact	containing VBG B-verb.stative	calcium NN B-noun.substance	, , 0	iron NN B-noun.person	, , 0	or CC 0	zinc NN B-noun.group	may MD 0	substantially RB B-adv.all	decrease VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	ciprofloxacin NN B-noun.person	, , 0	resulting VBG B-verb.stative	in IN 0	serum NN B-noun.body	and CC 0	urine NN B-noun.body	levels NNS B-noun.attribute	considerably RB B-adv.all	lower JJR B-adj.all	than IN 0	desired VBN B-verb.emotion	. . 0	. . 0
DDI-DrugBank.d314.s5	If IN 0	possible JJ B-adj.all	, , 0	anticholinesterase_agents NNS B-noun.location	should MD 0	be VB 0	withdrawn VBN B-verb.contact	at IN 0	least JJS 0	24 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	initiating VBG B-verb.possession	corticosteroid JJ B-adj.all	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d175.s23	Allopurinol NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	healthy JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	no DT 0	significant JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	occurred VBD B-verb.cognition	when WRB 0	captopril NN B-noun.person	and CC 0	allopurinol NN B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	for IN 0	6 CD B-adj.all	days NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d364.s17	Another DT 0	study NN B-noun.person	showed VBD B-verb.communication	that IN 0	alosetron RB 0	had VBD 0	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	the DT 0	oral JJ B-noun.group	contraceptive_agents NNS I-noun.group	ethinyl_estradiol NN B-noun.state	and CC 0	levonorgestrel NN B-noun.attribute	( ( 0	CYP3A4 JJ B-adj.all	substrates NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-MedLine.d7.s0	Enhanced VBN B-verb.change	theophylline JJ 0	clearance NN B-noun.attribute	secondary JJ B-adj.all	to TO 0	phenytoin VB B-verb.consumption	therapy NN I-verb.consumption	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d53.s0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	nelfinavir NN B-noun.person	at IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	with IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	azithromycin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d236.s5	Urinary NNP B-noun.person	alkalinizing VBG B-verb.communication	agents NNS B-noun.person	( ( 0	acetazolamide NN 0	, , 0	some DT 0	thiazides NNS B-noun.artifact	) ) 0	increase VB B-verb.change	the DT 0	concentration NN B-noun.event	of IN 0	the DT 0	non NN B-noun.person	- : 0	ionized VBD B-verb.communication	species NNS B-noun.person	of IN 0	the DT 0	amphetamine JJ B-adj.all	molecule NN B-noun.person	, , 0	thereby RB 0	decreasing VBG B-verb.creation	urinary JJ B-adj.all	excretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d419.s2	In IN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trials NNS B-noun.cognition	of IN 0	AUGMENTIN_XR NNP B-noun.person	, , 0	22 CD B-adj.all	patients NNS B-noun.person	received VBD B-verb.possession	concomitant JJ B-adj.all	allopurinol NN B-noun.person	and CC 0	AUGMENTIN_XR NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d234.s12	Because IN 0	of IN 0	the DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	adverse JJ B-adj.all	reactions NNS B-noun.cognition	in IN 0	patients NNS B-noun.person	who WP 0	have VBP 0	been VBN 0	taking VBG B-verb.social	benzodiazepines NNS I-verb.social	on IN 0	a DT 0	regular JJ B-adj.all	basis NN B-noun.cognition	, , 0	it PRP 0	is VBZ B-verb.stative	particularly RB B-adv.all	important JJ B-adj.all	that IN 0	physicians NNS B-noun.person	query NN 0	patients NNS B-noun.person	or CC 0	their PRP$ 0	guardians NNS B-noun.person	carefully RB B-adv.all	about IN 0	benzodiazepine NN B-noun.person	, , 0	alcohol NN B-noun.person	and CC 0	sedative JJ B-adj.all	use NN 0	as IN 0	part NN 0	of IN 0	the DT 0	history NN B-noun.cognition	prior RB 0	to TO 0	any DT 0	procedure NN B-noun.act	in IN 0	which WDT 0	the DT 0	use NN 0	of IN 0	ROMAZICON NNP B-noun.group	is VBZ 0	planned VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d345.s13	No DT 0	depressant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	blood NN B-noun.location	levels NNS B-noun.state	in IN 0	humans NNS B-noun.person	was VBD 0	noted VBN B-verb.perception	when WRB 0	colestipol_hydrochloride NN 0	was VBD 0	administered VBN B-verb.possession	with IN 0	any DT 0	of IN 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	aspirin NN B-noun.person	, , 0	clindamycin NN B-noun.person	, , 0	clofibrate NN B-noun.person	, , 0	methyldopa NN B-noun.person	, , 0	nicotinic_acid JJ 0	( ( 0	niacin NN 0	) ) 0	, , 0	tolbutamide NN 0	, , 0	phenytoin NN B-noun.person	or CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d103.s8	Other JJ 0	Drugs NNP B-noun.person	, , 0	Drugs NNS B-noun.person	such JJ 0	as IN 0	quinidine NN B-noun.location	, , 0	disopyramide NN 0	, , 0	procainamide NN B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	antihistamines NNS B-noun.attribute	, , 0	and CC 0	tricyclic_antidepressants NNS B-noun.act	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	QT SYM 0	- : 0	interval JJ B-adj.all	prolongation NN B-noun.act	and CC 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	ventricular JJ B-adj.all	arrhythmia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d223.s8	While IN 0	all PDT 0	the DT 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	e.g. NNP B-noun.person	, , 0	citalopram NN B-noun.person	, , 0	escitalopram NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	and CC 0	paroxetine NN B-noun.person	, , 0	inhibit VBP B-verb.stative	P450 JJ 0	2D6 NN 0	, , 0	they PRP 0	may MD 0	vary VB B-verb.stative	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d199.s0	Metoclopramide NNP B-noun.person	, , 0	When WRB 0	coadministered VBN B-verb.communication	with IN 0	MONUROL NNP B-noun.group	, , 0	metoclopramide NN B-noun.attribute	, , 0	a DT 0	drug NN B-noun.artifact	which WDT 0	increases VBZ B-verb.change	gastrointestinal JJ B-adj.all	motility NN B-noun.motive	, , 0	lowers VBZ B-verb.change	the DT 0	serum NN B-noun.body	concentration NN B-noun.event	and CC 0	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	fosfomycin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d30.s0	No DT 0	significant JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.person	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	have VBP 0	been VBN 0	found VBN B-verb.possession	in IN 0	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	hydrochlorothiazide NN 0	, , 0	digoxin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	cimetidine NN B-noun.person	and CC 0	phenobarbital NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d133.s0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	BOTOX NNP B-noun.group	and CC 0	aminoglycosides NNS B-noun.artifact	or CC 0	other JJ 0	agents NNS B-noun.person	interfering VBG B-verb.social	with IN 0	neuromuscular JJ B-adj.all	transmission NN B-noun.communication	( ( 0	e.g. UH 0	, , 0	curare NN B-noun.person	- : 0	like_compounds NNS B-noun.time	) ) 0	should MD 0	only RB B-adv.all	be VB 0	performed VBN B-verb.social	with IN 0	caution NN B-noun.cognition	as IN 0	the DT 0	effect NN B-noun.cognition	of IN 0	the DT 0	toxin NN B-noun.location	may MD 0	be VB 0	potentiated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d48.s5	If IN 0	SPRYCEL NNP B-noun.group	must MD 0	be VB 0	administered VBN B-verb.possession	with IN 0	a DT 0	CYP3A4 JJ B-noun.person	inducer NN I-noun.person	, , 0	a DT 0	dose NN B-noun.event	increase NN B-noun.process	in IN 0	SPRYCEL NNP B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d325.s11	It PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that IN 0	results NNS B-noun.location	of IN 0	studies NNS B-noun.food	in IN 0	animals NNS B-noun.animal	indicate VBP B-verb.communication	that IN 0	dopamine NN B-noun.person	- : 0	induced VBN B-verb.creation	ventricular JJ B-adj.all	arrhythmias NN B-noun.artifact	during IN 0	anesthesia NN 0	can MD 0	be VB 0	reversed VBN B-verb.change	by IN 0	propranolol NN B-noun.person	. . 0	. . 0
DDI-MedLine.d93.s6	The DT 0	20 CD B-adj.all	% NN 0	v IN 0	/ CD 0	v DT 0	solution NN B-noun.cognition	of IN 0	alcohol NN B-noun.person	was VBD 0	prepared VBN B-verb.creation	in IN 0	water NN 0	from IN 0	a DT 0	stock NN B-noun.person	solution NN B-noun.person	of IN 0	95 CD 0	% NN 0	ethanol NN 0	. . 0	. . 0
DDI-DrugBank.d88.s1	There EX 0	was VBD B-verb.stative	a DT 0	small JJ B-adj.all	increase NN B-noun.event	in IN 0	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	capecitabine NN B-noun.act	and CC 0	one CD 0	metabolite NN B-noun.cognition	( ( 0	5-DFCR NN 0	) ) 0	, , 0	. . 0
DDI-MedLine.d102.s1	The DT 0	aim NN 0	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	investigate VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	low JJ B-adj.all	and CC 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	estradiol NN B-noun.act	, , 0	and CC 0	of IN 0	progesterone NN B-noun.person	on IN 0	the DT 0	response NN B-noun.communication	to TO 0	noradrenaline VB B-verb.communication	in IN 0	rat PRP$ 0	thoracic JJ B-noun.body	aorta NN I-noun.body	. . 0	. . 0
DDI-DrugBank.d97.s63	CRIXIVAN NN B-noun.act	may MD 0	not RB 0	be VB B-verb.stative	effective JJ B-adj.all	due JJ 0	to TO 0	decreased VBD B-verb.communication	indinavir NN B-noun.person	concentrations NNS B-noun.food	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	these DT 0	agents NNS B-noun.person	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d202.s1	Serious JJ B-adj.all	anticholinergic JJ B-adj.all	symptoms NNS B-noun.relation	( ( 0	severe JJ B-adj.all	dry JJ B-noun.artifact	mouth NN I-noun.artifact	, , 0	urinary JJ B-adj.all	retention NN B-noun.person	, , 0	blurred VBD B-verb.cognition	vision NN I-verb.cognition	) ) 0	have VBP 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	elevations NNS B-noun.person	in IN 0	the DT 0	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	tricyclic_antidepressants NNS B-noun.group	when WRB 0	cimetidine NN B-noun.person	is VBZ 0	added VBN B-verb.change	to TO 0	the DT 0	drug NN B-noun.person	regimen NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d442.s0	Increases NNS B-noun.person	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	have VBP 0	been VBN 0	noted VBN B-verb.perception	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	long- JJ B-adj.all	term NN B-noun.body	warfarin NN 0	therapy NN 0	after IN 0	flutamide NN B-noun.person	was VBD 0	initiated VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d210.s3	Aspirin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	low JJ B-adj.all	- : 0	dose NN 0	aspirin NN 0	with IN 0	VIOXX NNP B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increased VBN B-adj.all	rate NN B-noun.time	of IN 0	GI NNP 0	ulceration NN B-noun.communication	or CC 0	other JJ B-adj.all	complications NNS B-noun.person	, , 0	compared VBN B-verb.cognition	to TO 0	use VB B-verb.consumption	of IN 0	VIOXX NNP B-noun.group	alone RB 0	. . 0	. . 0
DDI-DrugBank.d456.s5	If IN 0	the DT 0	TARCEVA NNP B-noun.location	dose NN 0	is VBZ 0	adjusted VBN B-verb.change	upward RB B-adv.all	, , 0	the DT 0	dose NN B-noun.group	will MD 0	need VB 0	to TO 0	be VB 0	reduced VBN B-verb.change	upon IN 0	discontinuation NN B-noun.act	of IN 0	rifampicin NN B-noun.communication	or CC 0	other JJ B-adj.all	inducers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s26	Sulindac NNP B-noun.person	, , 0	The DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.state	and CC 0	sulindac NN B-noun.person	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	resulted VBD B-verb.social	in IN 0	lowering VBG B-verb.motion	of IN 0	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	the DT 0	active JJ B-adj.all	sulindac NN B-noun.group	sulfide NN 0	metabolite NN B-noun.attribute	by IN 0	approximately RB B-adj.all	one CD 0	- : 0	third LS 0	. . 0	. . 0
DDI-DrugBank.d536.s11	There EX 0	is VBZ B-verb.stative	little JJ 0	if IN 0	any DT 0	clinically RB B-adj.all	significant JJ B-adj.all	interaction NN B-noun.relation	between IN 0	Acarbose NNP B-noun.person	and CC 0	metformin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d43.s9	In IN 0	eight CD 0	HIV NNP 0	- : 0	infected JJ B-adj.all	patients NNS B-noun.person	, , 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	AUC NNP 0	of IN 0	ciprofloxacin NN B-noun.person	was VBD 0	decreased VBN B-verb.change	an DT 0	average NN B-noun.act	of IN 0	26 CD B-adj.all	% NN 0	( ( 0	95 CD 0	% NN 0	CI NN 0	= SYM 0	14 CD B-adj.all	% NN 0	, , 0	37 CD 0	% NN 0	) ) 0	when WRB 0	ciprofloxacin NN B-noun.person	was VBD 0	administered VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	a DT 0	marketed VBN B-verb.cognition	chewable JJ B-adj.all	/ CC 0	dispersible JJ B-adj.all	tablet NN B-noun.group	formulation NN B-noun.act	of IN 0	VIDEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d568.s7	Cimetidine NNP B-noun.person	; : 0	In IN 0	subjects NNS B-noun.person	who WP 0	had VBD 0	received VBN B-verb.possession	21 CD B-adj.all	days NNS B-noun.time	of IN 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	racemic JJ B-adj.all	citalopram NN B-noun.person	, , 0	combined VBN B-verb.change	administration NN B-noun.time	of IN 0	400 CD 0	mg RB 0	/ JJ 0	day NN 0	cimetidine NN 0	for IN 0	8 CD B-adj.all	days NNS B-noun.person	resulted VBD B-verb.communication	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	citalopram NN B-noun.person	AUC NNP I-noun.person	and CC 0	Cmax NNP B-noun.person	of IN 0	43 CD B-adj.all	% NN 0	and CC 0	39 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d531.s42	A DT 0	dose NN B-noun.event	increase NN B-noun.process	of IN 0	lopinavir NN B-noun.quantity	/ : 0	ritonavir NN B-noun.person	to TO 0	533/133 CD 0	mg NN B-noun.quantity	( ( 0	4 CD B-adj.all	capsules NNS B-noun.communication	or CC 0	6.5 CD 0	mL CD B-noun.quantity	) ) 0	twice RB 0	daily RB 0	taken VBN 0	with IN 0	food NN B-noun.food	is VBZ 0	recommended VBN B-verb.communication	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	SUSTIVA NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d314.s18	Hepatic NNP B-noun.person	Enzyme NNP I-noun.person	Inducers NNP I-noun.person	, , 0	Inhibitors NNP B-noun.person	and CC 0	Substrates NNP B-noun.person	, , 0	Drugs NNP B-noun.person	which WDT 0	induce VBP B-verb.cognition	cytochrome RB 0	P450 JJ 0	3A4 NN 0	( ( 0	CYP NNP B-noun.group	3A4 NNP I-noun.group	) ) 0	enzyme NN B-noun.phenomenon	activity NN B-noun.process	( ( 0	e.g. UH 0	, , 0	barbiturates NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	rifampin NN 0	) ) 0	may MD 0	enhance VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	corticosteroids NNS B-noun.food	and CC 0	require VB B-verb.communication	that IN 0	the DT 0	dosage NN B-noun.quantity	of IN 0	the DT 0	corticosteroid JJ B-noun.group	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d269.s12	Both DT 0	digoxin NN B-noun.person	and CC 0	COREG NNP B-noun.group	slow JJ B-adj.all	AV NNP 0	conduction NN 0	. . 0	. . 0
DDI-DrugBank.d76.s25	Accordingly RB B-adv.all	, , 0	diazepam NN B-noun.person	and CC 0	fluvoxamine NN B-noun.plant	should MD 0	not RB B-adv.all	ordinarily RB B-adv.all	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d568.s37	Coadministration NN B-noun.person	of IN 0	LEXAPRO NNP B-noun.group	and CC 0	metoprolol NN B-noun.person	had VBD B-verb.social	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	blood NN B-noun.act	pressure NN B-noun.act	or CC 0	heart NN B-noun.body	rate NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d443.s4	Nonsteroidal_Antiinflammatory JJ B-adj.all	Agents NNS B-noun.person	, , 0	Aspirin NNP B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	in IN 0	patients NNS B-noun.person	who WP 0	are VBP B-verb.stative	hypersensitive JJ B-adj.all	to TO 0	nonsteroidal_anti JJ 0	- : 0	inflammatory JJ B-adj.all	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d438.s26	Morphine NN B-noun.person	, , 0	A DT 0	literature NN B-noun.communication	article NN B-noun.communication	reported VBD B-verb.communication	that IN 0	when WRB 0	a DT 0	60-mg JJ 0	controlled VBN B-verb.social	- : 0	release NN B-verb.body	morphine NN 0	capsule NN B-noun.location	was VBD 0	administered VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	a DT 0	600-mg JJ B-noun.person	Neurontin NNP I-noun.person	_ ( 0	capsule NN B-noun.quantity	( ( 0	N=12 NN 0	) ) 0	, , 0	mean JJ B-adj.all	gabapentin NN 0	AUC NNP 0	increased VBN B-verb.change	by IN 0	44 CD 0	% NN 0	compared VBN B-verb.communication	to TO 0	gabapentin VB B-verb.social	administered VBN B-verb.body	without IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d127.s2	DOXIL NNP B-noun.group	_ CC 0	may MD 0	interact VB B-verb.change	with IN 0	drugs NNS B-noun.artifact	known VBN B-verb.cognition	to TO 0	interact VB B-verb.contact	with IN 0	the DT 0	conventional JJ B-adj.all	formulation NN B-noun.attribute	of IN 0	doxorubicin_HCl NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d321.s4	Cimetidine NNP B-noun.person	, , 0	Albendazole_sulfoxide IN 0	concentrations NNS B-noun.attribute	in IN 0	bile NN B-noun.possession	and CC 0	cystic JJ B-adj.all	fluid NN B-noun.state	were VBD 0	increased VBN B-verb.change	( ( 0	about IN 0	2-fold JJ B-noun.location	) ) 0	in IN 0	hydatid JJ B-adj.all	cyst NN B-noun.person	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	cimetidine NN B-noun.person	( ( 0	10 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	/ FW 0	day NN 0	) ) 0	( ( 0	n=7 NNP 0	) ) 0	compared VBN B-verb.stative	with IN 0	albendazole NN B-noun.person	( ( 0	20 CD 0	mg FW 0	/ FW 0	kg FW 0	/ FW 0	day NN 0	) ) 0	alone RB 0	( ( 0	n=12 NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d411.s6	Amiodarone NNP B-noun.person	, , 0	Amiodarone NNP B-noun.person	therapy NN 0	alone RB 0	can MD 0	cause VB B-verb.creation	hypothyroidism NN B-noun.artifact	or CC 0	hyperthyroidism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d458.s5	Pharmacokinetic JJ B-adj.all	data NNS B-noun.cognition	indicate VBP B-verb.communication	that IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.group	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	astemizole NN B-noun.location	, , 0	resulting VBG B-verb.stative	in IN 0	elevated JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	astemizole NN B-noun.shape	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.attribute	desmethylastemizole NN B-noun.communication	which WDT 0	may MD 0	prolong VB B-verb.stative	QT NNP 0	intervals NNS 0	. . 0	. . 0
DDI-DrugBank.d487.s8	There EX 0	are VBP 0	reports NNS B-noun.artifact	of IN 0	enhanced VBN B-verb.change	as RB 0	well RB 0	as IN 0	diminished JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	anticoagulants NNS B-noun.animal	when WRB 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d303.s3	Accordingly RB B-adv.all	, , 0	careful JJ B-adj.all	patient NN B-noun.person	monitoring NN B-verb.perception	and CC 0	dose NN B-noun.communication	adjustment NN B-noun.communication	of IN 0	metformin NN B-noun.food	is VBZ 0	recommended VBN B-verb.communication	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	taking VBG 0	cephalexin NN B-noun.communication	and CC 0	metformin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d346.s0	Studies NNS B-noun.person	to TO 0	evaluate VB B-verb.communication	possible JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	REVIA NNP B-noun.group	and CC 0	drugs NNS B-noun.artifact	other JJ 0	than IN 0	opiates NNS B-noun.person	have VBP 0	not RB 0	been VBN 0	performed VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d64.s0	Addition NN B-noun.act	or CC 0	deletion NN B-noun.act	of IN 0	any DT 0	drug NN B-noun.person	from IN 0	the DT 0	therapeutic JJ B-adj.pert	regimen NNS B-noun.person	of IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	oral JJ B-adj.all	anticoagulants NNS B-noun.object	may MD 0	affect VB B-verb.change	patient JJ B-adj.all	response NN B-noun.communication	to TO 0	the DT 0	anticoagulant NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d51.s3	Caution NN B-noun.person	is VBZ B-verb.stative	therefore RB B-adv.all	advised VBD B-verb.communication	in IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	ATROVENT NNP B-noun.group	Inhalation NNP I-noun.group	Aerosol NNP I-noun.group	with IN 0	other JJ 0	anticholinergic JJ B-adj.pert	- : 0	containing VBG B-verb.communication	drugs NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d109.s5	Samples NNS B-noun.cognition	for IN 0	plasma NN B-noun.substance	and CC 0	urine NN 0	immunoreactive JJ B-adj.all	digoxin NN B-noun.person	concentrations NNS I-noun.person	were VBD 0	collected VBN B-verb.possession	through IN 0	120 CD 0	hours NNS 0	following VBG B-verb.stative	the DT 0	digoxin NN B-noun.person	dose NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d380.s5	In IN 0	many JJ 0	of IN 0	these DT 0	cases NNS B-noun.artifact	, , 0	buprenorphine NN B-noun.person	was VBD 0	misused VBN B-verb.emotion	by IN 0	self PRP 0	- : 0	injection NN B-noun.act	of IN 0	crushed JJ B-adj.all	SUBUTEX NNP B-noun.group	tablets NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d387.s2	Doxylamine NNP B-noun.person	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	epinephrine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d283.s6	The DT 0	benefits NNS B-noun.person	and CC 0	risks NNS B-noun.act	of IN 0	using VBG B-verb.consumption	TRICOR NNP 0	with IN 0	immunosuppressants NNS B-noun.person	and CC 0	other JJ 0	potentially RB B-adj.all	nephrotoxic JJ B-adj.all	agents NNS B-noun.person	should MD 0	be VB 0	carefully RB B-adv.all	considered VBN B-verb.cognition	, , 0	and CC 0	the DT 0	lowest JJS B-adj.all	effective JJ B-adj.all	dose NN B-noun.person	employed VBN B-verb.consumption	. . 0
DDI-DrugBank.d123.s2	Some DT 0	quinolones NNS B-noun.communication	, , 0	including VBG B-verb.change	ciprofloxacin NN B-noun.food	, , 0	have VBP 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	transient JJ B-adj.all	elevations NNS B-noun.person	in IN 0	serum NN 0	creatinine NN 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	cyclosporine NN B-noun.person	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d434.s34	Steady NNP B-noun.person	- : 0	state NN B-adj.all	plasma NN B-noun.person	felbamate NN B-noun.person	concentrations NNS B-noun.person	were VBD 0	found VBN B-verb.perception	to TO 0	be VB B-verb.stative	29 CD B-adj.all	% NN 0	lower JJR B-adj.all	than IN 0	the DT 0	mean JJ B-adj.all	concentrations NNS B-noun.cognition	of IN 0	a DT 0	group NN 0	of IN 0	newly RB B-adj.all	diagnosed VBN I-adj.all	subjects NNS B-noun.person	with IN 0	epilepsy NN B-noun.person	also RB B-adv.all	receiving VBG B-verb.communication	2400 CD 0	mg NN B-noun.quantity	of IN 0	felbamate NN B-noun.person	a DT 0	day NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d188.s0	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	HEXALEN NNP B-noun.group	and CC 0	antidepressants_of_the_MAO_inhibitor_class NNP B-noun.group	may MD 0	cause VB B-verb.cognition	severe JJ 0	orthostatic JJ B-adj.all	hypotension NN B-noun.act	. . 0	Cimetidine NNP B-noun.person	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	microsomal JJ B-adj.all	drug NN B-noun.group	metabolism NN B-noun.attribute	, , 0	increased VBD B-verb.change	altretamines NNS B-noun.artifact	half RB B-adv.all	- JJ 0	life NN B-noun.person	and CC 0	toxicity NN B-noun.attribute	in IN 0	a DT 0	rat NN B-noun.artifact	model NN B-noun.person	. . 0	. . 0
DDI-MedLine.d8.s0	In IN 0	vitro NN B-noun.animal	activity NN B-noun.process	of IN 0	KRM-1648 NNP B-noun.other	, , 0	either CC 0	singly RB B-adv.all	or CC 0	in IN 0	combination NN 0	with IN 0	ofloxacin NN B-noun.person	, , 0	against IN 0	Mycobacterium NNP B-noun.person	ulcerans NNS I-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d78.s7	Serum NNP B-noun.person	theophylline NN 0	concentrations NNS 0	increase NN 0	when WRB 0	grepafloxacin NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	in IN 0	a DT 0	patient NN B-noun.person	maintained VBN B-verb.consumption	on IN 0	theophylline PRP 0	. . 0	. . 0
DDI-DrugBank.d258.s8	Loratadine NNP B-noun.person	Descarboethoxyloratadine NNP I-noun.person	. . 0
DDI-DrugBank.d3.s6	In IN 0	another DT 0	study NN B-noun.artifact	, , 0	TORADOLIV NNP 0	/ ( 0	IM NNP 0	was VBD 0	given VBN B-verb.possession	with IN 0	two CD 0	doses NNS B-noun.quantity	of IN 0	5000 CD 0	U NNP 0	of IN 0	heparin NN 0	to TO 0	11 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	mean JJ B-adj.all	template JJ B-adj.all	bleeding NN B-noun.act	time NN 0	of IN 0	6.4 CD 0	minutes NNS B-noun.time	( ( 0	3.2 CD 0	to TO 0	11.4 CD 0	min NN B-noun.quantity	) ) 0	compared VBN B-verb.cognition	to TO 0	a DT 0	mean NN B-noun.attribute	of IN 0	6.0 CD 0	minutes NNS B-noun.time	( ( 0	3.4 CD 0	to TO 0	7.5 CD 0	min NN B-noun.quantity	) ) 0	for IN 0	heparin NN 0	alone RB 0	and CC 0	5.1 CD 0	minutes NNS B-noun.time	( ( 0	3.5 CD 0	to TO 0	8.5 CD 0	min NN B-noun.quantity	) ) 0	for IN 0	placebo NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d43.s11	In IN 0	a DT 0	single JJ B-adj.all	subject JJ B-noun.artifact	given VBN B-verb.possession	one CD 0	dose NN B-noun.event	of IN 0	ciprofloxacin NN B-noun.communication	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	a DT 0	dose NN B-noun.quantity	of IN 0	didanosine NN B-noun.person	- : 0	placebo NN B-noun.substance	tablets NNS B-noun.artifact	, , 0	a DT 0	greater JJR B-adj.all	than IN 0	50 CD B-adj.all	% NN 0	reduction NN B-noun.act	in IN 0	the DT 0	AUC NNP B-noun.group	of IN 0	ciprofloxacin NN B-noun.person	was VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d97.s90	Tadalafil NNP B-noun.person	dose NN I-noun.person	should MD 0	not RB B-adv.all	exceed VB B-verb.stative	a DT 0	maximum NN B-noun.person	of IN 0	10 CD B-adj.all	mg NN B-noun.quantity	in IN 0	a DT 0	72- JJ 0	hour NN 0	period NN B-noun.time	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	indinavir NN B-noun.person	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d468.s5	Nicardipine_HCl NN B-noun.artifact	usually RB B-adv.all	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	digoxin NN B-noun.person	, , 0	however RB 0	, , 0	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	evaluated VBN B-verb.communication	after IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	nicardipine_HCl NNP B-noun.person	is VBZ 0	initiated VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d386.s27	Conversely RB B-adv.all	, , 0	decreases VBZ B-verb.change	in IN 0	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	the DT 0	tricyclic_antidepressants NNS B-noun.plant	have VBP 0	been VBN 0	reported VBN B-verb.communication	upon IN 0	discontinuation NN B-noun.act	of IN 0	cimetidine NN B-noun.act	which WDT 0	may MD 0	result VB B-verb.stative	in IN 0	the DT 0	loss NN B-noun.process	of IN 0	the DT 0	therapeutic JJ B-adj.all	efficacy NN B-noun.phenomenon	of IN 0	the DT 0	tricyclic_antidepressant JJ B-noun.communication	6 CD B-adj.all	. . 0	. . 0
DDI-MedLine.d5.s2	A DT 0	daily JJ B-noun.event	dose NN 0	of IN 0	2 CD B-adj.all	mg NN B-noun.quantity	of IN 0	coumaphos NNS B-noun.communication	/ : 0	kg NN B-noun.quantity	of IN 0	body NN 0	weight NN B-noun.attribute	for IN 0	6 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	plasma NN B-noun.substance	enzymes NNS B-noun.artifact	or CC 0	the DT 0	antiprothrombinemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	bishydroxy JJ B-adj.pert	- : 0	coumarin NN B-noun.person	in IN 0	wethers NNS B-noun.animal	. . 0	. . 0
DDI-MedLine.d81.s0	Hypothermia NNP B-noun.person	as IN 0	an DT 0	index NN B-noun.communication	of IN 0	the DT 0	disulfiram NN B-noun.person	- : 0	ethanol NN 0	reaction NN B-noun.process	in IN 0	the DT 0	rat NN B-noun.artifact	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d458.s18	It PRP 0	is VBZ B-verb.stative	, , 0	therefore RB B-adv.all	, , 0	advisable JJ 0	to TO 0	monitor VB B-verb.perception	digoxin NN I-verb.perception	concentrations NNS B-noun.food	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d440.s1	Products NNS B-noun.artifact	containing VBG B-verb.stative	calcium NN B-noun.substance	and CC 0	other JJ 0	multivalent JJ B-adj.all	cations NNS B-noun.person	( ( 0	such JJ 0	as IN 0	aluminum NN B-noun.person	, , 0	magnesium NN B-noun.person	, , 0	iron NN B-noun.person	) ) 0	are VBP B-verb.stative	likely JJ B-adj.all	to TO 0	interfere VB B-verb.stative	with IN 0	absorption NN B-noun.act	of IN 0	Ibandronate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d325.s14	It PRP 0	is VBZ 0	suggested VBN B-verb.communication	that IN 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	dopamine_HCl NNP B-noun.person	, , 0	alternatives NNS B-noun.person	to TO 0	phenytoin VB B-verb.social	should MD 0	be VB 0	used VBN B-verb.consumption	if IN 0	anticonvulsant JJ B-adj.all	therapy NN B-noun.person	is VBZ 0	needed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d238.s5	The DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	CMI NNP B-noun.group	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	be VB 0	increased VBN B-verb.change	by IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	haloperidol NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d359.s6	Caution NN B-noun.person	is VBZ B-verb.stative	therefore RB B-adv.all	advised VBD B-verb.communication	when WRB 0	administering VBG B-verb.perception	PEGANONE NNP 0	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	coumarin_anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d325.s12	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	vasopressors NNS B-noun.person	, , 0	vasoconstricting VBG B-verb.stative	agents NNS B-noun.person	( ( 0	such JJ 0	as IN 0	ergonovine NN 0	) ) 0	and CC 0	some DT 0	oxytocic_drugs NNS B-noun.object	may MD 0	result VB B-verb.stative	in IN 0	severe JJ 0	hypertension NN 0	. . 0	. . 0
DDI-DrugBank.d382.s23	The DT 0	potential JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	midazolam NN B-noun.time	or CC 0	other JJ 0	benzodiazepines NNS 0	metabolized VBN B-verb.stative	via IN 0	CYP3A4 NNP B-noun.person	( ( 0	alprazolam NN B-noun.person	, , 0	triazolam NN 0	) ) 0	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	coadministering VBG B-verb.communication	these DT 0	agents NNS B-noun.person	with IN 0	Aprepitant NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s5	It PRP 0	is VBZ B-verb.stative	advisable JJ B-adj.all	to TO 0	check VB B-verb.social	coagulation NN B-adj.all	time NN B-noun.time	within IN 0	the DT 0	first JJ B-adj.all	few JJ B-noun.animal	days NNS B-noun.phenomenon	after IN 0	the DT 0	start NN B-noun.artifact	and CC 0	discontinuation NN B-noun.act	of IN 0	cisapride JJ B-adj.all	therapy NN B-noun.act	, , 0	with IN 0	an DT 0	appropriate JJ B-adj.all	adjustment NN B-noun.act	of IN 0	the DT 0	anticoagulant JJ B-adj.all	dose NN B-noun.person	, , 0	if IN 0	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d82.s31	The DT 0	potential JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	INDOCIN NNP B-noun.group	and CC 0	potassium NN B-noun.person	- : 0	sparing_diuretics NNS B-noun.person	on IN 0	potassium NN B-noun.person	kinetics NNS B-noun.person	and CC 0	renal JJ B-adj.all	function NN B-noun.act	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	these DT 0	agents NNS B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d489.s1	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Kerlone NNP B-noun.person	with IN 0	the DT 0	oral JJ B-adj.all	anticoagulant JJ B-adj.all	warfarin NN B-noun.communication	has VBZ 0	been VBN 0	shown VBN B-verb.cognition	not RB 0	to TO 0	potentiate VB B-verb.communication	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d47.s0	Activity NN B-noun.process	of IN 0	buforin_II NNP B-noun.person	alone RB I-noun.person	and CC 0	in IN 0	combination NN 0	with IN 0	azithromycin NN B-noun.person	and CC 0	minocycline NN 0	against IN 0	Cryptosporidium NNP B-noun.person	parvum NN I-noun.person	in IN 0	cell NN B-noun.body	culture NN I-noun.body	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d420.s2	There EX 0	are VBP B-verb.stative	no DT 0	significant JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	cefdinir NN B-noun.person	pharmacokinetics NNS B-noun.person	if IN 0	the DT 0	antacid NN B-noun.object	is VBZ 0	administered VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	or CC 0	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	cefdinir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s21	Paroxetine NNP B-noun.person	produced VBD B-verb.creation	only RB B-adv.all	minor JJ B-adj.all	changes NNS B-noun.communication	in IN 0	the DT 0	levels NNS B-noun.state	of IN 0	clozapine NN B-noun.act	and CC 0	its PRP$ 0	metabolites NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d567.s19	Lovastatin NNP B-noun.person	therapy NN I-noun.person	has VBZ 0	not RB 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	bleeding NN B-noun.act	or CC 0	with IN 0	changes NNS B-noun.food	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	in IN 0	patients NNS 0	not RB 0	taking VBG 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s18	Theophylline PRP 0	; : 0	Combined VBN B-verb.cognition	administration NN B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	for IN 0	21 CD B-adj.all	days NNS B-noun.act	) ) 0	and CC 0	the DT 0	CYP1A2 NNP B-noun.person	substrate VB B-verb.communication	theophylline PRP 0	( ( 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	300 CD 0	mg NN B-noun.quantity	) ) 0	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	theophylline NN 0	. . 0	. . 0
DDI-DrugBank.d314.s10	Cholestyramine NN B-noun.person	, , 0	Cholestyramine NNP B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-MedLine.d2.s0	Failure NN B-noun.person	of IN 0	neomycin NN B-noun.act	to TO 0	modify VB B-verb.change	ACTH NNP B-noun.group	induced VBD B-verb.creation	hypertension NN B-noun.person	in IN 0	sheep NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d125.s0	The DT 0	mode NN B-noun.attribute	of IN 0	toxic JJ B-adj.all	action NN B-noun.state	of IN 0	the DT 0	pesticide NN B-noun.person	gliftor NN B-noun.person	, , 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	1,3-difluoroacetone JJ 0	to TO 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate NN B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d277.s9	The DT 0	addition NN 0	of IN 0	tiagabine NN B-noun.location	in IN 0	a DT 0	limited JJ B-adj.all	number NN B-noun.attribute	of IN 0	patients NNS B-noun.person	in IN 0	three CD 0	well RB 0	- : 0	controlled VBN B-verb.social	studies NNS B-noun.person	caused VBD B-verb.communication	no DT 0	systematic JJ B-adj.all	changes NNS B-noun.relation	in IN 0	phenobarbital JJ B-adj.all	or CC 0	primidone NN B-noun.substance	concentrations NNS B-noun.artifact	when WRB 0	compared VBN B-verb.cognition	to TO 0	placebo VB B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d172.s8	The DT 0	effects NNS B-noun.phenomenon	celecoxib NN B-noun.event	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	and/or CC 0	pharmacodynamics NNS B-noun.person	of IN 0	glyburide NN 0	, , 0	ketoconazole NN B-noun.person	, , 0	methotrexate NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	tolbutamide NN 0	, , 0	and CC 0	warfarin NN B-noun.act	have VBP 0	been VBN 0	studied VBN B-verb.cognition	in IN 0	vivo NN B-noun.animal	and CC 0	clinically RB B-adv.all	important JJ B-adj.all	interactions NNS B-noun.communication	have VBP 0	not RB 0	been VBN 0	found VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d458.s3	The DT 0	following VBG 0	drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	been VBN 0	identified VBN B-verb.cognition	involving VBG B-verb.stative	NIZORAL NNP B-noun.group	Tablets NNPS I-noun.group	and CC 0	other JJ 0	drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	the DT 0	cytochrome NN 0	P450 RB 0	3A4 JJ 0	enzyme NN B-noun.cognition	system NN I-noun.cognition	, , 0	Ketoconazole NNP B-noun.person	tablets NNS I-noun.person	inhibit VBP B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	terfenadine NN B-noun.artifact	, , 0	resulting VBG B-verb.stative	in IN 0	an DT 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	terfenadine NN B-noun.artifact	and CC 0	a DT 0	delay NN B-noun.food	in IN 0	the DT 0	elimination NN B-noun.act	of IN 0	its PRP$ 0	acid NN B-noun.act	metabolite NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d284.s3	Concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	methylxanthines NNS B-noun.attribute	( ( 0	aminophylline NN B-noun.person	, , 0	theophylline NN 0	) ) 0	, , 0	steroids NNS B-noun.communication	, , 0	or CC 0	diuretics NNS B-noun.person	may MD 0	potentiate VB B-verb.cognition	any DT 0	hypokalemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	adrenergic_agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d289.s19	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan NN B-noun.substance	decreased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	glyburide NN 0	by IN 0	approximately RB B-noun.communication	40 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d87.s14	In IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	receiving VBG B-verb.communication	cimetidine NN B-noun.person	( ( 0	1 CD 0	gm PRP$ 0	daily JJ B-noun.event	) ) 0	for IN 0	one CD B-adj.all	week NN B-noun.time	, , 0	plasma NN 0	flecainide NN 0	levels NNS B-noun.attribute	increased VBN B-verb.change	by IN 0	about IN 0	30 CD B-adj.all	% NN 0	and CC 0	half NN B-noun.person	- : 0	life NN B-noun.time	increased VBN B-verb.change	by IN 0	about IN 0	10 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d76.s10	Although IN 0	it PRP 0	has VBZ 0	not RB 0	been VBN 0	definitively RB B-adv.all	demonstrated VBD B-verb.cognition	that IN 0	fluvoxamine NN B-noun.person	is VBZ B-verb.stative	a DT 0	potent JJ B-noun.person	IIIA4 JJ I-noun.person	inhibitor NN I-noun.person	, , 0	it PRP 0	is VBZ B-verb.stative	likely JJ B-adj.all	to TO 0	be VB B-verb.stative	, , 0	given VBN B-verb.possession	the DT 0	substantial JJ B-adj.all	interaction NN B-noun.act	of IN 0	fluvoxamine NN B-noun.substance	with IN 0	alprazolam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d277.s21	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	ethanol NN B-noun.person	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	multiple JJ B-noun.person	- : 0	dose JJ B-adj.all	administration NN B-noun.time	of IN 0	tiagabine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d340.s3	Coadministration NN B-noun.person	of IN 0	VIRACEPT NNP B-noun.group	and CC 0	drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.cognition	CYP3A NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	nelfinavir JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	and CC 0	reduce VB B-verb.change	its PRP$ 0	therapeutic JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d63.s6	Intraventricular JJ B-adj.all	injection NN B-noun.act	of IN 0	naloxone NN 0	at IN 0	doses NNS B-noun.act	of IN 0	1.2 CD 0	to TO 0	12 CD B-adj.all	micrograms NNS B-noun.quantity	equally RB B-adv.all	antagonized VBN B-verb.social	in IN 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	manner NN B-noun.person	the DT 0	tail NN B-noun.body	- : 0	flick NN 0	inhibition NN 0	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	beta NN B-noun.food	- : 0	endorphin NN B-noun.person	and CC 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d404.s5	Some DT 0	reports NNS B-noun.artifact	have VBP 0	shown VBN B-verb.cognition	that IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	thiazides NNS 0	with IN 0	vitamin_D NNP B-noun.person	causes VBZ B-verb.creation	hypercalcemia NN I-verb.creation	. . 0	. . 0
DDI-DrugBank.d154.s4	When WRB 0	phenobarbital NN B-noun.animal	is VBZ 0	added VBN B-verb.change	to TO 0	or CC 0	withdrawn VBN B-verb.contact	from IN 0	treatment NN B-noun.communication	, , 0	dosage NN B-noun.phenomenon	adjustment NN B-noun.process	of IN 0	Nalfon NNP B-noun.person	may MD 0	be VB 0	required VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d221.s0	The DT 0	risk NN 0	of IN 0	a DT 0	potential JJ B-adj.all	interaction NN B-noun.act	between IN 0	NovoSeven NNP B-noun.person	and CC 0	coagulation_factor NNP B-noun.person	concentrates VBZ B-verb.social	has VBZ 0	not RB 0	been VBN 0	adequately RB B-adv.all	evaluated VBN B-verb.change	in IN 0	preclinical JJ B-adj.all	or CC 0	clinical JJ B-adj.all	studies NNS B-noun.communication	. . 0	. . 0
DDI-MedLine.d30.s11	Haloperidol NNP B-noun.person	reduced VBD B-verb.change	or CC 0	eliminated VBN B-verb.cognition	the DT 0	increases NNS B-noun.event	in IN 0	FI NNP 0	responding VBG 0	produced VBN B-verb.creation	by IN 0	intermediate JJ B-adj.all	doses NNS B-noun.quantity	of IN 0	either DT 0	( ( 0	+ UH 0	) ) 0	-NANM NN B-noun.location	or CC 0	PCP NNP B-noun.group	in IN 0	pigeons NNS B-noun.animal	, , 0	but CC 0	did VBD 0	not RB B-adv.all	antagonize VB B-verb.cognition	the DT 0	decreases NNS B-noun.food	in IN 0	FI NNP 0	or CC 0	FR NNP 0	responding VBG 0	produced VBN B-verb.creation	by IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	PCP NNP B-noun.group	or CC 0	either DT 0	stereoisomer NN B-noun.state	of IN 0	NANM NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d565.s7	Controlled VBN B-verb.social	and CC 0	uncontrolled JJ B-adj.all	domestic JJ B-adj.all	studies NNS B-noun.act	suggest VBP B-verb.communication	that IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	diltiazem_hydrochloride JJ B-noun.other	and CC 0	beta JJ B-noun.body	- : 0	blockers NNS B-noun.person	is VBZ B-verb.stative	usually RB B-adv.all	well RB 0	tolerated VBN 0	, , 0	but CC 0	available JJ B-adj.all	data NNS B-noun.cognition	are VBP B-verb.stative	not RB B-adv.all	sufficient JJ B-adj.all	to TO 0	predict VB B-verb.contact	the DT 0	effects NNS B-noun.phenomenon	of IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	in IN 0	patients NNS B-noun.person	with IN 0	left JJ B-adj.all	ventricular JJ B-adj.all	dysfunction NN B-noun.act	or CC 0	cardiac JJ B-adj.all	conduction NN B-noun.act	abnormalities NNS B-noun.event	. . 0	. . 0
DDI-DrugBank.d64.s89	Because IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.object	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	phenytoin NN B-noun.food	, , 0	toxic JJ B-adj.all	levels NNS B-noun.state	of IN 0	the DT 0	anticonvulsant NN B-noun.object	may MD 0	occur VB B-verb.cognition	when WRB 0	an DT 0	oral JJ B-adj.all	anticoagulant NN B-noun.attribute	and CC 0	phenytoin NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d276.s1	The DT 0	mechanism NN B-noun.attribute	for IN 0	this DT 0	interaction NN B-noun.cognition	probably RB I-noun.cognition	is VBZ B-verb.stative	adsorption NN B-noun.act	of IN 0	nitrofurantoin NN 0	onto IN 0	the DT 0	surface NN B-noun.location	of IN 0	magnesium_trisilicate NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d0.s5	Other JJ 0	concomitant JJ B-adj.all	therapies NNS B-noun.person	, , 0	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	the DT 0	safety NN B-noun.artifact	profile NN B-noun.artifact	in IN 0	subjects NNS B-noun.person	treated VBN B-verb.social	with IN 0	Acamprosate NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	anxiolytics NNS B-noun.person	, , 0	hypnotics NNS B-noun.person	and CC 0	sedatives NNS B-noun.person	( ( 0	including VBG B-verb.stative	benzodiazepines NNS 0	) ) 0	, , 0	or CC 0	non RB B-adj.all	- : 0	opioid_analgesics NNS B-noun.person	was VBD B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	of IN 0	subjects NNS B-noun.person	taking VBG B-verb.social	placebo NN I-verb.social	with IN 0	these DT 0	concomitant JJ B-adj.all	medications NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s14	Increasing VBG B-verb.change	the DT 0	felbamate NN B-noun.person	dose NN B-noun.quantity	to TO 0	1800 CD 0	mg RB 0	/ JJ 0	day NN 0	in IN 0	six CD 0	of IN 0	these DT 0	subjects NNS B-noun.person	increased VBD B-verb.change	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	phenytoin NN B-noun.person	Cmin NNP I-noun.person	to TO 0	25 CD B-adj.all	7 CD B-adj.all	micrograms NNS B-noun.quantity	/ . 0	mL. NNP B-noun.person	. . 0
DDI-DrugBank.d94.s11	Agents NNS B-noun.person	that WDT 0	have VBP 0	been VBN 0	found VBN B-verb.possession	, , 0	or CC 0	are VBP 0	expected VBN B-verb.cognition	to TO 0	have VB 0	decreased VBN B-verb.change	plasma NN B-noun.substance	levels NNS B-noun.state	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	EQUETROTM NNP B-noun.group	due JJ 0	to TO 0	induction NN B-noun.act	of IN 0	CYP NNP B-noun.person	enzymes NNS I-noun.person	are VBP B-verb.stative	the DT 0	following NN 0	, , 0	Acetaminophen NNP B-noun.person	, , 0	alprazolam NN B-noun.person	, , 0	amitriptyline NN B-noun.person	, , 0	bupropion NN B-noun.person	, , 0	buspirone NN 0	, , 0	citalopram NN B-noun.person	, , 0	clobazam NN B-noun.person	, , 0	clonazepam NN B-noun.person	, , 0	clozapine NN B-noun.person	, , 0	cyclosporin NN B-noun.person	, , 0	delavirdine NN B-noun.person	, , 0	desipramine NN B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	dicumarol NN B-noun.person	, , 0	doxycycline NN B-noun.person	, , 0	ethosuximide NN 0	, , 0	felbamate NN B-noun.person	, , 0	felodipine NN B-noun.person	, , 0	glucocorticoids NNS B-noun.person	, , 0	haloperidol NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	lamotrigine NN 0	, , 0	levothyroxine NN B-noun.attribute	, , 0	lorazepam NN B-noun.person	, , 0	methadone NN B-noun.person	, , 0	midazolam NN B-noun.person	, , 0	mirtazapine NN B-noun.person	, , 0	nortriptyline NN B-noun.person	, , 0	olanzapine JJ 0	, , 0	oral JJ B-adj.all	contraceptives(3 NN B-noun.feeling	) ) 0	, , 0	oxcarbazepine NN B-noun.person	, , 0	Phenytoin(4 NN 0	) ) 0	, , 0	praziquantel NN B-noun.location	, , 0	protease NN B-noun.person	inhibitors NNS B-noun.person	, , 0	quetiapine NN B-noun.person	, , 0	risperidone NN 0	, , 0	theophylline PRP 0	, , 0	topiramate NN B-noun.location	, , 0	tiagabine NN 0	, , 0	tramadol NN B-noun.person	, , 0	triazolam NN B-noun.person	, , 0	valproate NN B-noun.attribute	, , 0	warfarin(5 NNP B-noun.location	) ) 0	, , 0	ziprasidone NN B-noun.person	, , 0	and CC 0	zonisamide NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d249.s0	Aspirin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diclofenac NN B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	because IN 0	diclofenac NN B-noun.person	is VBZ 0	displaced VBN B-verb.creation	from IN 0	its PRP$ 0	binding JJ B-adj.pert	sites NNS B-noun.location	during IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.food	, , 0	resulting VBG B-verb.stative	in IN 0	lower JJR B-adj.all	plasma NN B-noun.substance	concentrations NNS I-noun.substance	, , 0	peak JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	, , 0	and CC 0	AUC NNP B-noun.group	values NNS B-noun.attribute	. . 0	. . 0
DDI-MedLine.d111.s4	The DT 0	following VBG 0	eight CD 0	target NN B-noun.artifact	drug NN I-noun.artifact	/ : 0	added VBN B-verb.communication	drug NN B-noun.person	combinations NNS B-noun.person	were VBD 0	studied VBN B-verb.cognition	, , 0	acetaminophen RB 0	/ JJ 0	phenobarbital NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d305.s5	The DT 0	combination NN B-noun.event	of IN 0	therapeutic JJ B-adj.all	doses NNS B-noun.event	of IN 0	intravenous JJ B-adj.all	dantrolene_sodium NN B-noun.person	and CC 0	verapamil NN B-noun.person	in IN 0	halothane NN 0	a SYM 0	- : 0	chloralose NN 0	anesthetized VBN B-verb.communication	swine NN B-noun.person	has VBZ 0	resulted VBN B-verb.change	in IN 0	ventricular JJ B-adj.all	fibrillation NN B-noun.act	and CC 0	cardiovascular JJ B-adj.all	collapse NN B-noun.food	in IN 0	association NN 0	with IN 0	marked JJ B-adj.all	hyperkalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d487.s5	This DT 0	could MD 0	lead VB B-verb.cognition	to TO 0	decreased VBN B-verb.change	salicylate NN B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	or CC 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	salicylate JJ B-adj.all	toxicity NN B-noun.attribute	when WRB 0	corticosteroid NN B-noun.person	is VBZ 0	withdrawn VBN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d212.s19	Warfarin NNP B-noun.person	Keppra NNP I-noun.person	_ . 0	( ( 0	1000 CD 0	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	R NNP 0	and CC 0	S_warfarin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d53.s8	Co SYM 0	- : 0	administration NN B-noun.time	with IN 0	efavirenz NN B-noun.person	or CC 0	fluconazole NN B-noun.communication	had VBD B-verb.creation	a DT 0	modest JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	azithromycin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d154.s0	The DT 0	coadministration NN B-noun.person	of IN 0	aspirin NN B-noun.substance	decreases VBZ B-verb.change	the DT 0	biologic JJ B-adj.pert	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	fenoprofen NN B-noun.animal	because IN 0	of IN 0	an DT 0	increase NN B-noun.act	in IN 0	metabolic JJ B-adj.all	clearance NN B-noun.attribute	that WDT 0	results VBZ B-verb.stative	in IN 0	a DT 0	greater JJR B-adj.all	amount NN B-noun.possession	of IN 0	hydroxylated_fenoprofen CD 0	in IN 0	the DT 0	urine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d565.s41	Coadministration NN B-noun.person	of IN 0	rifampin NN 0	with IN 0	diltiazem NN B-noun.person	lowered VBD B-verb.motion	the DT 0	diltiazem NN 0	plasma NN 0	concentrations NNS 0	to TO 0	undetectable JJ B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d531.s39	When WRB 0	indinavir NN B-noun.person	at IN 0	an DT 0	increased VBN B-adj.all	dose NN B-noun.substance	( ( 0	1000 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	was VBD 0	given VBN B-verb.possession	with IN 0	SUSTIVA NNP B-noun.group	( ( 0	600 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily JJ I-adv.all	) ) 0	, , 0	the DT 0	indinavir NN B-noun.person	AUC NNP I-noun.person	and CC 0	Cmin NNP B-noun.person	were VBD 0	decreased VBN B-verb.change	on IN 0	average NN B-noun.act	by IN 0	33 CD 0	- : 0	46 CD 0	% NN 0	and CC 0	39 CD 0	- : 0	57 CD 0	% NN 0	, , 0	respectively RB B-adv.all	, , 0	compared VBN B-verb.cognition	to TO 0	when WRB 0	indinavir NN B-noun.person	( ( 0	800 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.artifact	) ) 0	was VBD 0	given VBN B-verb.possession	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d179.s22	- : 0	Plicamycin NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Mithracin NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d43.s16	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	nelfinavir NN B-noun.person	are VBP 0	not RB B-adv.all	altered VBN B-verb.change	to TO 0	a DT 0	clinically RB B-adv.all	significant JJ B-adj.all	degree NN B-noun.communication	when WRB 0	it PRP 0	is VBZ 0	administered VBN B-verb.possession	with IN 0	a DT 0	light JJ B-adj.all	meal NN B-noun.communication	1 CD B-adj.all	hour NN B-noun.communication	after IN 0	VIDEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d43.s15	To TO 0	avoid VB B-verb.social	this DT 0	interaction NN B-noun.act	, , 0	delavirdine NN B-noun.act	or CC 0	indinavir NN B-noun.group	should MD 0	be VB 0	given VBN B-verb.possession	1 CD B-adj.all	hour NN 0	prior RB 0	to TO 0	dosing VBG B-verb.social	with IN 0	VIDEX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d183.s1	INOmax NNP B-noun.person	has VBZ 0	been VBN 0	administered VBN B-verb.possession	with IN 0	tolazoline NN 0	, , 0	dopamine NN 0	, , 0	dobutamine NN B-noun.person	, , 0	steroids NNS B-noun.communication	, , 0	surfactant JJ B-adj.all	, , 0	and CC 0	high JJ B-noun.group	- : 0	frequency NN B-noun.person	ventilation NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d388.s4	Blunting VBG 0	of IN 0	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	beta JJ B-adj.pert	- : 0	adrenoceptor_blocking_agents NNS B-noun.person	by IN 0	nonsteroidal_anti NNS B-noun.person	- : 0	inflammatory_drugs NNS B-noun.cognition	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d429.s0	Antacids NNP B-noun.person	and CC 0	kaolin NN B-noun.person	, , 0	Antacids NNP B-noun.person	and CC 0	kaolin NN B-noun.person	can MD 0	reduce VB B-verb.change	absorption NN B-noun.act	of IN 0	chloroquine NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d178.s4	These DT 0	drugs NNS B-noun.artifact	include VBP B-verb.change	the DT 0	thiazides NNS B-noun.artifact	and CC 0	other JJ 0	diuretics NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	phe SYM 0	- : 0	nothiazines NNS 0	, , 0	thyroid_products NNS B-noun.body	, , 0	estrogens VBZ B-verb.cognition	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	nicotinic_acid JJ 0	, , 0	sympathomimet NN B-noun.person	- : 0	ics NNS B-noun.person	, , 0	calcium_channel_blocking_drugs NNS B-noun.communication	, , 0	and CC 0	isoniazid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d561.s6	Oral NNP B-noun.group	Anticoagulants NNPS I-noun.group	Interaction NNP I-noun.group	studies NNS B-noun.artifact	with IN 0	warfarin NN B-noun.act	and CC 0	acenocoumarol NN B-noun.person	failed VBD B-verb.social	to TO 0	identify VB B-verb.cognition	any DT 0	clinically RB B-adv.all	important JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	the DT 0	serum NN B-noun.body	concentrations NNS B-noun.attribute	or CC 0	clinical JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	these DT 0	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d452.s0	Administration NN B-noun.person	of IN 0	thiazide_diuretics NNS B-noun.person	to TO 0	hypoparathyroid VB B-verb.social	patients NNS B-noun.person	who WP 0	are VBP 0	concurrently RB 0	being VBG 0	treated VBN B-verb.change	with IN 0	dihydrotachysterol NN B-noun.act	may MD 0	cause VB B-verb.emotion	hypercalcemia NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d196.s3	In IN 0	patients NNS B-noun.person	with IN 0	chronic JJ B-adj.all	hepatitis NN 0	C NNP 0	treated VBN B-verb.change	with IN 0	PEGASYS NNP B-noun.group	in IN 0	combination NN 0	with IN 0	COPEGUS NNP B-noun.group	, , 0	PEGASYS NNP B-noun.person	treatment NN I-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	ribavirin JJ B-adj.all	distribution NN B-noun.act	or CC 0	clearance NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d224.s6	An DT 0	additive JJ B-adj.all	hypotensive JJ B-adj.all	effect NN B-noun.cognition	has VBZ 0	been VBN 0	reported VBN B-verb.communication	with IN 0	the DT 0	combination NN B-noun.event	of IN 0	systemic JJ B-adj.all	clonidine NN B-noun.artifact	and CC 0	neuroleptic JJ B-adj.all	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d17.s9	Amphotericin_B JJ B-noun.possession	or CC 0	Corticosteroids NNPS B-noun.person	or CC 0	Corticotropin NNP B-noun.person	( ( 0	ACTH NNP 0	) ) 0	. . 0
DDI-MedLine.d104.s3	Then RB B-adv.all	, , 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	metabotropic NN B-noun.food	glutamate NN B-adj.all	receptor NN B-noun.person	( ( 0	mGluR NNP 0	) ) 0	agonists NNS B-noun.person	, , 0	DCG NNP B-noun.group	- : 0	IV NNP 0	and CC 0	L NNP 0	- : 0	CCG-1 NN B-noun.other	, , 0	on IN 0	the DT 0	above JJ 0	behavioral JJ B-adj.all	changes NNS B-noun.phenomenon	induced VBN B-verb.creation	by IN 0	PCP NNP 0	were VBD 0	found VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d443.s7	Phenytoin NN B-noun.person	, , 0	Serum NNP B-noun.person	phenytoin NN I-noun.person	levels NNS B-noun.state	may MD 0	be VB 0	increased VBN B-verb.change	by IN 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d226.s6	Adenosine JJ B-adj.all	effects NNS B-noun.phenomenon	are VBP 0	potentiated VBN B-verb.communication	by IN 0	dipyridamole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d506.s5	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	Norpace NNP B-noun.location	and CC 0	quinidine NN B-noun.location	resulted VBD B-verb.stative	in IN 0	slight JJ B-adj.all	increases NNS B-noun.event	in IN 0	plasma NN B-noun.substance	disopyramide NN 0	levels NNS B-noun.state	and CC 0	slight JJ B-adj.all	decreases NNS B-noun.event	in IN 0	plasma NN B-noun.plant	quinidine NN B-noun.body	levels NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d335.s5	In IN 0	bioavailability NN B-noun.phenomenon	studies NNS B-noun.artifact	with IN 0	normal JJ B-adj.all	subjects NNS B-noun.person	, , 0	the DT 0	concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	antacids NNS B-noun.object	at IN 0	therapeutic JJ B-adj.all	levels NNS B-noun.attribute	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	influence VB B-verb.communication	the DT 0	bioavailability NN B-noun.cognition	of IN 0	TRANXENE NNP B-noun.group	tablets NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d163.s10	Phenytoin NN B-noun.person	, , 0	Accutane NNP B-noun.person	has VBZ 0	not RB 0	been VBN 0	shown VBN B-verb.perception	to TO 0	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	phenytoin NN B-noun.food	in IN 0	a DT 0	study NN B-noun.artifact	in IN 0	seven CD 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d99.s21	Cimetidine NNP B-noun.person	is VBZ 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	certain JJ B-adj.all	tricyclic_antidepressants NNS B-noun.person	, , 0	thereby RB 0	delaying VBG B-verb.stative	elimination NN B-noun.act	and CC 0	increasing VBG B-verb.change	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	concentrations NNS B-noun.cognition	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d116.s6	The DT 0	effect NN B-noun.cognition	of IN 0	rifampin NN B-noun.person	on IN 0	the DT 0	warfarin NN B-noun.location	requirement NN B-noun.person	of IN 0	our PRP$ 0	patient NN B-noun.person	appeared VBD B-verb.social	to TO 0	be VB B-verb.stative	maximal JJ B-adj.all	5 CD 0	to TO 0	7 CD B-adj.all	days NNS B-noun.act	after IN 0	the DT 0	initiation NN B-noun.act	of IN 0	rifampin NN B-noun.communication	and CC 0	extended VBD B-verb.change	a DT 0	similar JJ B-adj.all	length NN B-noun.person	of IN 0	time NN B-noun.time	after IN 0	rifampin JJ B-adj.all	withdrawal NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d440.s2	Ibandronate NNP B-noun.person	should MD 0	be VB 0	taken VBN B-verb.possession	at IN 0	least JJS 0	60 CD B-adj.all	minutes NNS B-noun.time	before IN 0	any DT 0	oral JJ B-adj.all	medications NNS B-noun.artifact	containing VBG B-verb.stative	multivalent JJ B-adj.all	cations NNS B-noun.person	( ( 0	including VBG B-verb.body	antacids NNS I-verb.body	, , 0	supplements NNS B-noun.artifact	or CC 0	vitamins NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d565.s34	The DT 0	elimination NN B-noun.person	half DT B-adj.all	life NN B-noun.cognition	of IN 0	midazolam NN B-noun.food	and CC 0	triazolam NN B-noun.person	also RB B-adv.all	increased VBD B-verb.change	( ( 0	1.5 CD 0	- : 0	2.5 CD 0	fold NN B-noun.quantity	) ) 0	during IN 0	coadministration NN B-noun.person	with IN 0	diltiazem NN B-noun.person	. . 0	. . 0
DDI-MedLine.d55.s0	Increased VBN B-verb.change	hepatotoxicity NN B-noun.attribute	of IN 0	acetaminophen NN B-noun.quantity	by IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	caffeine NN B-noun.person	in IN 0	the DT 0	rat NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d143.s32	Quinidine NNP B-noun.person	and CC 0	procainamide JJ B-adj.all	doses NNS B-noun.group	should MD 0	be VB 0	reduced VBN B-verb.change	by IN 0	one CD 0	- : 0	third JJ 0	when WRB 0	either CC 0	is VBZ 0	administered VBN B-verb.possession	with IN 0	amiodarone NN 0	. . 0	. . 0
DDI-MedLine.d44.s2	In IN 0	this DT 0	study NN B-noun.artifact	, , 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	etofibrate NN 0	upon IN 0	chylomicron NN B-noun.artifact	metabolism NN B-noun.artifact	was VBD 0	tested VBN B-verb.social	by IN 0	determination NN B-noun.cognition	of IN 0	the DT 0	plasma NN B-noun.plant	kinetics NNS B-noun.cognition	of IN 0	a DT 0	chylomicron NN B-noun.person	- : 0	like IN 0	emulsion NN B-noun.artifact	model NN B-noun.person	in IN 0	12 CD B-adj.all	patients NNS B-noun.person	with IN 0	coronary JJ B-adj.all	artery NN B-noun.artifact	disease NN I-noun.artifact	, , 0	aged VBN B-verb.consumption	59+/-11 CD 0	years NNS B-noun.time	, , 0	( ( 0	total JJ B-adj.all	cholesterol NN B-noun.act	, , 0	240+/-41 FW 0	mg FW 0	/ FW 0	dl FW 0	, , 0	triglycerides VBZ B-verb.social	, , 0	188+/-42 JJ 0	mg IN 0	/ : 0	dl LS 0	) ) 0	submitted VBN B-verb.cognition	to TO 0	a DT 0	randomized VBN B-verb.cognition	, , 0	crossover NN B-noun.person	, , 0	double RB 0	- : 0	blind NN B-noun.person	, , 0	placebo NN B-noun.person	- : 0	controlled VBN B-verb.social	study NN B-noun.artifact	with IN 0	administration NN B-noun.time	of IN 0	1 CD B-adj.all	g FW 0	per FW 0	day NN 0	etofibrate NN B-noun.state	or CC 0	placebo NN B-noun.substance	for IN 0	1-month JJ 0	. . 0	. . 0
DDI-DrugBank.d41.s15	Because IN 0	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	ARAVA NNP B-noun.group	levels NNS B-noun.attribute	to TO 0	continue VB B-verb.motion	to TO 0	increase VB B-verb.change	with IN 0	multiple JJ B-adj.all	dosing NN B-noun.act	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	if IN 0	patients NNS B-noun.person	are VBP 0	to TO 0	be VB 0	receiving VBG B-verb.perception	both DT 0	ARAVA NNP B-noun.group	and CC 0	rifampin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d462.s0	Aminoglycosides NNS B-noun.person	, , 0	The DT 0	mixing NN B-noun.act	of IN 0	piperacillin NN B-noun.food	with IN 0	an DT 0	aminoglycoside NN B-noun.food	in IN 0	vitro NN B-noun.animal	can MD 0	result VB B-verb.stative	in IN 0	substantial JJ B-adj.all	inactivation NN B-noun.act	of IN 0	the DT 0	aminoglycoside NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d314.s32	Routine JJ B-adj.all	administration NN B-noun.time	of IN 0	vaccines NNS B-noun.animal	or CC 0	toxoids NNS B-noun.communication	should MD 0	be VB 0	deferred VBN B-verb.stative	until IN 0	corticosteroid JJ B-adj.all	therapy NN B-noun.person	is VBZ 0	discontinued VBN B-verb.communication	if IN 0	possible JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d313.s1	The DT 0	following NN 0	are VBP B-verb.stative	examples NNS B-noun.cognition	of IN 0	substances NNS B-noun.artifact	that WDT 0	may MD 0	increase VB B-verb.change	the DT 0	blood NN B-noun.act	- : 0	glucose NN B-noun.person	- : 0	lowering VBG B-verb.motion	effect NN 0	and CC 0	susceptibility NN 0	to TO 0	hypoglycemia NN B-noun.person	, , 0	oral JJ B-adj.all	antidiabetic_products NNS B-noun.location	, , 0	ACE_inhibitors NNS B-noun.person	, , 0	disopyramide NN 0	, , 0	fibrates NNS B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	, , 0	propoxyphene NN B-noun.person	, , 0	salicylates NNS B-noun.person	, , 0	somatostatin_analog RB 0	( ( 0	e.g. UH 0	, , 0	octreotide NN 0	) ) 0	, , 0	sulfonamide_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d386.s26	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.act	and CC 0	tricyclic_antidepressants NNS B-noun.person	can MD 0	produce VB B-verb.cognition	clinically RB B-adv.all	significant JJ B-adj.all	increases NNS B-noun.event	in IN 0	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	the DT 0	tricyclic_antidepressants NNS B-noun.plant	. . 0	. . 0
DDI-DrugBank.d131.s1	The DT 0	steady JJ B-adj.all	state NN B-noun.state	plasma NN I-noun.state	concentrations NNS B-noun.cognition	of IN 0	imipramine NN B-noun.act	and CC 0	desipramine NN B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	be VB 0	increased VBN B-verb.change	an DT 0	average NN B-noun.act	of IN 0	31 CD 0	% NN 0	and CC 0	20 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	by IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	alprazolam NN B-noun.food	tablets NNS B-noun.artifact	in IN 0	doses NNS B-noun.quantity	up IN 0	to TO 0	4 CD 0	mg RB 0	/ JJ 0	day NN 0	. . 0	. . 0
DDI-MedLine.d82.s5	However RB 0	, , 0	total JJ B-adj.all	mucosal JJ B-adj.all	accumulation NN B-noun.act	of IN 0	As(V NNP B-noun.location	) ) 0	and CC 0	that IN 0	transferred VBN B-verb.social	to TO 0	the DT 0	body NN B-noun.object	increase NN I-noun.object	in IN 0	a DT 0	linear JJ B-adj.all	logarithmic JJ B-adj.all	fashion NN B-noun.event	from IN 0	0.05 CD 0	to TO 0	5 CD 0	mm IN 0	As(V NNP B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d460.s9	Diclofenac NNP B-noun.person	, , 0	Administration NNP B-noun.person	of IN 0	morning NN B-noun.act	and CC 0	lunch NN B-noun.body	doses NNS B-noun.event	of IN 0	Starlix NNP B-noun.communication	120 CD 0	mg NN B-noun.quantity	in IN 0	combination NN 0	with IN 0	a DT 0	single JJ B-adj.all	75-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	diclofenac NN B-noun.food	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	resulted VBD B-verb.social	in IN 0	no DT 0	significant JJ B-adj.all	changes NNS B-noun.relation	to TO 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	agent NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d413.s12	Thiazide_Diuretics NNS B-noun.artifact	, , 0	The DT 0	reports NNS B-noun.communication	that IN 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	allopurinol NN B-noun.animal	and CC 0	thiazide_diuretics NNS B-noun.person	may MD 0	contribute VB B-verb.cognition	to TO 0	the DT 0	enhancement NN B-noun.person	of IN 0	allopurinol NN B-noun.phenomenon	toxicity NN B-noun.attribute	in IN 0	some DT 0	patients NNS B-noun.person	have VBP 0	been VBN 0	reviewed VBN B-verb.change	in IN 0	an DT 0	attempt NN B-noun.act	to TO 0	establish VB B-verb.cognition	a DT 0	cause NN B-noun.act	- : 0	and CC 0	- : 0	effect NN B-noun.substance	relationship NN B-noun.relation	and CC 0	a DT 0	mechanism NN B-noun.object	of IN 0	causation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d367.s23	Sedatives NNS B-noun.person	and CC 0	tranquilizers NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	diazepam NN B-noun.person	) ) 0	. . 0	. . 0
DDI-DrugBank.d186.s1	A DT 0	causal NN B-adj.all	relationship NN B-noun.state	between IN 0	these DT 0	events NNS B-noun.event	and CC 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lithium NN B-noun.substance	and CC 0	HALDOL NNP B-noun.group	has VBZ 0	not RB 0	been VBN 0	established VBN B-verb.creation	, , 0	. . 0
DDI-MedLine.d12.s4	Higher JJR B-adj.all	concentrations NNS B-noun.attribute	of IN 0	dexamethasone NN 0	( ( 0	10(-8 JJ 0	) ) 0	; : 0	10(-6 LS 0	) ) 0	M NNP 0	) ) 0	or CC 0	retinyl_acetate JJ B-noun.other	( ( 0	3 CD B-adj.all	X NNP B-noun.other	10(-8 NNP I-noun.other	) ) 0	; : 0	10(-7 LS 0	) ) 0	M NNP 0	) ) 0	enhance VB B-verb.change	the DT 0	mitogenic JJ B-adj.pert	activity NN B-noun.state	of IN 0	EGF NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d95.s1	Ibuprofen NNP B-noun.person	; : 0	L SYM 0	- : 0	arginine NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	absorption NN B-noun.artifact	of IN 0	ibuprofen NNS B-noun.person	if IN 0	taken VBN 0	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d434.s21	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	similar JJ B-adj.all	changes NNS B-noun.phenomenon	in IN 0	carbamazepine NN 0	and CC 0	carbamazepine_epoxide NNP 0	were VBD 0	seen VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d529.s17	Patients NNS B-noun.person	receiving VBG B-verb.communication	flurbiprofen NN B-noun.person	and CC 0	furosemide NN B-noun.attribute	or CC 0	other JJ B-adj.all	diuretics NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	is VBZ 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d384.s10	However RB 0	, , 0	in IN 0	vivo JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.act	of IN 0	ketoconazole NN B-noun.shape	with IN 0	vitamin_D NNS B-noun.plant	have VBP 0	not RB 0	been VBN 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d135.s10	If IN 0	TYKERB NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	with IN 0	drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	Pgp NNP B-noun.person	, , 0	increased VBD B-verb.change	concentrations NNS B-noun.attribute	of IN 0	lapatinib NN B-noun.animal	are VBP B-verb.stative	likely JJ B-adj.all	, , 0	and CC 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d334.s18	Lithium NNP B-noun.person	, , 0	Lithium NNP B-noun.person	toxicity NN I-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	lithium NN I-verb.communication	concomitantly RB B-adv.all	with IN 0	drugs NNS B-noun.artifact	which WDT 0	cause VBP B-verb.communication	elimination NN B-noun.act	of IN 0	sodium NN B-noun.person	, , 0	including VBG B-verb.stative	ACE_inhibitors NNS I-verb.stative	. . 0	. . 0
DDI-DrugBank.d251.s0	Antiacid NNP B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	Didanosine NNP B-noun.person	, , 0	Fluconazole NNP B-noun.person	, , 0	Fluoxetine NNP B-noun.person	, , 0	Indanavir NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.person	, , 0	Phenytoin NNP B-noun.person	, , 0	Phenobarbitol NNP B-noun.person	, , 0	carbamazepine NN 0	, , 0	Rifabutin NNP B-noun.person	, , 0	Rifampin NNP B-noun.person	, , 0	Ritanovir NNP B-noun.person	, , 0	Saquinavir NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d512.s1	Effect NN 0	of IN 0	Sensipar NNP B-noun.person	on IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	Drugs NNS B-noun.person	metabolized VBN B-verb.social	by IN 0	cytochrome JJ B-noun.person	P450 JJ I-noun.person	2D6 NN I-noun.person	( ( I-noun.person	CYP2D6 NNP I-noun.person	) ) 0	, , 0	Sensipar NNP B-noun.person	_ ( 0	is VBZ B-verb.stative	a DT 0	strong JJ B-adj.all	in IN 0	vitro NN 0	inhibitor NN 0	of IN 0	CYP2D6 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d489.s5	Literature NN 0	reports NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	oral JJ B-adj.all	calcium_antagonists NNS B-noun.group	may MD 0	be VB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	beta JJ B-noun.body	- : 0	adrenergic_blocking_agents NNS B-noun.group	when WRB 0	heart NN 0	function NN B-noun.attribute	is VBZ B-verb.stative	normal JJ B-adj.all	, , 0	but CC 0	should MD 0	be VB 0	avoided VBN B-verb.social	in IN 0	patients NNS B-noun.person	with IN 0	impaired JJ B-adj.all	cardiac NN B-noun.artifact	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d334.s3	When WRB 0	a DT 0	diuretic JJ B-noun.person	is VBZ 0	added VBN B-verb.change	to TO 0	the DT 0	therapy NN B-noun.act	of IN 0	a DT 0	patient NN B-noun.person	receiving VBG B-verb.body	PRINIVIL NNP B-noun.group	, , 0	an DT 0	additional JJ B-adj.all	antihypertensive JJ B-adj.all	effect NN B-noun.phenomenon	is VBZ B-verb.stative	usually RB B-adv.all	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d562.s8	Quinolones NNS B-noun.communication	, , 0	including VBG B-verb.change	cinoxacin NN B-noun.food	, , 0	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	such JJ 0	as IN 0	warfarin NN B-noun.act	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d126.s7	Thus RB 0	, , 0	the DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	cypermethrin NN B-adj.all	exposure NN B-noun.cognition	of IN 0	rats NNS B-noun.animal	results NNS I-noun.animal	in IN 0	free JJ B-adj.all	radical JJ B-noun.substance	- : 0	mediated VBN B-verb.cognition	tissue NN 0	damage NN 0	, , 0	as IN 0	indicated VBN B-verb.communication	by IN 0	elevated JJ B-adj.all	cerebral NN B-noun.body	and CC 0	hepatic JJ B-adj.all	lipid NN B-noun.body	peroxidation NN I-noun.body	, , 0	which WDT 0	was VBD 0	prevented VBN B-verb.creation	by IN 0	allopurinol NN B-noun.person	and CC 0	Vitamin_E. NNP B-noun.person	. . 0
DDI-MedLine.d27.s0	[ IN 0	The DT 0	GABA NNP B-noun.other	- : 0	ergic JJ B-adj.all	system NN B-noun.body	and CC 0	brain NN B-noun.person	edema NN B-noun.person	] : 0	_ : 0	It PRP 0	has VBZ 0	been VBN 0	shown VBN B-verb.creation	in IN 0	rats NNS B-noun.animal	with IN 0	experimental JJ B-adj.all	toxic NN B-noun.attribute	and CC 0	traumatic JJ B-adj.all	edemas NNS B-noun.communication	that WDT 0	picrotoxin NN B-noun.state	( ( 0	1 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	removes VBZ B-verb.change	the DT 0	antiedematous JJ B-adj.all	action NN B-noun.state	of IN 0	diazepam NN B-noun.person	, , 0	phenazepam NN B-noun.person	, , 0	phenibut NN B-noun.person	and CC 0	amizyl NN B-noun.person	and CC 0	reduces VBZ B-verb.change	the DT 0	action NN B-noun.process	of IN 0	phentolamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s2	Monoamine_Oxidase_Inhibitors NNS B-noun.person	( ( 0	MAOIs NNP 0	) ) 0	. . 0
DDI-DrugBank.d3.s19	Psychoactive_Drugs NNS B-noun.artifact	, , 0	Hallucinations NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	TORADOL NNP B-noun.person	was VBD 0	used VBN B-verb.consumption	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	psychoactive_drugs NNS I-verb.social	( ( 0	fluoxetine NN B-noun.substance	, , 0	thiothixene NN B-noun.person	, , 0	alprazolam NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d132.s13	Since IN 0	acetaminophen NN B-noun.person	in IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	hepatotoxicity NN B-noun.attribute	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.state	and CC 0	acetaminophen NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	, , 0	with IN 0	careful JJ B-adj.all	monitoring NN B-noun.person	of IN 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d254.s2	Following VBG 0	the DT 0	administration NN B-noun.time	of IN 0	INAPSINE NNP B-noun.group	, , 0	the DT 0	dose NN B-noun.quantity	of IN 0	other JJ B-adj.all	CNS_depressant_drugs NNS B-noun.object	should MD 0	be VB 0	reduced VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d397.s12	In IN 0	addition NN 0	, , 0	deaths NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	rarely RB B-adv.all	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	terfenadine NN B-noun.artifact	and CC 0	erythromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d238.s24	Because IN 0	Anafranil NNP B-noun.person	is VBZ B-verb.stative	highly RB B-adv.all	bound VBN B-verb.communication	to TO 0	serum VB B-verb.social	protein NN B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	Anafranil NNP B-noun.person	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	highly RB B-adv.all	bound VBN B-verb.communication	to TO 0	protein VB B-verb.consumption	( ( 0	e.g. UH 0	, , 0	warfarin NN B-noun.location	, , 0	digoxin NN 0	) ) 0	may MD 0	cause VB B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	these DT 0	drugs NNS B-noun.artifact	, , 0	potentially RB B-adv.all	resulting VBG B-verb.stative	in IN 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d30.s4	Fluconazole NNP B-noun.person	, , 0	an DT 0	inhibitor NN B-noun.person	of IN 0	P450 JJ B-noun.artifact	2C9 NN I-noun.artifact	, , 0	decreased VBD B-verb.change	active JJ B-adj.all	metabolite NN B-noun.food	concentration NN B-noun.event	and CC 0	increased VBD B-verb.change	losartan JJ B-adj.all	concentration NN B-noun.event	. . 0	. . 0
DDI-MedLine.d97.s10	Recommendations NNS B-noun.person	were VBD 0	to TO 0	avoid VB B-verb.social	administration NN B-noun.act	of IN 0	diffusible JJ B-adj.all	anti NNS B-noun.person	- : 0	helminthic JJ B-adj.all	treatment NN B-noun.artifact	during IN 0	the DT 0	cure NN B-noun.communication	, , 0	and CC 0	to TO 0	improve VB B-verb.change	the DT 0	general JJ B-adj.all	conditions NNS B-noun.cognition	of IN 0	patients NNS B-noun.person	before IN 0	the DT 0	cure NN B-noun.communication	of IN 0	melarsoprol NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d414.s4	A DT 0	number NN B-noun.quantity	of IN 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.change	ethacrynic_acid JJ I-verb.change	, , 0	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	displace VB B-verb.social	warfarin NN B-noun.act	from IN 0	plasma NN B-noun.person	protein NN B-noun.person	, , 0	. . 0
DDI-MedLine.d86.s6	Apparent JJ B-adj.all	oral JJ B-adj.all	clearance NN B-noun.person	and CC 0	volume NN B-noun.attribute	of IN 0	distribution NN B-noun.act	of IN 0	sirolimus NN B-noun.attribute	decreased VBD B-verb.change	with IN 0	38 CD 0	% NN 0	and CC 0	45 CD 0	% NN 0	, , 0	respectively RB B-adv.all	, , 0	when WRB 0	sirolimus NN B-noun.person	was VBD 0	given VBN B-verb.possession	with IN 0	diltiazem NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d252.s0	Although IN 0	BETAGAN NNP B-noun.person	used VBD B-verb.consumption	alone RB 0	has VBZ B-verb.possession	little JJ B-noun.attribute	or CC 0	no DT 0	effect NN B-noun.cognition	on IN 0	pupil NN B-noun.artifact	size NN I-noun.artifact	, , 0	mydriasis NN 0	resulting VBG B-verb.stative	from IN 0	concomitant JJ B-adj.all	therapy NN B-noun.person	with IN 0	BETAGAN NNP B-noun.group	and CC 0	epinephrine NN B-noun.location	may MD 0	occur VB B-verb.stative	. . 0	. . 0
DDI-DrugBank.d209.s2	Compounds NNS B-noun.person	that WDT 0	have VBP 0	been VBN 0	tested VBN B-verb.social	in IN 0	man NN B-noun.animal	include VBP B-verb.change	antipyrine NN B-noun.attribute	, , 0	digoxin NN B-noun.person	, , 0	propranolol NN B-noun.person	, , 0	theophylline PRP 0	, , 0	and CC 0	warfarin NN B-noun.act	and CC 0	no DT 0	clinically RB B-adv.all	meaningful JJ B-adj.all	interactions NNS B-noun.artifact	were VBD 0	found VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d356.s5	Therefore RB 0	, , 0	when WRB 0	MIDAMOR NNP B-noun.group	and CC 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_agents NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	of IN 0	the DT 0	diuretic NN B-noun.person	is VBZ 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d529.s0	Antacids NNP B-noun.person	, , 0	Administration NNP B-noun.person	of IN 0	flurbiprofen NN B-noun.person	to TO 0	volunteers NNS B-noun.person	under IN 0	fasting NN B-verb.creation	conditions NNS I-verb.creation	, , 0	or CC 0	with IN 0	antacid JJ B-adj.all	suspension NN B-noun.person	yielded VBD B-verb.possession	similar JJ B-adj.all	serum NN B-noun.phenomenon	flurbiprofen JJ B-adj.all	time NN B-noun.possession	profiles NNS I-noun.possession	in IN 0	young JJ B-adj.all	subjects NNS B-noun.person	( ( 0	n=12 NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d415.s8	H-2 NN 0	Antagonists NNPS B-noun.person	, , 0	In IN 0	studies NNS B-noun.artifact	with IN 0	human JJ B-adj.all	volunteers NNS B-noun.person	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	cimetidine NN B-noun.act	or CC 0	ranitidine NN B-noun.substance	with IN 0	ibuprofen NNS B-noun.person	had VBD B-verb.social	no DT 0	substantive JJ B-adj.all	effect NN B-noun.cognition	on IN 0	ibuprofen JJ B-adj.all	serum NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d411.s13	Ketamine NNP B-noun.person	, , 0	Marked NNP B-noun.person	hypertension NN B-noun.feeling	and CC 0	tachycardia NNS B-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	association NN 0	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	levothyroxine_sodium NN B-noun.state	and CC 0	ketamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d163.s5	Although IN 0	other JJ 0	hormonal_contraceptives NNS B-noun.person	are VBP B-verb.stative	highly RB B-adv.all	effective JJ B-adj.all	, , 0	there EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	pregnancy NN B-noun.person	from IN 0	women NNS B-noun.person	who WP 0	have VBP 0	used VBN B-verb.consumption	combined_oral_contraceptives NNS I-verb.consumption	, , 0	as RB 0	well RB 0	as IN 0	topical JJ 0	/ CC 0	injectable JJ B-adj.all	/ CC 0	implantable JJ B-adj.all	/ CC 0	insertable JJ B-adj.all	hormonal JJ B-adj.all	birth NN 0	control NN B-noun.act	products NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d223.s2	Poor JJ B-adj.all	metabolizers NNS B-noun.person	have VBP 0	higher JJR 0	than IN 0	expected VBN B-verb.cognition	plasma NN 0	concentrations NNS 0	of IN 0	tricyclic_antidepressants NNS B-noun.person	( ( 0	TCAs NNP B-noun.other	) ) 0	when WRB 0	given VBN B-verb.possession	usual JJ B-adj.all	doses NNS B-noun.act	. . 0	. . 0
DDI-MedLine.d46.s15	Cisapride NNP B-noun.person	was VBD B-verb.stative	well RB 0	tolerated VBN 0	when WRB 0	administered VBN B-verb.perception	alone RB B-adv.all	or CC 0	with IN 0	fluoxetine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d131.s9	Data NNS B-noun.cognition	from IN 0	in IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	of IN 0	alprazolam NN B-noun.person	suggest VBP B-verb.communication	a DT 0	possible JJ B-adj.all	drug NN B-noun.artifact	interaction NN 0	with IN 0	alprazolam NN B-noun.food	for IN 0	the DT 0	following NN 0	, , 0	sertraline NN B-noun.person	and CC 0	paroxetine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d395.s4	Trough JJ B-adj.all	plasma NN B-noun.plant	enoxacin NN B-noun.body	levels NNS B-noun.state	were VBD 0	also RB B-adv.all	20 CD B-adj.all	% NN 0	higher JJR B-adj.all	when WRB 0	caffeine NN B-noun.person	and CC 0	enoxacin NN B-noun.person	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d162.s4	Cholestyramine NN B-noun.person	and CC 0	colestipol NN B-noun.act	resins NNS B-noun.artifact	, , 0	Absorption NNP B-noun.person	of IN 0	hydrochlorothiazide NN 0	is VBZ 0	impaired VBN B-verb.change	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	anionic_exchange_resins NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d165.s16	Cyclosporine NNP B-noun.person	, , 0	tacrolimus NN B-noun.person	and CC 0	digoxin NN B-noun.person	concentrations NNS B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.perception	at IN 0	the DT 0	initiation NN B-noun.act	of IN 0	Itraconazole NNP B-noun.person	therapy NN I-noun.person	and CC 0	frequently RB B-adv.all	thereafter RB 0	, , 0	and CC 0	the DT 0	dose NN B-noun.quantity	of IN 0	these DT 0	three CD 0	drug NN 0	products NNS 0	adjusted VBN B-verb.change	appropriately RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d426.s4	If IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	frovatriptan JJ 0	and CC 0	an DT 0	SSRI NNP B-noun.group	is VBZ B-verb.stative	clinically RB B-adv.all	warranted VBN B-verb.communication	, , 0	appropriate JJ B-adj.all	observation NN B-noun.act	of IN 0	the DT 0	patient NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d434.s2	The DT 0	net JJ B-adj.all	effect NN B-noun.cognition	of IN 0	these DT 0	interactions NNS B-noun.possession	is VBZ 0	summarized VBN B-verb.communication	in IN 0	the DT 0	following VBG 0	table NN B-noun.artifact	, , 0	AED NNP B-noun.group	AED NNP I-noun.group	Felbatol NNP I-noun.group	. . 0
DDI-MedLine.d80.s1	In IN 0	order NN 0	to TO 0	provide VB B-verb.communication	information NN B-noun.cognition	for IN 0	the DT 0	appropriate JJ B-adj.all	package NN B-noun.artifact	insert NN B-noun.artifact	labeling NN B-noun.act	of IN 0	progestin NN B-noun.person	- : 0	only_oral_contraceptives NNS B-noun.time	( ( 0	POC NNP 0	) ) 0	in IN 0	the DT 0	US NNP 0	, , 0	a DT 0	comprehensive JJ B-adj.all	review NN B-noun.act	was VBD 0	made VBN B-verb.social	of IN 0	norgestrel NN B-noun.substance	( ( 0	0.075 CD 0	mg NN B-noun.quantity	) ) 0	and CC 0	norethindrone NN B-noun.person	( ( 0	0.35 CD 0	mg NN B-noun.quantity	) ) 0	, , 0	with IN 0	the DT 0	clinical JJ B-adj.all	differences NNS B-noun.communication	indicated VBN B-verb.cognition	where WRB 0	applicable JJ B-adj.all	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d384.s0	Interactions NNS B-noun.person	for IN 0	vitamin_D_analogues NNS B-noun.time	( ( 0	Vitamin_D2 FW 0	, , 0	Vitamin_D3 NNP B-noun.person	, , 0	Calcitriol NNP B-noun.person	, , 0	and CC 0	Calcidiol NNP B-noun.location	) ) 0	, , 0	Cholestyramine NNP B-noun.person	, , 0	Cholestyramine NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	reduce VB B-verb.change	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	fat_soluble_vitamins NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d72.s0	Itraconazole NNP B-noun.person	decreases VBZ B-verb.change	busulfan JJ B-adj.all	clearance NN B-noun.person	by IN 0	up RB 0	to TO 0	25 CD B-adj.all	% NN 0	, , 0	and CC 0	may MD 0	produce VB B-verb.cognition	AUCs NNP B-noun.group	__ $ 0	1500 CD 0	_ CD 0	M NNP 0	min NN 0	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d29.s3	Drug NN 0	interaction NN 0	studies NNS B-noun.artifact	have VBP 0	shown VBN B-verb.cognition	that DT 0	esomeprazole NN B-noun.communication	does VBZ 0	not RB B-adv.all	have VB B-verb.change	any DT 0	clinically RB B-adj.all	significant JJ B-adj.all	interactions NNS B-noun.person	with IN 0	phenytoin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	quinidine NN B-noun.location	, , 0	clarithromycin NN B-noun.person	or CC 0	amoxicillin NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d331.s4	- : 0	Probenecid NN B-noun.person	, , 0	Pretreatment NNP B-noun.person	with IN 0	probenecid NN B-noun.person	reduces VBZ B-verb.contact	both DT 0	the DT 0	natriuresis NN B-noun.location	and CC 0	hyperreninemia NN 0	produced VBN B-verb.creation	by IN 0	bumetanide NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s13	However RB 0	, , 0	the DT 0	pharmacodynamics NNS B-noun.person	of IN 0	coadministration NN B-noun.person	of IN 0	zaleplon NN B-noun.person	and CC 0	promethazine NN B-noun.person	have VBP 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d135.s5	Acute NNP B-noun.person	dosing VBG B-verb.social	with IN 0	clozapine NN B-noun.person	failed VBD B-verb.social	to TO 0	alter VB B-verb.change	the DT 0	behavioral JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	PCP NNP B-noun.group	in IN 0	either CC 0	procedure VB B-verb.change	even RB B-adv.all	when WRB 0	tested VBN B-verb.communication	up RP 0	to TO 0	doses NNS B-noun.act	that WDT 0	produced VBD B-verb.perception	pharmacological JJ B-adj.pert	effects NNS B-noun.phenomenon	alone RB 0	. . 0	. . 0
DDI-DrugBank.d426.s1	Due JJ 0	to TO 0	a DT 0	theoretical JJ 0	risk NN 0	of IN 0	a DT 0	pharmacodynamic JJ B-adj.all	interaction NN B-noun.act	, , 0	use NN 0	of IN 0	ergotamine NN B-noun.person	- : 0	containing VBG B-verb.communication	or CC 0	ergot NN B-noun.person	- : 0	type_medications NNS B-noun.person	( ( 0	like IN 0	dihydroergotamine NN B-noun.person	or CC 0	methysergide NN B-noun.attribute	) ) 0	and CC 0	FROVA NNP 0	within IN 0	24 CD B-adj.all	hours NNS B-noun.time	of IN 0	each DT 0	other JJ 0	should MD 0	be VB 0	avoided VBN B-verb.social	( ( 0	see VB 0	_ RP 0	a DT 0	href= JJ B-noun.other	frova_od.htm#CI IN I-noun.other	CONTRAINDICATIONS NNP I-noun.other	) ) 0	. . 0	. . 0
DDI-DrugBank.d328.s13	Patients NNS B-noun.person	already RB B-adv.all	stabilized VBN B-verb.communication	on IN 0	valdecoxib NN B-noun.artifact	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	for IN 0	loss NN B-noun.process	of IN 0	symptom NN B-noun.communication	control NN B-noun.act	with IN 0	phenytoin NN B-noun.person	coadministration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d219.s11	Nevertheless RB B-adv.all	, , 0	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	as RB 0	well RB 0	as IN 0	postmarketing VBG B-verb.stative	observations NNS B-noun.act	have VBP 0	shown VBN B-verb.cognition	that IN 0	Lodine NNP B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d338.s6	Consequently RB B-adv.all	, , 0	estazolam NN B-noun.communication	should MD 0	be VB 0	avoided VBN B-verb.social	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	ketoconazole NN B-noun.person	and CC 0	itraconazole NN B-noun.artifact	, , 0	which WDT 0	are VBP B-verb.stative	very RB B-adv.all	potent JJ B-adj.all	inhibitors NNS B-noun.person	of IN 0	CYP3A. NNP B-noun.location	. . 0
DDI-DrugBank.d527.s1	The DT 0	following NN 0	are VBP B-verb.stative	examples NNS B-noun.cognition	of IN 0	substances NNS B-noun.artifact	that WDT 0	may MD 0	increase VB B-verb.change	the DT 0	blood NN B-noun.act	- : 0	glucose NN B-noun.person	- : 0	lowering VBG B-verb.motion	effect NN 0	and CC 0	susceptibility NN 0	to TO 0	hypoglycemia NN B-noun.person	, , 0	oral JJ B-adj.all	antidiabetes NNS B-noun.location	products NNS B-noun.person	, , 0	ACE_inhibitors NNS B-noun.person	, , 0	disopyramide NN 0	, , 0	fibrates NNS B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	MAO_inhibitors NNS B-noun.person	, , 0	propoxyphene NN B-noun.person	, , 0	salicylates NNS B-noun.person	, , 0	somatostatin_analog RB 0	( ( 0	e.g. UH 0	, , 0	octreotide NN 0	) ) 0	, , 0	sulfonamide_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d98.s11	Corticosteroids NNS B-noun.person	, , 0	A DT 0	relationship NN B-noun.state	of IN 0	functional JJ B-adj.all	antagonism NN B-noun.attribute	exists VBZ B-verb.stative	between IN 0	vitamin_D_analogues NNS B-noun.location	, , 0	which WDT 0	promote VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	, , 0	and CC 0	corticosteroids NNS B-noun.person	, , 0	which WDT 0	inhibit VBP B-verb.stative	calcium NN B-adj.all	absorption NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d509.s19	Carbamazepine NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	carbamazepine NN 0	( ( 0	200 CD 0	mg IN 0	BID NNP 0	) ) 0	, , 0	a DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inducer NN I-noun.person	, , 0	with IN 0	aripiprazole NN B-noun.cognition	( ( 0	30 CD 0	mg IN 0	QD NNP 0	) ) 0	resulted VBD B-verb.stative	in IN 0	an DT 0	approximate JJ B-adj.all	70 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	values NNS B-noun.attribute	of IN 0	both DT 0	aripiprazole NN B-noun.group	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	dehydro FW 0	- : 0	aripiprazole NN B-noun.group	. . 0	. . 0
DDI-MedLine.d132.s6	Limited JJ B-adj.all	comparative JJ B-adj.all	data NNS B-noun.cognition	in IN 0	patients NNS B-noun.person	with IN 0	high JJ B-adj.all	viral JJ B-noun.body	loads NNS I-noun.body	treated VBN B-verb.change	with IN 0	nevirapine- JJ B-noun.group	or CC 0	delavirdine NN B-noun.act	- : 0	based VBN B-verb.cognition	regimens NNS 0	currently RB B-adv.all	exist VBP B-verb.stative	. . 0	. . 0
DDI-DrugBank.d444.s0	The DT 0	use NN 0	of IN 0	FLUDARA NNP B-noun.group	FOR IN 0	INJECTION NN B-noun.act	in IN 0	combination NN 0	with IN 0	pentostatin NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.possession	due JJ 0	to TO 0	the DT 0	risk NN 0	of IN 0	severe JJ B-adj.all	pulmonary NN B-noun.artifact	toxicity NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d564.s4	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	vasopressor_drugs NNS B-noun.artifact	( ( 0	for IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	hypotension NN 0	related VBN B-verb.cognition	to TO 0	obstetric JJ B-adj.all	blocks NNS B-noun.event	) ) 0	and CC 0	ergot NN B-noun.person	- : 0	type_oxytocic_drugs NNS B-noun.object	may MD 0	cause VB B-verb.cognition	severe JJ 0	, , 0	persistent JJ B-adj.all	hypertension NN B-noun.feeling	or CC 0	cerebrovascular JJ B-adj.all	accidents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d314.s22	Ketoconazole NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.communication	the DT 0	metabolism NN B-noun.attribute	of IN 0	certain JJ B-adj.all	corticosteroids NNS B-noun.shape	by IN 0	up RB 0	to TO 0	60 CD B-adj.all	% NN 0	, , 0	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	risk NN 0	of IN 0	corticosteroid JJ B-adj.all	side NN B-noun.body	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d143.s59	There EX 0	have VBP 0	been VBN 0	reports NNS B-noun.communication	of IN 0	QTc NNP B-noun.person	prolongation NN I-noun.person	, , 0	with IN 0	or CC 0	without IN 0	TdP NNP 0	, , 0	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	amiodarone NN I-verb.social	when WRB 0	fluoroquinolones NNS B-noun.animal	, , 0	macrolide_antibiotics NNS B-noun.person	, , 0	or CC 0	azoles NNS B-noun.artifact	were VBD 0	administered VBN B-verb.perception	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d224.s2	Tricyclic_antidepressants NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	blunt VB B-verb.communication	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	systemic JJ B-adj.all	clonidine NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d172.s24	However RB 0	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	administering VBG B-verb.creation	CELEBREX NNP I-verb.creation	with IN 0	warfarin NN 0	since IN 0	these DT 0	patients NNS B-noun.person	are VBP B-verb.stative	at IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding VBG B-verb.body	complications NNS I-verb.body	. . 0	. . 0
DDI-MedLine.d110.s14	While IN 0	18-MC NNP B-noun.person	and CC 0	ibogaine NN B-noun.person	have VBP B-verb.change	similar JJ B-adj.all	affinities NNS B-noun.food	for IN 0	kappa NN B-noun.person	opioid NN B-noun.person	and CC 0	possibly RB B-adj.all	nicotinic JJ B-adj.pert	receptors NNS B-noun.person	, , 0	18-MC WDT 0	has VBZ B-verb.possession	much RB 0	lower JJR B-adj.all	affinities NNS B-noun.communication	than IN 0	ibogaine NN B-noun.person	for IN 0	NMDA NNP B-noun.group	and CC 0	sigma-2 JJ B-adj.all	receptors NNS B-noun.person	, , 0	sodium NN B-noun.artifact	channels NNS B-noun.artifact	, , 0	and CC 0	the DT 0	5-HT JJ B-noun.artifact	transporter NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d416.s3	Therefore RB 0	, , 0	patients NNS B-noun.person	receiving VBG B-verb.communication	probenecid NN B-noun.person	will MD 0	have VB 0	erroneously RB B-adv.all	low JJ B-adj.all	ERPF NNP B-noun.person	and CC 0	Tm NNP B-noun.person	PAH NNP I-noun.person	values NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d560.s1	If IN 0	you PRP 0	are VBP 0	also RB B-adv.all	using VBG B-verb.consumption	a DT 0	steroid JJ B-adj.all	inhaler NN B-noun.person	, , 0	take VBP B-verb.cognition	bitolterol JJ B-noun.act	first JJ I-noun.act	and CC 0	then RB B-adv.all	wait VB B-verb.cognition	about IN 0	15 CD B-adj.all	minutes NNS B-noun.time	before IN 0	using VBG B-verb.consumption	the DT 0	steroid JJ B-adj.all	inhaler NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s39	- : 0	Methyldopa NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Aldomet NNP B-noun.location	) ) 0	Use NNP 0	of IN 0	methyldopa NN B-noun.food	with IN 0	sulfapyridine NN 0	may MD 0	increase VB B-verb.change	the DT 0	chance NN B-noun.act	of IN 0	side JJ B-adj.all	effects NNS B-noun.phenomenon	affecting VBG B-verb.change	the DT 0	liver NN B-noun.possession	and/or CC 0	the DT 0	blood NN B-noun.location	. . 0
DDI-DrugBank.d103.s10	It PRP 0	is VBZ B-verb.stative	important JJ B-adj.all	that IN 0	patients NNS B-noun.person	understand VBP B-verb.cognition	how WRB 0	to TO 0	use VB B-verb.consumption	FORADIL NNP B-noun.group	_ . 0	( ( 0	formoterol_fumarate JJ 0	) ) 0	capsules NNS B-noun.quantity	with IN 0	the DT 0	supplied VBN B-adj.all	AerolizerTM JJ B-noun.phenomenon	inhalation NN I-noun.phenomenon	device NN B-noun.person	and CC 0	how WRB 0	it PRP 0	should MD 0	be VB 0	used VBN B-verb.consumption	in IN 0	relation NN 0	to TO 0	other JJ 0	asthma NN B-noun.attribute	or CC 0	COPD NNP B-noun.group	medications NNS B-noun.artifact	they PRP 0	are VBP 0	taking VBG 0	. . 0	. . 0
DDI-DrugBank.d97.s26	Combinations NNS B-noun.person	of IN 0	these DT 0	drugs NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	and CC 0	coadministration NN B-noun.person	of IN 0	CRIXIVAN NNP B-noun.group	and CC 0	atazanavir NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d60.s3	During IN 0	phenytoin NN B-noun.person	and CC 0	fluvoxamine JJ B-adj.all	treatment NN B-noun.plant	, , 0	ataxia NN B-noun.location	, , 0	a DT 0	typical JJ B-adj.all	side NN 0	effect NN 0	of IN 0	phenytoin NN B-noun.food	, , 0	was VBD 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d328.s10	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	post NN B-noun.person	- : 0	marketing NN B-noun.act	observations NNS B-noun.act	, , 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d216.s16	Warfarin NNP B-noun.person	, , 0	Eszopiclone NNP B-noun.communication	3 CD B-adj.all	mg NN B-noun.quantity	administered VBN B-verb.possession	daily RB B-adv.all	for IN 0	5 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of_(R)- JJ I-noun.person	or CC 0	( ( 0	S)-warfarin NN 0	, , 0	nor CC 0	were VBD 0	there EX 0	any DT 0	changes NNS B-noun.possession	in IN 0	the DT 0	pharmacodynamic JJ B-adj.all	profile NN B-noun.person	( ( 0	prothrombin NN B-noun.person	time NN 0	) ) 0	following VBG B-verb.stative	a DT 0	single JJ 0	25 CD 0	mg IN 0	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	warfarin NN B-noun.act	. . 0
DDI-DrugBank.d257.s0	Interactions NNS B-noun.person	with IN 0	Other JJ 0	CNS NNP B-noun.group	Agents NNPS I-noun.group	, , 0	Concurrent JJ 0	use NN 0	of IN 0	Levo NNP B-noun.person	- : 0	Dromoran NN B-noun.person	with IN 0	all DT 0	central_nervous_system_depressants NNS B-noun.location	( ( 0	eg UH 0	, , 0	alcohol NN B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	hypnotics NNS B-noun.person	, , 0	other JJ 0	opioids NNS B-noun.person	, , 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	tranquilizers NNS B-noun.person	, , 0	skeletal_muscle_relaxants NNS B-noun.person	and CC 0	antihistamines NNS B-noun.attribute	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	additive JJ B-adj.all	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.cognition	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d76.s24	Moreover RB B-adv.all	, , 0	as IN 0	noted VBN B-verb.perception	with IN 0	alprazolam NN B-noun.person	, , 0	the DT 0	effect NN B-noun.cognition	of IN 0	fluvoxamine NN B-noun.phenomenon	may MD 0	even RB 0	be VB B-verb.stative	more RBR B-adv.all	pronounced JJ B-adj.all	when WRB 0	it PRP 0	is VBZ 0	administered VBN B-verb.possession	at IN 0	higher JJR B-adj.all	doses NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d170.s2	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	transdermal JJ B-adj.all	fentanyl NN B-noun.feeling	with IN 0	ritonavir NN B-noun.person	or CC 0	other JJ B-adj.all	potent JJ B-noun.person	3A4 CD I-noun.person	inhibitors NNS I-noun.person	such JJ 0	as IN 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	troleandomycin NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	nelfinavir NN B-noun.person	, , 0	and CC 0	nefazadone NN 0	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	fentanyl NN 0	plasma NN 0	concentrations NNS 0	. . 0	. . 0
DDI-MedLine.d67.s0	Effect NN 0	of IN 0	diazepam NN B-noun.person	and CC 0	midazolam NN B-noun.body	on IN 0	the DT 0	antinociceptive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	morphine NN B-noun.person	, , 0	metamizol NN B-noun.person	and CC 0	indomethacin NN B-noun.act	in IN 0	mice NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d238.s2	Anafranil NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	with IN 0	MAO_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d249.s1	Anticoagulants NNS B-noun.person	, , 0	While IN 0	studies NNS B-noun.communication	have VBP 0	not RB B-adv.all	shown VBN B-verb.perception	diclofenac NN I-verb.perception	to TO 0	interact VB B-verb.contact	with IN 0	anticoagulants_of_the_warfarin_type JJ B-noun.attribute	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	exercised VBN B-verb.body	, , 0	nonetheless RB 0	, , 0	since IN 0	interactions NNS B-noun.act	have VBP 0	been VBN 0	seen VBN B-verb.perception	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d114.s8	Myocardial JJ B-adj.all	injury NN B-noun.event	, , 0	including VBG B-verb.change	myocardial JJ B-adj.all	infarction NN B-noun.cognition	, , 0	myocarditis NN B-noun.location	, , 0	ventricular JJ B-adj.all	hypokinesia NN B-noun.location	, , 0	and CC 0	severe JJ B-adj.all	rhabdomyolysis NN B-noun.state	appear VBP B-verb.change	to TO 0	be VB 0	increased VBN B-verb.change	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	PROLEUKIN NNP B-noun.person	and CC 0	interferon NN B-noun.person	- : 0	alfa NN B-noun.person	concurrently RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d500.s6	Concurrent JJ B-adj.all	use NN 0	of IN 0	tetracycline NN B-noun.phenomenon	may MD 0	render VB B-verb.possession	oral JJ B-adj.all	contraceptives NNS B-noun.event	less RBR B-adv.all	effective JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d367.s4	In IN 0	a DT 0	placebo NN B-noun.person	- : 0	controlled VBN B-verb.social	trial NN B-noun.act	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	single JJ B-adj.all	1 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	doxazosin NN B-noun.person	on IN 0	day NN 0	1 CD 0	of IN 0	a DT 0	four CD 0	- : 0	day NN B-noun.person	regimen NNS B-noun.person	of IN 0	oral JJ B-adj.all	cimetidine NN B-noun.person	( ( 0	400 CD 0	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	resulted VBD B-verb.stative	in IN 0	a DT 0	10 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	AUC NNP B-noun.group	of IN 0	doxazosin NN B-noun.substance	( ( 0	p=0.006 NNP 0	) ) 0	, , 0	and CC 0	a DT 0	slight JJ B-adj.all	but CC 0	not RB B-adv.all	statistically RB B-adv.all	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	mean JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	mean JJ B-adj.all	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	doxazosin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d76.s20	Because IN 0	fluvoxamine NN B-noun.phenomenon	reduces VBZ B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	both DT 0	diazepam NN B-noun.person	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.food	, , 0	N NNP 0	- : 0	desmethyldiazepam NN B-noun.person	, , 0	there EX 0	is VBZ B-verb.stative	a DT 0	strong JJ B-adj.all	likelihood NN B-noun.act	of IN 0	substantial JJ B-adj.all	accumulation NN B-noun.act	of IN 0	both DT 0	species NNS B-noun.artifact	during IN 0	chronic NN B-noun.cognition	co SYM 0	- : 0	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d18.s0	Tablets NNS B-noun.artifact	, , 0	The DT 0	benzodiazepines NNS B-noun.artifact	, , 0	including VBG B-verb.change	lorazepam NN I-verb.change	, , 0	produce VBP B-verb.stative	CNS NNS I-verb.stative	- : 0	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	when WRB 0	administered VBN B-verb.possession	with IN 0	such JJ B-adj.all	medications NNS B-noun.communication	as IN 0	barbiturates NNS B-noun.event	or CC 0	alcohol NN B-noun.possession	. . 0	. . 0
DDI-DrugBank.d368.s6	Acetazolamide NNP B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	other JJ B-adj.all	folic_acid_antagonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d476.s1	Patients NNS B-noun.person	receiving VBG B-verb.communication	catecholamine NN B-noun.person	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.person	, , 0	such JJ 0	as IN 0	reserpine NN B-noun.act	or CC 0	guanethidine NN B-noun.location	, , 0	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	, , 0	because IN 0	the DT 0	added VBN B-verb.change	beta NN 0	- : 0	adrenergic JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	ZEBETA NNP B-noun.group	may MD 0	produce VB B-verb.cognition	excessive JJ B-adj.all	reduction NN B-noun.process	of IN 0	sympathetic JJ B-adj.all	activity NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d203.s2	Compounds NNS B-noun.person	tested VBN B-verb.social	in IN 0	man NN B-noun.animal	include VBP B-verb.change	warfarin NN B-noun.act	, , 0	theophylline PRP 0	, , 0	phenytoin NN B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	aminopyrine NN B-noun.person	and CC 0	antipyrine NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d314.s15	Digitalis_glycosides NNS B-noun.artifact	, , 0	Patients NNPS B-noun.person	on IN 0	digitalis_glycosides NNS B-noun.location	may MD 0	be VB B-verb.stative	at IN 0	increased VBN B-verb.change	risk NN 0	of IN 0	arrhythmias NNS 0	due JJ 0	to TO 0	hypokalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d350.s9	There EX 0	were VBD B-verb.stative	transient JJ B-adj.all	increases NNS B-noun.event	in IN 0	liver NN B-noun.animal	ALT NNP B-noun.group	and CC 0	AST NNP 0	when WRB 0	CANCIDAS NNP B-noun.group	and CC 0	cyclosporine NN B-noun.person	were VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d526.s1	Amphotericin_B JJ B-noun.possession	or CC 0	potassium NN B-noun.person	- : 0	depleting_diuretics NNS B-noun.person	( ( 0	benzothiadiazines NNS B-noun.person	and CC 0	related VBN B-verb.contact	drugs NNS B-noun.artifact	, , 0	ethacrynic_acid JJ 0	and CC 0	furosemide NN B-noun.artifact	) ) 0	enhanced VBN B-verb.change	hypokalemia NN I-verb.change	. . 0	. . 0
DDI-DrugBank.d529.s2	Anticoagulants NNS B-noun.person	, , 0	Flurbiprofen NNP B-noun.person	like IN 0	other JJ 0	nonsteroidal_anti JJ 0	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	affect VB B-verb.change	bleeding VBG B-verb.body	parameters NNS B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	anti NNS B-noun.person	- : 0	coagulants NNS B-noun.person	, , 0	and CC 0	serious JJ B-adj.all	clinical JJ B-adj.all	bleeding NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d339.s2	Warfarin NNP B-noun.person	and CC 0	Anticoagulants NNPS B-noun.person	, , 0	Increased VBD B-verb.change	prothrombin NN B-adj.all	time NN B-noun.time	, , 0	with IN 0	or CC 0	without IN 0	clinical JJ B-adj.all	bleeding NN B-noun.act	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	when WRB 0	cefixime NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d258.s4	Plasma NNP B-noun.person	concentrations NNS I-noun.person	( ( 0	AUC NNP B-noun.group	0 CD B-noun.quantity	- : 0	24 CD B-adj.all	hrs NNS B-noun.artifact	) ) 0	of IN 0	erythromycin NN B-noun.person	decreased VBD B-verb.change	15 CD B-adj.all	% NN 0	with IN 0	coadministration NN B-noun.person	of IN 0	loratadine NN 0	relative JJ 0	to TO 0	that DT 0	observed VBN B-verb.perception	with IN 0	erythromycin NN 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d283.s4	Resins NNS B-noun.person	, , 0	Since IN 0	bile_acid_sequestrants NNS B-noun.group	may MD 0	bind VB B-verb.social	other JJ 0	drugs NNS B-noun.person	given VBN B-verb.possession	concurrently RB B-adv.all	, , 0	patients NNS B-noun.person	should MD 0	take VB B-verb.motion	TRICOR NNP 0	at IN 0	least JJS 0	1 CD B-adj.all	hour NN 0	before IN 0	or CC 0	4 CD B-adj.all	- : 0	6 CD B-adj.all	hours NNS B-noun.time	after IN 0	a DT 0	bile_acid_binding_resin NN B-noun.communication	to TO 0	avoid VB B-verb.social	impeding VBG B-verb.change	its PRP$ 0	absorption NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d115.s4	Co SYM 0	- : 0	medications NNS B-noun.communication	that WDT 0	induce VBP B-verb.cognition	CYP3A4 NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	dexamethasone NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	rifampin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	or CC 0	St. NNP B-noun.location	. . 0
DDI-MedLine.d46.s1	STUDY NNP B-noun.group	OBJECTIVE NNP I-noun.group	, , 0	To TO 0	evaluate VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	fluoxetine NN B-noun.person	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	and CC 0	cardiovascular JJ B-adj.all	safety NN B-noun.artifact	of IN 0	cisapride NN 0	at IN 0	steady JJ B-adj.all	state NN B-noun.state	in IN 0	healthy JJ B-adj.all	men NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d516.s24	Warfarin NNP B-noun.person	, , 0	Quinolones NNPS 0	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	oral JJ B-adj.all	anticoagulant NN B-noun.attribute	, , 0	warfarin NN B-noun.location	, , 0	or CC 0	its PRP$ 0	derivatives NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d117.s0	Concomitant JJ B-adj.all	use NN 0	with IN 0	iron_supplements NNS B-noun.person	may MD 0	result VB B-verb.stative	in IN 0	the DT 0	reduced JJ B-adj.all	absorption NN B-noun.process	of IN 0	iron NN B-noun.person	. . 0	. . 0
DDI-MedLine.d84.s4	The DT 0	antimicrobial JJ B-adj.all	combinations NNS B-noun.person	of IN 0	GL NNP 0	with IN 0	four CD 0	antibiotics NNS B-noun.person	resulted VBD B-verb.communication	in IN 0	additive JJ B-adj.all	effect NN B-noun.cognition	in IN 0	most JJS 0	instances NNS B-noun.location	, , 0	synergism NN B-noun.artifact	in IN 0	two CD 0	instances NNS B-noun.person	, , 0	and CC 0	antagonism NN B-noun.attribute	in IN 0	two CD 0	instances NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d234.s4	Although IN 0	ROMAZICON NNP B-noun.group	exerts VBZ B-verb.social	a DT 0	slight JJ B-adj.all	intrinsic JJ B-adj.all	anticonvulsant JJ B-adj.all	effect NN B-noun.cognition	, , 0	its PRP$ 0	abrupt JJ B-noun.event	suppression NN I-noun.event	of IN 0	the DT 0	protective JJ B-adj.all	effect NN B-noun.cognition	of IN 0	a DT 0	benzodiazepine NN B-noun.person	agonist NN B-noun.person	can MD 0	give VB B-verb.creation	rise VB I-verb.creation	to TO 0	convulsions NNS B-noun.person	in IN 0	epileptic JJ B-adj.all	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d519.s3	Laboratory NNP B-noun.group	Tests NNPS I-noun.group	Response NNP I-noun.group	to TO 0	Plenaxis NNP B-noun.location	should MD 0	be VB 0	monitored VBN B-verb.perception	by IN 0	measuring VBG B-verb.cognition	serum NN 0	total JJ B-adj.all	testosterone NN 0	concentrations NNS B-noun.artifact	just RB B-adv.all	prior RB 0	to TO 0	administration NN B-noun.person	on IN 0	Day NNP 0	29 CD 0	and CC 0	every DT 0	8 CD B-adj.all	weeks NNS B-noun.time	thereafter RB 0	. . 0	. . 0
DDI-DrugBank.d207.s7	Drugs NNS B-noun.artifact	that WDT 0	cause VBP B-verb.creation	significant JJ B-adj.all	sustained JJ B-adj.all	elevation NN B-noun.person	in IN 0	gastric JJ B-adj.all	pH NN B-noun.attribute	( ( 0	histamine_H2-receptor_antagonists NNS B-noun.person	such JJ 0	as IN 0	ranitidine NN B-noun.person	or CC 0	cimetidine NN B-noun.location	) ) 0	may MD 0	reduce VB B-verb.change	plasma NN B-noun.food	concentrations NNS B-noun.attribute	of IN 0	IRESSA NNP B-noun.person	and CC 0	therefore RB B-adv.all	potentially RB I-adv.all	may MD 0	reduce VB B-verb.change	efficacy NN B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d94.s16	Additionally RB B-adv.all	, , 0	anti NNS B-noun.person	- : 0	malarial_drugs NNS B-noun.person	, , 0	such JJ 0	as IN 0	chloroquine NN 0	and CC 0	mefloquine NN B-noun.person	, , 0	may MD 0	antagonize VB B-verb.cognition	the DT 0	activity NN B-noun.process	of IN 0	carbamazepine NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d163.s13	No DT 0	formal JJ B-adj.all	clinical JJ B-adj.all	studies NNS B-noun.group	have VBP 0	been VBN 0	conducted VBN B-verb.social	to TO 0	assess VB B-verb.communication	if IN 0	there EX 0	is VBZ B-verb.stative	an DT 0	interactive JJ B-adj.all	effect NN B-noun.cognition	on IN 0	bone NN 0	loss NN B-noun.process	between IN 0	phenytoin NN B-noun.person	and CC 0	Accutane NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d357.s0	5HT3_Antagonists NNS B-noun.person	, , 0	Based VBN B-verb.cognition	on IN 0	reports NNS B-noun.artifact	of IN 0	profound JJ B-adj.all	hypotension NN B-noun.act	and CC 0	loss NN B-noun.process	of IN 0	consciousness NN B-noun.feeling	when WRB 0	apomorphine NN B-noun.person	was VBD 0	administered VBN B-verb.possession	with IN 0	ondansetron NN B-noun.person	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	apomorphine NN B-noun.person	with IN 0	drugs NNS B-noun.artifact	of IN 0	the DT 0	5HT3_antagonist_class NNP B-noun.other	( ( 0	including VBG B-verb.change	, , 0	for IN 0	example NN B-noun.person	, , 0	ondansetron NN B-noun.person	, , 0	granisetron NN B-noun.person	, , 0	dolasetron NN B-noun.person	, , 0	palonosetron NN B-noun.person	, , 0	and CC 0	alosetron RB 0	) ) 0	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d162.s5	Single JJ B-adj.all	doses NNS B-noun.event	of IN 0	either DT 0	cholestyramine NN B-noun.location	or CC 0	colestipol NN B-noun.person	resins NNS I-noun.person	bind VBP B-verb.social	the DT 0	hydrochlorothiazide NN B-noun.artifact	and CC 0	reduce VB B-verb.change	its PRP$ 0	absorption NN B-noun.act	from IN 0	the DT 0	gastrointestinal JJ B-adj.all	tract NN B-noun.body	by IN 0	up RB 0	to TO 0	85 CD 0	and CC 0	43 CD B-adj.all	percent NN B-noun.person	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d289.s21	Bosentan NNP B-noun.person	is VBZ B-verb.stative	also RB B-adv.all	expected VBN B-verb.cognition	to TO 0	reduce VB B-verb.change	plasma NN B-noun.food	concentrations NNS B-noun.attribute	of IN 0	other JJ 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	that WDT 0	are VBP B-verb.stative	predominantly RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	CYP2C9 CD 0	or CC 0	CYP3A4 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s7	In IN 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	, , 0	bleeding NN B-verb.body	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	on IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	anticoagulants NNS B-noun.person	and CC 0	INDOCIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d416.s2	Probenecid NNP B-noun.person	depresses VBZ B-verb.change	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	certain JJ B-adj.all	weak JJ B-adj.all	acids NNS B-noun.substance	such JJ 0	as IN 0	PAH NNP 0	. . 0	. . 0
DDI-DrugBank.d328.s4	Aspirin NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	aspirin NN B-noun.person	with IN 0	valdecoxib NN B-noun.artifact	may MD 0	result VB B-verb.stative	in IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	GI NNP 0	ulceration NN 0	and CC 0	complications NNS B-noun.person	compared VBN B-verb.cognition	to TO 0	valdecoxib VB B-verb.stative	alone RB I-verb.stative	. . 0	. . 0
DDI-DrugBank.d3.s3	In IN 0	vitro NN B-noun.animal	studies NNS I-noun.animal	indicate VBP B-verb.cognition	that IN 0	, , 0	at IN 0	therapeutic JJ B-adj.all	concentrations NNS B-noun.attribute	of IN 0	salicylate NN B-noun.substance	( ( 0	300 CD 0	m NN B-noun.quantity	g IN 0	/ : 0	mL LS 0	) ) 0	, , 0	the DT 0	binding NN B-noun.act	of IN 0	ketorolac NN B-noun.person	was VBD 0	reduced VBN B-verb.change	from IN 0	approximately RB B-adv.all	99.2 CD 0	% NN 0	to TO 0	97.5 CD 0	% NN 0	, , 0	representing VBG B-verb.social	a DT 0	potential JJ B-adj.all	twofold JJ B-adj.all	increase NN B-noun.act	in IN 0	unbound JJ B-adj.all	ketorolac NN B-noun.artifact	plasma NN B-noun.substance	levels NNS B-noun.state	. . 0	. . 0
DDI-MedLine.d124.s10	It PRP 0	was VBD 0	concluded VBN B-verb.cognition	that IN 0	oral JJ B-adj.all	oxycodone NN B-noun.person	and CC 0	levofloxacin NN B-noun.state	can MD 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	without IN 0	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	AUC NNP 0	, , 0	Cmax NNP B-noun.person	, , 0	or CC 0	tmax NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d224.s1	Although IN 0	no DT 0	specific JJ B-adj.all	drug NN B-noun.act	interactions NNS I-noun.act	with IN 0	topical JJ B-adj.all	glaucoma NN B-noun.artifact	drugs NNS B-noun.artifact	or CC 0	systemic JJ B-adj.all	medications NNS B-noun.person	were VBD 0	identified VBN B-verb.cognition	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.group	of IN 0	IOPIDINE NNP B-noun.group	0.5 CD 0	% NN 0	Ophthalmic NNP B-noun.location	Solution NNP I-noun.location	, , 0	the DT 0	possibility NN B-noun.state	of IN 0	an DT 0	additive JJ B-adj.all	or CC 0	potentiating VBG B-verb.motion	effect NN 0	with IN 0	CNS_depressants NNS B-noun.person	( ( 0	alcohol NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	opiates NNS B-noun.person	, , 0	sedatives NNS B-noun.person	, , 0	anesthetics NNS B-noun.location	) ) 0	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d310.s4	This DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	mediated VBN B-verb.cognition	by IN 0	the DT 0	known VBN B-adj.all	inhibition NN B-noun.attribute	of IN 0	hepatic JJ B-adj.all	cytochrome NN B-noun.event	P- $ 0	450 CD 0	by IN 0	cimetidine NN B-noun.person	, , 0	which WDT 0	could MD 0	decrease VB B-verb.cognition	first JJ B-adj.all	pass NN B-noun.communication	metabolism NN B-noun.attribute	of IN 0	nimodipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d394.s0	The DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	sodium_nitroprusside NN 0	is VBZ 0	augmented VBN B-verb.change	by IN 0	that DT 0	of IN 0	most JJS 0	other JJ 0	hypotensive_drugs NNS 0	, , 0	including VBG B-verb.stative	ganglionic_blocking_agents NNS I-verb.stative	, , 0	negative JJ B-adj.all	inotropic JJ B-adj.all	agents NNS B-noun.person	, , 0	and CC 0	inhaled JJ B-adj.all	anesthetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s17	This DT 0	interaction NN B-noun.act	, , 0	which WDT 0	has VBZ 0	not RB 0	been VBN 0	investigated VBN B-verb.contact	using VBG B-verb.consumption	higher JJR B-adj.all	doses NNS B-noun.person	of IN 0	fluvoxamine NN B-noun.substance	, , 0	may MD 0	be VB B-verb.stative	more RBR B-adv.all	pronounced JJ B-adj.all	if IN 0	a DT 0	300 CD 0	mg NN B-noun.quantity	daily JJ 0	dose NN 0	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	, , 0	particularly RB B-adv.all	since IN 0	fluvoxamine NN B-noun.state	exhibits VBZ B-verb.stative	non RB I-verb.stative	- : 0	linear NN B-noun.person	pharmacokinetics NNS B-noun.person	over IN 0	the DT 0	dosage NN B-noun.artifact	range NN B-noun.artifact	100 CD 0	- : 0	300 CD 0	mg NN B-noun.quantity	. . 0	If IN 0	alprazolam NN B-noun.person	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	Fluvoxamine NNP B-noun.person	Tablets NNPS I-noun.person	, , 0	the DT 0	initial JJ B-adj.all	alprazolam NN B-noun.artifact	dosage NN B-noun.artifact	should MD 0	be VB B-verb.stative	at IN 0	least JJS 0	halved JJ B-adj.all	and CC 0	titration NN 0	to TO 0	the DT 0	lowest JJS B-adj.all	effective JJ B-noun.phenomenon	dose NN I-noun.phenomenon	is VBZ 0	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d75.s10	It PRP 0	is VBZ 0	known VBN B-verb.cognition	that IN 0	CYP1A2 NNP B-noun.person	is VBZ 0	inhibited VBN B-verb.change	by IN 0	several JJ B-adj.all	medicinal JJ B-adj.all	products NNS B-noun.person	, , 0	including VBG B-verb.change	fluvoxamine NN B-noun.substance	, , 0	and CC 0	such JJ B-adj.all	medicinal JJ B-adj.all	products NNS B-noun.person	could MD 0	theoretically RB B-adv.all	adversely RB B-adv.all	influence VB B-verb.communication	the DT 0	clearance NN B-noun.act	of IN 0	anagrelide NN 0	. . 0	. . 0
DDI-DrugBank.d57.s0	In IN 0	vitro NN 0	mixing NN 0	of IN 0	an DT 0	aminoglycoside NN 0	with IN 0	beta JJ B-noun.body	- : 0	lactamtype NN B-noun.person	antibiotics NNS B-noun.person	( ( 0	penicillins NNS B-noun.person	or CC 0	cephalosporins NNS B-noun.artifact	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	a DT 0	significant JJ B-adj.all	mutual JJ B-noun.relation	inactivation NN I-noun.relation	. . 0	. . 0
DDI-DrugBank.d550.s1	Although IN 0	the DT 0	clinical JJ B-adj.all	significance NN B-noun.communication	is VBZ B-verb.stative	not RB B-adj.all	known VBN I-adj.all	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	that IN 0	cefditoren_pivoxil NNP 0	be VB 0	taken VBN B-verb.cognition	concomitantly RB B-adv.all	with IN 0	antacids NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d529.s10	Flurbiprofen NNP B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	either DT 0	drug NN B-noun.person	, , 0	and CC 0	the DT 0	mechanism NN B-noun.artifact	under IN 0	lying VBG B-verb.stative	the DT 0	interference NN B-noun.act	with IN 0	propranolols NNS B-noun.artifact	hypotensive JJ 0	effect NN 0	is VBZ B-verb.stative	unknown JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d165.s19	The DT 0	physician NN B-noun.communication	is VBZ 0	advised VBN B-verb.communication	to TO 0	monitor VB B-verb.perception	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	itraconazole NN B-noun.group	when WRB 0	any DT 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	is VBZ 0	taken VBN 0	concurrently RB B-adv.all	, , 0	and CC 0	to TO 0	increase VB B-verb.change	the DT 0	dose NN B-noun.quantity	of IN 0	Itraconazole NNP B-noun.person	if IN 0	necessary JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d236.s29	Drug NN 0	/ '' 0	Laboratory NNP B-noun.other	Test NNP I-noun.other	Interactions NNP I-noun.other	, , 0	Amphetamines NNPS B-noun.person	can MD 0	cause VB B-verb.creation	a DT 0	significant JJ B-adj.all	elevation NN B-noun.cognition	in IN 0	plasma NN B-noun.substance	corticosteroid JJ B-adj.all	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d434.s22	Valproate NNP B-noun.person	, , 0	Felbatol NNP B-noun.person	_ , 0	causes VBZ B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	valproate NN B-noun.possession	concentrations NNS B-noun.possession	. . 0	. . 0
DDI-DrugBank.d488.s1	Therefore RB 0	, , 0	when WRB 0	heparin_sodium NN 0	is VBZ 0	given VBN B-verb.possession	with IN 0	dicumarol NN B-noun.act	or CC 0	warfarin_sodium NN B-noun.location	, , 0	a DT 0	period NN B-noun.time	of IN 0	at IN 0	least JJS 0	5 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	the DT 0	last JJ B-adj.all	intravenous JJ B-adj.all	dose NN B-noun.event	or CC 0	24 CD B-adj.all	hours NNS B-noun.artifact	after IN 0	the DT 0	last JJ B-adj.all	subcutaneous JJ B-adj.all	dose NN B-noun.communication	should MD 0	elapse VB B-verb.motion	before IN 0	blood NN B-noun.time	is VBZ 0	drawn VBN B-verb.communication	if IN 0	a DT 0	valid JJ B-adj.all	prothrombin NN B-noun.person	time NN B-noun.person	is VBZ B-verb.stative	to TO 0	be VB 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d135.s8	Carbamazepine NNP B-noun.person	, , 0	In IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	receiving VBG B-verb.communication	the DT 0	CYP3A4 JJ B-adj.all	inducer NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	at IN 0	100 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	for IN 0	3 CD B-adj.all	days NNS B-noun.person	and CC 0	200 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	for IN 0	17 CD B-adj.all	days NNS B-noun.person	, , 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	( ( 0	AUC NNP 0	) ) 0	to TO 0	lapatinib NN B-noun.person	was VBD 0	decreased VBN B-verb.change	approximately RB B-adv.all	72 CD 0	% NN 0	. . 0	. . 0
DDI-DrugBank.d273.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	, , 0	The DT 0	pharmacokinetic JJ B-adj.all	and CC 0	pharmacodynamic JJ B-adj.all	interactions NNS B-noun.relation	between IN 0	UROXATRAL NNP B-noun.group	and CC 0	other JJ B-adj.all	alpha NN B-noun.person	- : 0	blockers NNS B-noun.person	have VBP 0	not RB 0	been VBN 0	determined VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d97.s4	Coadministration NN B-noun.person	of IN 0	CRIXIVAN NNP B-noun.group	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	CYP3A4 NNP I-verb.stative	may MD 0	decrease VB B-verb.cognition	the DT 0	clearance NN B-noun.act	of IN 0	indinavir NN B-noun.person	and CC 0	may MD 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	indinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d185.s2	Notably RB B-adv.all	, , 0	systemic JJ B-adj.all	exposure NN B-noun.cognition	( ( 0	AUC0 UH 0	- : 0	12 CD 0	) ) 0	of IN 0	dapsone_hydroxylamine NN 0	( ( 0	DHA NNP 0	) ) 0	was VBD B-verb.stative	more JJR B-noun.quantity	than IN 0	doubled VBN B-verb.contact	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	TMP NNP 0	/ POS 0	SMX NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d77.s2	Avoid VB B-verb.social	the DT 0	use NN 0	of IN 0	preparations NNS B-noun.substance	such JJ 0	as IN 0	decongestants NNS B-noun.person	and CC 0	local JJ B-adj.all	anesthetics NNS B-noun.group	which WDT 0	contain VBP B-verb.stative	any DT 0	sympathomimetic_amine NN 0	( ( 0	e.g. UH 0	, , 0	epinephrine NN B-noun.person	, , 0	norepinephrine NN B-noun.location	) ) 0	, , 0	since IN 0	it PRP 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	that IN 0	tricyclic_antidepressants NNS B-noun.person	can MD 0	potentiate VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	catecholamines NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d198.s40	Aspirin NNP B-noun.person	, , 0	Vardenafil NNP B-noun.person	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	20 CD B-adj.all	mg NN B-noun.quantity	) ) 0	did VBD 0	not RB B-adv.all	potentiate VB B-verb.communication	the DT 0	increase NN B-noun.event	in IN 0	bleeding VBG B-verb.body	time NN 0	caused VBN B-verb.creation	by IN 0	aspirin NN B-noun.person	( ( 0	two CD 0	81 CD 0	mg NN B-noun.quantity	tablets NNS B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d206.s0	Results NNS B-noun.location	of IN 0	preliminary JJ B-adj.all	studies NNS B-noun.act	in IN 0	humans NNS B-noun.animal	and CC 0	rats NNS B-noun.person	suggest VBP B-verb.communication	that IN 0	nonabsorbable JJ B-adj.all	antacids NNS B-noun.person	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	lactulose NN B-noun.act	may MD 0	inhibit VB B-verb.change	the DT 0	desired VBN B-verb.emotion	lactulose NN I-verb.emotion	- : 0	induced VBN B-verb.creation	drop NN B-noun.person	in IN 0	colonic JJ B-adj.all	pH. NNP B-noun.person	. . 0
DDI-DrugBank.d468.s9	Plasma NNP B-noun.person	concentrations NNS I-noun.person	of IN 0	cyclosporine NN B-noun.group	should MD 0	therefore RB 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	, , 0	and CC 0	its PRP$ 0	dosage NN B-noun.body	reduced VBD B-verb.change	accordingly RB B-adv.all	, , 0	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	nicardipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d460.s5	Metformin NNP B-noun.person	, , 0	When WRB 0	Starlix NNP B-noun.communication	120 CD 0	mg IN 0	three CD 0	times NNS 0	daily RB 0	before IN 0	meals NNS B-noun.food	was VBD 0	administered VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	metformin NN B-noun.communication	500 CD 0	mg IN 0	three CD 0	times NNS 0	daily RB 0	to TO 0	patients NNS B-noun.person	with IN 0	Type NNP B-noun.person	2 CD B-adj.all	diabetes NNS B-noun.person	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	agent NN B-noun.person	. . 0	. . 0
DDI-MedLine.d48.s11	Exposed VBN B-verb.perception	histidines NNS 0	on IN 0	toxin_A NN B-noun.artifact	are VBP B-verb.stative	available JJ B-adj.all	for IN 0	zinc NN B-noun.possession	chelation NN B-noun.communication	, , 0	and CC 0	these DT 0	have VBP 0	been VBN 0	exploited VBN B-verb.communication	in IN 0	the DT 0	development NN B-noun.process	of IN 0	a DT 0	novel JJ B-adj.all	purification NN 0	protocol NN 0	for IN 0	toxin_A NN 0	using VBG B-verb.consumption	zinc NN I-verb.consumption	- : 0	chelating VBG B-verb.cognition	chromatography NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d529.s11	Patients NNS B-noun.person	taking VBG 0	both DT 0	flurbiprofen NNS B-noun.person	and CC 0	a DT 0	beta NN B-noun.person	- : 0	blocker NN B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.perception	to TO 0	ensure VB B-verb.communication	that IN 0	a DT 0	satisfactory JJ B-adj.all	hypotensive JJ B-adj.all	effect NN B-noun.phenomenon	is VBZ 0	achieved VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d143.s8	Since IN 0	amiodarone NN 0	is VBZ B-verb.stative	a DT 0	substrate NN B-noun.person	for IN 0	CYP3A4 NNP B-noun.person	and CC 0	CYP2C8 NNP B-noun.person	, , 0	drugs NNS B-noun.artifact	/ POS 0	substances NNS B-noun.artifact	that WDT 0	inhibit VBP B-verb.stative	these DT 0	isoenzymes NNS B-noun.act	may MD 0	decrease VB B-verb.cognition	the DT 0	metabolism NN B-noun.artifact	and CC 0	increase VB B-verb.body	serum NN 0	concentration NN 0	of IN 0	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d338.s1	The DT 0	action NN B-noun.state	of IN 0	the DT 0	benzodiazepines NNS B-noun.object	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	anticonvulsants NNS B-noun.person	, , 0	antihistamines NNS B-noun.attribute	, , 0	alcohol NN B-noun.person	, , 0	barbiturates NNS B-noun.person	, , 0	monoamine_oxidase_inhibitors NNS B-noun.person	, , 0	narcotics NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	psychotropic_medications NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	produce VBP B-verb.stative	CNS NNP 0	depression NN 0	. . 0	. . 0
DDI-DrugBank.d198.s41	Other JJ 0	interactions NNS B-noun.motive	, , 0	Vardenafil NNP B-noun.person	had VBD B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacodynamics NNS B-noun.person	of IN 0	glyburide NN 0	( ( 0	glucose NN B-noun.person	and CC 0	insulin NN B-noun.body	concentrations NNS B-noun.attribute	) ) 0	and CC 0	warfarin NN B-noun.act	( ( 0	prothrombin NN B-noun.person	time NN B-noun.time	or CC 0	other JJ 0	pharmacodynamic JJ B-adj.all	parameters NNS B-noun.event	) ) 0	. . 0	. . 0
DDI-DrugBank.d506.s2	Other JJ 0	antiarrhythmic_drugs NNS B-noun.substance	( ( 0	eg UH 0	, , 0	quinidine NN B-noun.location	, , 0	procainamide NN B-noun.person	, , 0	lidocaine NN B-noun.person	, , 0	propranolol NN 0	) ) 0	have VBP 0	occasionally RB B-adv.all	been VBN 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	Norpace NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d522.s1	These DT 0	six CD B-adj.all	volunteers NNS B-noun.person	received VBD B-verb.possession	terfenadine NN B-noun.communication	alone RB B-adv.all	( ( 0	60 CD B-adj.all	mg NN B-noun.quantity	twice RB 0	daily JJ 0	) ) 0	for IN 0	8 CD B-adj.all	days NNS B-noun.time	, , 0	followed VBN B-verb.stative	by IN 0	terfenadine NN B-noun.person	in IN 0	combination NN 0	with IN 0	dirithromycin NN B-noun.person	( ( 0	500 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily JJ I-adv.all	) ) 0	for IN 0	10 CD B-adj.all	days NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d82.s4	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	INDOCIN NNP B-noun.group	with IN 0	other JJ 0	NSAIDs NNP B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.possession	due JJ 0	to TO 0	the DT 0	increased VBN B-verb.change	possibility NN B-noun.state	of IN 0	gastrointestinal JJ B-adj.all	toxicity NN B-noun.attribute	, , 0	with IN B-adv.all	little JJ I-adv.all	or CC 0	no DT 0	increase NN B-noun.act	in IN 0	efficacy NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d79.s2	We PRP 0	compared VBD B-verb.creation	indinavir JJ B-adj.all	pharmacokinetics NNS B-noun.person	and CC 0	gastric JJ B-adj.all	pH CD B-noun.attribute	in IN 0	12 CD B-adj.all	human JJ B-adj.all	immunodeficiency NN B-noun.person	virus NN B-noun.person	- : 0	positive JJ B-adj.all	patients NNS B-noun.person	by IN 0	use NN 0	of IN 0	800 CD 0	mg NN B-noun.quantity	of IN 0	indinavir NN B-noun.phenomenon	alone RB 0	versus JJR 0	800 CD 0	mg NN B-noun.quantity	of IN 0	indinavir NN B-noun.person	administered VBD B-verb.possession	1 CD B-adj.all	h NN 0	after IN 0	didanosine JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d228.s2	Reciprocal JJ B-adj.all	interactions NNS B-noun.possession	may MD 0	occur VB B-verb.stative	with IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	Antizol NNP B-noun.person	and CC 0	drugs NNS B-noun.artifact	that WDT 0	increase VBP B-verb.emotion	or CC 0	inhibit VB B-verb.change	the DT 0	cytochrome NN 0	P450 NN 0	system NN B-noun.substance	( ( 0	e.g. UH 0	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	cimetidine NN B-noun.person	, , 0	ketoconazole NN B-noun.artifact	) ) 0	, , 0	though IN 0	this DT 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0
DDI-DrugBank.d54.s2	Patients NNS B-noun.person	stabilized VBD B-verb.communication	on IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	who WP 0	are VBP 0	found VBN B-verb.cognition	to TO 0	require VB B-verb.consumption	thyroid JJ B-adj.all	replacement NN B-noun.person	therapy NN B-noun.group	should MD 0	be VB 0	watched VBN B-verb.social	very RB B-adv.all	closely RB B-adj.all	when WRB 0	thyroid NN B-noun.person	is VBZ 0	started VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d236.s16	Chlorpromazine NN 0	, , 0	Chlorpromazine NNP B-noun.person	blocks VBZ B-verb.change	dopamine NN 0	and CC 0	norepinephrine JJ B-adj.all	reuptake NN B-noun.person	, , 0	thus RB 0	inhibiting VBG B-verb.change	the DT 0	central JJ B-noun.body	stimulant JJ I-noun.body	effects NNS B-noun.phenomenon	of IN 0	amphetamines NNS B-noun.animal	, , 0	and CC 0	can MD 0	be VB 0	used VBN B-verb.consumption	to TO 0	treat VB B-verb.body	amphetamine JJ B-adj.all	poisoning NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d110.s3	unlike IN 0	ibogaine NN B-noun.person	, , 0	18-MC NN 0	does VBZ 0	not RB 0	affect VB 0	responding VBG B-verb.stative	for IN 0	a DT 0	nondrug NN 0	reinforcer NN 0	( ( 0	water NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d531.s74	Anticonvulsants NNS B-noun.person	, , 0	Phenytoin NNP B-noun.person	Phenobarbital NNP I-noun.person	Carbamazepine NNP I-noun.person	. . 0
DDI-MedLine.d109.s13	Rofecoxib NNP B-noun.person	did VBD 0	not RB B-adv.all	influence VB B-verb.emotion	the DT 0	plasma NN B-noun.plant	pharmacokinetics NNS B-noun.body	or CC 0	renal JJ B-adj.all	elimination NN B-noun.act	of IN 0	a DT 0	single JJ B-adj.all	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d18.s0	Note NN 0	, , 0	dissolution NN B-noun.act	of IN 0	aerosol NN B-noun.phenomenon	particles NNS B-noun.event	of IN 0	budesonide NN B-noun.food	in IN 0	Survanta NNP B-noun.other	, , 0	a DT 0	model NN B-noun.person	lung_surfactant NN I-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d185.s0	A DT 0	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	study NN B-noun.artifact	evaluated VBD B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	the DT 0	use NN 0	of IN 0	ACZONE NNP B-noun.other	Gel NNP I-noun.other	, , 0	5 CD B-adj.all	% NN 0	, , 0	in IN 0	combination NN 0	with IN 0	double JJ B-adj.all	strength NN B-noun.attribute	( ( 0	160 CD 0	mg/800 CD 0	mg NN B-noun.quantity	) ) 0	trimethoprim VBP B-verb.change	/ : 0	sulfamethoxazole NN B-noun.quantity	( ( 0	TMP NNP 0	/ POS 0	SMX NNP B-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d316.s19	Other JJ 0	Concomitant NNP B-noun.person	Therapy NNP I-noun.person	_ ( 0	In IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	interactions NNS B-noun.time	when WRB 0	felodipine NN B-noun.person	was VBD 0	given VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	indomethacin NN B-noun.act	or CC 0	spironolactone NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d504.s0	There EX 0	have VBP 0	been VBN B-verb.stative	rare JJ B-adj.all	reports NNS B-noun.artifact	of IN 0	significant JJ B-adj.all	respiratory JJ B-noun.body	depression NN I-noun.body	, , 0	stupor NN B-noun.group	and/or CC 0	hypotension NN 0	with IN 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	loxapine NN B-noun.location	and CC 0	lorazepam NN B-noun.person	. . 0	. . 0
DDI-MedLine.d38.s0	Acute NNP B-noun.person	hydrocortisone NN 0	administration NN B-noun.time	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	subjective JJ B-adj.all	responses NNS B-noun.act	to TO 0	d SYM 0	- : 0	amphetamine NN B-noun.person	in IN 0	humans NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d133.s2	Excessive JJ B-adj.all	neuromuscular JJ B-adj.all	weakness NN B-noun.artifact	may MD 0	be VB 0	exacerbated VBN B-verb.communication	by IN 0	administration NN B-noun.time	of IN 0	another DT 0	botulinum_toxin NN B-noun.location	prior RB B-adj.all	to TO 0	the DT 0	resolution NN B-noun.act	of IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	a DT 0	previously RB B-adv.all	administered VBN B-verb.possession	botulinum_toxin NN 0	. . 0	. . 0
DDI-DrugBank.d303.s2	Although IN 0	not RB B-adv.all	observed VBN B-verb.perception	in IN 0	this DT 0	study NN B-noun.artifact	, , 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	could MD 0	potentially RB B-adv.all	arise VB B-verb.change	from IN 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	cephalexin NN B-noun.food	and CC 0	metformin NN B-noun.person	by IN 0	inhibition NN B-noun.time	of IN 0	tubular JJ B-adj.all	secretion NN B-noun.act	via IN 0	organic JJ B-adj.all	cationic NN B-adj.pert	transporter NN B-noun.event	systems NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d438.s12	N=17 LS 0	) ) 0	were VBD B-verb.stative	not RB B-adv.all	different JJ B-adj.all	and CC 0	neither DT 0	were VBD B-verb.stative	gabapentin JJ B-adj.all	pharmacokinetic JJ B-adj.all	parameters NNS B-noun.person	affected VBN B-verb.change	by IN 0	valproic_acid NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s12	Digoxin NNP B-noun.person	, , 0	Rofecoxib NNP B-noun.person	75 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	11 CD B-adj.all	days NNS B-noun.time	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.possession	profile NN B-noun.possession	or CC 0	renal JJ B-adj.all	elimination NN B-noun.act	of IN 0	digoxin NN B-noun.food	after IN 0	a DT 0	single JJ B-adj.all	0.5 CD 0	mg IN 0	oral JJ B-adj.all	dose NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d400.s14	Antacids NNP B-noun.person	, , 0	In IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	study NN B-noun.artifact	( ( 0	n=6 NNP 0	) ) 0	, , 0	ingestion NN B-noun.act	of IN 0	an DT 0	antacid NN B-noun.attribute	containing VBG B-verb.stative	1.7-gram CD B-noun.other	of IN I-noun.other	magnesium_hydroxide NN I-noun.other	with IN I-noun.other	500-mg JJ I-noun.other	of IN I-noun.other	mefenamic_acid JJ I-noun.other	increased VBD B-verb.change	the DT 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	mefenamic_acid JJ 0	by IN 0	125 CD 0	% NN 0	and CC 0	36 CD 0	% NN 0	, , 0	respectively RB B-adv.all	. . 0	_ IN 0	A DT 0	number NN B-noun.quantity	of IN 0	compounds NNS B-noun.person	are VBP B-verb.stative	inhibitors NNS B-noun.person	of IN 0	CYP2C9 NNP B-noun.person	including VBG B-verb.social	fluconazole NN I-verb.social	, , 0	lovastatin NN B-noun.person	and CC 0	trimethoprim VBP B-verb.social	. . 0	. . 0
DDI-DrugBank.d225.s13	The DT 0	mean JJ B-adj.all	percentage NN B-noun.possession	increase NN B-noun.act	in IN 0	the DT 0	glipizide NN B-noun.group	AUC NNP B-noun.group	after IN 0	fluconazole JJ B-adj.all	administration NN B-noun.person	was VBD B-verb.stative	56.9 CD 0	% NN 0	( ( 0	range NN B-noun.person	, , 0	35 CD 0	to TO 0	81 CD 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d17.s25	( ( 0	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	the DT 0	steroidal_anti NNS B-noun.artifact	- : 0	inflammatory_agent NN B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	diuretic JJ B-adj.all	, , 0	natriuretic JJ B-adj.all	, , 0	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	loop NN B-noun.location	, , 0	potassium_sparing VBG B-verb.motion	, , 0	and CC 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d129.s2	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	oxyphenbutazone NN B-noun.substance	and CC 0	androgens NNS B-noun.animal	may MD 0	result VB B-verb.stative	in IN 0	elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	oxyphenbutazone NN 0	. . 0	. . 0
DDI-DrugBank.d460.s14	Certain JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.stative	nonsteroidal_anti JJ I-verb.stative	- : 0	inflammatory_agents NNS B-noun.person	( ( 0	NSAIDs NNP B-noun.person	) ) 0	, , 0	salicylates NNS B-noun.person	, , 0	monoamine_oxidase_inhibitors NNS B-noun.person	, , 0	and CC 0	non NN B-noun.person	- : 0	selective_beta SYM B-verb.cognition	- : 0	adrenergic JJ B-adj.pert	- : 0	blocking_agents NNS B-noun.group	may MD 0	potentiate VB B-verb.communication	the DT 0	hypoglycemic JJ B-adj.all	action NN B-noun.state	of IN 0	Starlix NNP B-noun.person	and CC 0	other JJ 0	oral JJ B-adj.all	antidiabetic_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d485.s8	Antibiotics NNS B-noun.person	( ( 0	ampicillin NN B-noun.person	, , 0	tetracycline NN 0	) ) 0	, , 0	Pregnancy NNP B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	concomitant JJ B-adj.all	use NN B-noun.person	, , 0	however RB 0	, , 0	pharmacokinetic JJ B-adj.all	studies NNS B-noun.group	have VBP 0	not RB B-adv.all	shown VBN B-verb.perception	consistent JJ I-verb.perception	effects NNS B-noun.phenomenon	with IN 0	these DT 0	antibiotics NNS B-noun.person	on IN 0	plasma NN B-verb.creation	concentrations NNS B-noun.attribute	of IN 0	synthetic_steroids NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d424.s3	Rifampin NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	rifampin NN B-noun.communication	and CC 0	MEPRON NNP B-noun.group	Suspension NNP I-noun.group	results NNS B-noun.communication	in IN 0	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	average JJ B-adj.all	steady- JJ B-adj.all	state NN B-adj.all	plasma NN B-noun.plant	atovaquone NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d328.s7	Methotrexate NNP B-noun.person	, , 0	Valdecoxib_10_mg NNP B-noun.person	BID NNP I-noun.person	did VBD 0	not RB B-adv.all	show VB B-verb.communication	a DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	plasma NN B-noun.plant	exposure NN B-noun.state	or CC 0	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d76.s22	In IN 0	these DT 0	subjects NNS B-noun.person	( ( 0	R= IN 0	B NNP 0	) ) 0	, , 0	the DT 0	clearance NN B-noun.act	of IN 0	diazepam NN B-noun.person	was VBD 0	reduced VBN B-verb.change	by IN 0	65 CD 0	% NN 0	and CC 0	that IN 0	of IN 0	N NNP 0	- : 0	desmethyldiazepam NN B-noun.person	to TO 0	a DT 0	level NN B-noun.attribute	that WDT 0	was VBD B-verb.stative	too RB B-adv.all	low JJ B-adj.all	to TO 0	measure VB B-verb.stative	over IN 0	the DT 0	course NN B-noun.location	of IN 0	the DT 0	2 CD B-adj.all	week NN B-noun.quantity	long JJ B-adj.all	study NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d110.s7	only RB B-adv.all	ibogaine JJ B-adj.all	enhances NNS B-noun.artifact	cocaine VBP B-verb.stative	- : 0	induced VBN B-verb.creation	increases NNS B-noun.event	in IN 0	accumbal JJ B-adj.all	dopamine NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d67.s1	In IN 0	three CD 0	separate JJ B-adj.all	controlled VBN B-verb.social	, , 0	parallel JJ B-adj.all	group NN 0	clinical JJ B-adj.all	pharmacology NN B-noun.body	studies NNS I-noun.body	, , 0	desloratadine NN B-noun.person	at IN 0	the DT 0	clinical JJ B-adj.all	dose NN B-noun.quantity	of IN 0	5 CD B-adj.all	mg NN B-noun.quantity	has VBZ 0	been VBN 0	coadministered VBN B-verb.contact	with IN 0	azithromycin NN B-noun.communication	500 CD 0	mg NN B-noun.quantity	followed VBN B-verb.stative	by IN 0	250 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	4 CD B-adj.all	days NNS B-noun.phenomenon	( ( 0	n=18 NN 0	) ) 0	or CC 0	with IN 0	fluoxetine JJ B-adj.all	20 CD B-adj.all	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	for IN 0	7 CD B-adj.all	days NNS B-noun.act	after IN 0	a DT 0	23 CD B-adj.all	day NN B-noun.person	pretreatment JJ B-adj.all	period NN B-noun.person	with IN 0	fluoxetine NN B-noun.substance	( ( 0	n=18 NN 0	) ) 0	or CC 0	with IN 0	cimetidine JJ 0	600 CD 0	mg IN 0	every DT 0	12 CD B-adj.all	hours NNS B-noun.person	for IN 0	14 CD B-adj.all	days NNS B-noun.phenomenon	( ( 0	n=18 NN 0	) ) 0	under IN 0	steady JJ B-adj.all	state NN B-noun.state	conditions NNS I-noun.state	to TO 0	normal JJ B-adj.all	healthy JJ B-adj.all	male NN B-noun.person	and CC 0	female JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d48.s5	Treatment NN B-noun.person	of IN 0	toxin_A NN 0	with IN 0	[ : 0	( ( 0	14)C]-diethyl_pyrocarbonate NNP B-noun.person	revealed VBD B-verb.perception	concentration NN I-verb.perception	dependent JJ B-adj.all	labelling NN B-noun.act	of IN 0	histidine NN B-noun.phenomenon	residues NNS B-noun.artifact	on IN 0	the DT 0	toxin NN B-noun.object	molecules NNS I-noun.object	. . 0	. . 0
DDI-DrugBank.d567.s20	Propranolol NNP B-noun.person	, , 0	In IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	there EX 0	was VBD B-verb.stative	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	pharmacokinetic JJ B-noun.relation	or CC 0	pharmacodynamic JJ B-adj.all	interaction NN B-noun.act	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	lovastatin NN B-noun.feeling	and CC 0	propranolol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d435.s2	Co SYM 0	- : 0	medications NNS B-noun.communication	that WDT 0	induce VBP B-verb.emotion	CYP NNP B-noun.group	3A4 NNP I-noun.group	( ( 0	e.g. UH 0	, , 0	rifampicin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	phenobarbital JJ B-adj.all	, , 0	or CC 0	St. NNP B-noun.group	John NNP I-noun.group	s PRP$ 0	wort NN B-noun.body	) ) 0	may MD 0	significantly RB 0	decrease VB B-verb.communication	exposure NN B-noun.person	to TO 0	exemestane VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d110.s0	The DT 0	administration NN B-noun.time	of IN 0	local JJ B-adj.all	anesthetic_solutions NNS 0	containing VBG B-verb.stative	epinephrine NN B-noun.substance	or CC 0	norepinephrine NN B-noun.person	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	monoamine_oxidase_inhibitors NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.plant	or CC 0	phenothiazines NNS B-noun.animal	may MD 0	produce VB B-verb.cognition	severe JJ 0	, , 0	prolonged VBD B-verb.communication	hypotension NN B-noun.person	or CC 0	hypertension NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d305.s6	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	the DT 0	combination NN B-noun.event	of IN 0	intravenous JJ B-adj.all	dantrolene_sodium NN B-noun.person	and CC 0	calcium_channel_blockers NNS B-noun.person	, , 0	such JJ 0	as IN 0	verapamil NN B-noun.artifact	, , 0	not RB B-adv.all	be VB 0	used VBN B-verb.consumption	together RB B-adv.all	during IN 0	the DT 0	management NN B-noun.group	of IN 0	malignant JJ B-adj.all	hyperthermia NN B-noun.person	crisis NN B-noun.person	until IN 0	the DT 0	relevance NN B-noun.relation	of IN 0	these DT 0	findings NNS B-noun.act	to TO 0	humans NNS B-noun.person	is VBZ 0	established VBN B-verb.creation	. . 0	. . 0
DDI-DrugBank.d210.s15	Ketoconazole NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.communication	400 CD 0	mg NN B-noun.quantity	daily RB 0	did VBD 0	not RB B-adv.all	have VB B-verb.change	any DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	rofecoxib NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d186.s5	In IN 0	5 CD B-adj.all	other JJ 0	schizophrenic JJ B-adj.all	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	oral JJ B-adj.all	haloperidol NN B-noun.person	and CC 0	rifampin NN B-noun.person	, , 0	discontinuation NN B-noun.act	of IN 0	rifampin NN B-noun.person	produced VBD B-verb.creation	a DT 0	mean JJ B-adj.all	3.3-fold JJ B-noun.artifact	increase NN I-noun.artifact	in IN 0	haloperidol NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d427.s8	Antacids NNS B-noun.person	containing VBG B-verb.social	magnesium NN I-verb.social	, , 0	aluminum NN B-noun.person	, , 0	or CC 0	calcium NN B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d373.s2	Digitalis NNP B-noun.person	, , 0	Immediate NNP B-noun.other	Release NNP I-noun.other	Capsules NNP I-noun.other	, , 0	Since IN 0	there EX 0	have VBP 0	been VBN 0	isolated VBN B-verb.change	reports NNS B-noun.artifact	of IN 0	patients NNS B-noun.person	with IN 0	elevated JJ B-adj.all	digoxin NN B-noun.person	levels NNS B-noun.state	, , 0	and CC 0	there EX 0	is VBZ B-verb.stative	a DT 0	possible JJ B-adj.all	interaction NN B-noun.act	between IN 0	digoxin NN B-noun.person	and CC 0	nifedipine NN B-noun.person	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	digoxin NN B-noun.state	levels NNS B-noun.state	be VB 0	monitored VBN B-verb.perception	when WRB 0	initiating VBG B-verb.communication	, , 0	adjusting NN B-verb.change	, , 0	and CC 0	discontinuing VBG B-verb.communication	nifedipine NN B-noun.person	to TO 0	avoid VB B-verb.social	possible JJ B-adj.all	over- JJ B-noun.other	or CC 0	under IN 0	- : 0	digitalization NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d566.s3	Because IN 0	cholestyramine NN B-noun.person	binds VBZ B-verb.social	bile JJ B-adj.all	acids NNS B-noun.person	, , 0	cholestyramine JJ B-adj.all	resin NN B-noun.act	may MD 0	interfere VB B-verb.stative	with IN 0	normal JJ B-adj.all	fat JJ 0	digestion NN B-noun.person	and CC 0	absorption NN B-noun.artifact	and CC 0	thus RB 0	may MD 0	prevent VB B-verb.emotion	absorption NN B-noun.process	of IN 0	fat_soluble_vitamins NNS B-noun.event	such JJ 0	as IN 0	A DT 0	, , 0	D NNP 0	, , 0	E NNP 0	, , 0	and CC 0	K. NNP 0	. . 0
DDI-DrugBank.d130.s2	Antagonism NNP B-noun.attribute	between IN 0	lincomycin NN B-noun.communication	and CC 0	erythromycin NN B-noun.person	in IN 0	vitro NN B-noun.animal	has VBZ 0	been VBN 0	demonstrated VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d437.s10	Coadministration NN B-noun.person	of IN 0	amprenavir NN B-noun.person	and CC 0	methadone NN B-noun.attribute	as IN 0	compared VBN 0	to TO 0	a DT 0	non NN B-noun.person	- : 0	matched VBN B-verb.contact	historicalcontrol NN 0	group NN 0	resulted VBD B-verb.stative	in IN 0	a DT 0	30 CD B-adj.all	% NN 0	, , 0	27 CD B-adj.all	% NN 0	, , 0	and CC 0	25 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	serum NN 0	amprenavir IN 0	AUC NNP B-noun.group	, , 0	Cmax NNP B-noun.person	, , 0	andCmin NNP B-noun.person	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d54.s19	Ketamine NNP B-noun.person	, , 0	When WRB 0	administered VBN B-verb.communication	to TO 0	patients NNS B-noun.person	on IN 0	a DT 0	thyroid_preparation NN B-noun.act	, , 0	this DT 0	parenteral JJ B-adj.all	anesthetic JJ 0	may MD 0	cause VB B-verb.communication	hypertension NN B-noun.person	and CC 0	tachycardia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d395.s16	or CC 0	with IN 0	multivitamins NNS B-noun.person	containing VBG B-verb.stative	zinc NN B-noun.group	may MD 0	substantially RB B-verb.possession	interfere VB 0	with IN 0	drug NN B-noun.artifact	absorption NN B-noun.artifact	and CC 0	result NN B-noun.act	in IN 0	insufficient JJ B-adj.all	plasma NN B-noun.substance	and CC 0	tissue NN B-noun.body	quinolone NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d270.s24	Ethinyl_estradiol NN B-noun.artifact	and CC 0	Norethindrone NNP B-noun.person	. . 0
DDI-DrugBank.d40.s15	Similarly RB B-adv.all	, , 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	phenytoin NN B-noun.person	on IN 0	phenobarbital NN B-noun.artifact	, , 0	valproic_acid NNP B-noun.person	and CC 0	sodium NN B-noun.artifact	plasma NN B-noun.substance	valproate NN B-noun.location	concentrations NNS B-noun.person	are VBP B-verb.stative	unpredictable JJ B-adj.all	. . 0
DDI-DrugBank.d434.s18	In IN 0	nine CD 0	otherwise RB 0	healthy JJ B-adj.all	subjects NNS B-noun.person	with IN 0	epilepsy NN B-noun.person	ingesting VBG B-verb.emotion	carbamazepine NN I-verb.emotion	, , 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	trough NN B-noun.person	( ( 0	Cmin NNP 0	) ) 0	carbamazepine NN 0	concentration NN B-noun.event	was VBD B-verb.stative	8 CD B-adj.all	2 CD B-adj.all	micrograms NNS B-noun.quantity	/ . 0	mL. NNP B-noun.person	. . 0
DDI-MedLine.d125.s3	Administration NN B-noun.person	of IN 0	1,3-difluoroacetone JJ 0	( ( 0	100 CD 0	mg IN 0	kg(-1 NNP 0	) ) 0	body NN 0	weight NN B-noun.attribute	) ) 0	to TO 0	rats NNS B-verb.weather	in IN 0	vivo NN 0	resulted VBD B-verb.stative	in IN 0	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate JJ B-adj.all	synthesis NN B-noun.cognition	in IN 0	the DT 0	kidney NN B-noun.person	, , 0	which WDT 0	was VBD 0	preceded VBN B-verb.creation	by IN 0	an DT 0	elevation NN B-noun.act	in IN 0	fluoride JJ B-adj.all	levels NNS B-noun.state	and CC 0	followed VBN B-verb.stative	by IN 0	citrate JJ B-adj.all	accumulation NN B-noun.person	. . 0	. . 0
DDI-MedLine.d68.s1	The DT 0	higher JJR B-adj.all	verografine NN B-noun.person	and CC 0	iodamide JJ B-adj.all	excretion NN B-noun.act	was VBD B-verb.stative	due JJ 0	to TO 0	their PRP$ 0	increased VBN B-verb.change	renal JJ B-adj.all	tubular JJ B-adj.all	secretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d46.s7	- : 0	Cholestyramine NN B-noun.person	and CC 0	colestipol NN B-noun.act	resins NNS B-noun.artifact	, , 0	Cholestytamine NNP B-noun.person	and CC 0	colestipol NN B-noun.act	resins NNS B-noun.artifact	have VBP 0	the DT 0	potential NN B-noun.person	of IN 0	binding JJ B-adj.pert	thiazide_diuretics NNS B-noun.person	and CC 0	reducing VBG B-verb.change	diuretic JJ B-adj.all	absorption NN B-noun.event	from IN 0	the DT 0	gastrointestinal JJ B-adj.all	tract NN B-noun.body	. . 0
DDI-DrugBank.d0.s0	The DT 0	concomitant JJ B-adj.all	intake NN B-noun.person	of IN 0	alcohol NN B-noun.food	and CC 0	Acamprosate NNP B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	alcohol NN B-noun.state	or CC 0	acamprosate VB B-verb.social	. . 0	. . 0
DDI-DrugBank.d392.s0	Patients NNS B-noun.person	who WP 0	are VBP 0	applying VBG B-verb.stative	Panretin NNP 0	gel NN 0	should MD 0	not RB B-adv.all	concurrently RB B-adv.all	use VBP B-verb.consumption	products NNS B-noun.artifact	that WDT 0	contain VBP B-verb.stative	DEET NNP I-verb.stative	( ( 0	N NNP 0	, , 0	N NNP 0	- : 0	diethyl NN B-noun.person	- : 0	m SYM 0	- : 0	toluamide NN 0	) ) 0	, , 0	a DT 0	common JJ B-noun.person	component NN B-noun.person	of IN 0	insect JJ B-adj.all	repellent JJ B-adj.all	products NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d223.s28	Tolazamide NNP 0	, , 0	A DT 0	case NN B-noun.state	of IN 0	severe JJ B-adj.all	hypoglycemia NN B-noun.state	has VBZ 0	been VBN 0	reported VBN B-verb.communication	in IN 0	a DT 0	type NN B-noun.person	II NNP 0	diabetic JJ B-adj.all	patient NN B-noun.person	maintained VBN B-verb.consumption	on IN 0	tolazamide NN 0	( ( 0	1 CD 0	gm RB 0	/ JJ 0	day NN 0	) ) 0	11 CD B-adj.all	days NNS B-noun.act	after IN 0	the DT 0	addition NN B-noun.act	of IN 0	doxepin NN 0	( ( 0	75 CD 0	mg RB 0	/ JJ 0	day NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d82.s1	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	combined VBN B-verb.stative	use NN 0	of IN 0	INDOCIN NNP B-noun.group	and CC 0	diflunisal NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	fatal JJ B-adj.all	gastrointestinal JJ B-adj.pert	hemorrhage NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d141.s4	In IN 0	the DT 0	first JJ B-adj.all	study NN B-noun.artifact	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	0.2 CD 0	mg DT B-noun.quantity	cerivastatin_sodium NN B-noun.artifact	and CC 0	12 CD B-adj.all	g IN 0	cholestyramine NN B-noun.person	resulted VBD B-verb.communication	in IN 0	decreases NNS B-noun.time	of IN 0	more JJR B-noun.quantity	than IN 0	22 CD B-adj.all	% NN 0	for IN 0	AUC NNP B-noun.group	and CC 0	40 CD B-adj.all	% NN 0	for IN 0	Cmax NNP B-noun.person	when WRB 0	compared VBN B-verb.cognition	to TO 0	dosing VBG B-verb.social	cerivastatin_sodium NN 0	alone RB 0	. . 0	. . 0
DDI-DrugBank.d7.s0	The DT 0	rate NN B-noun.time	of IN 0	metabolism NN B-noun.attribute	and CC 0	the DT 0	leukopenic JJ B-adj.pert	activity NN B-noun.state	of IN 0	cyclophosphamide NN 0	reportedly RB B-adv.all	are VBP 0	increased VBN B-verb.change	by IN 0	chronic JJ B-adj.pert	administration NN B-noun.time	of IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	phenobarbital NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d286.s1	It PRP 0	may MD 0	increase VB B-verb.change	excretion NN B-noun.act	of IN 0	barbiturates NNS B-noun.location	, , 0	lithium NN B-noun.person	, , 0	and CC 0	ASA NNP B-noun.person	and CC 0	may MD 0	also RB 0	increase VB B-verb.change	the DT 0	toxicity NN B-noun.attribute	of IN 0	salicylates NNS B-noun.substance	. . 0	. . 0
DDI-DrugBank.d246.s7	These DT 0	results NNS B-noun.communication	suggest VBP B-verb.communication	that IN 0	the DT 0	analgesic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	STADOL_NS NNS B-noun.group	may MD 0	be VB 0	diminished VBN B-verb.change	when WRB 0	it PRP 0	is VBZ 0	administered VBN B-verb.possession	shortly RB B-adv.all	after IN 0	sumatriptan JJ B-adj.all	nasal NN B-noun.act	spray NN B-noun.artifact	, , 0	but CC 0	by IN 0	30 CD B-adj.all	minutes NNS B-noun.time	any DT 0	such JJ B-adj.all	reduction NN B-noun.group	in IN 0	effect NN 0	should MD 0	be VB B-verb.stative	minimal JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d533.s9	Furosemide RB 0	, , 0	When WRB 0	aliskiren RB 0	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	furosemide NN B-noun.artifact	, , 0	the DT 0	AUC NNP B-noun.group	and CC 0	Cmax NNP B-noun.person	of IN 0	furosemide NN B-noun.food	were VBD 0	reduced VBN B-verb.change	by IN 0	about IN 0	30 CD B-adj.all	% NN 0	and CC 0	50 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d487.s1	Drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.emotion	hepatic JJ B-adj.all	enzymes NNS B-noun.event	such JJ 0	as IN 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	and CC 0	rifampin NN B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	corticosteroids NNS B-noun.food	and CC 0	may MD 0	require VB B-verb.stative	increases NNS B-noun.event	in IN 0	corticosteroid JJ B-adj.all	dose NN B-noun.quantity	to TO 0	achieve VB B-verb.social	the DT 0	desired VBN B-verb.emotion	response NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d324.s7	Additionally RB B-adv.all	, , 0	paroxetine NN B-noun.person	did VBD 0	not RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	Sonata NNP B-noun.person	, , 0	reflecting VBG B-verb.perception	the DT 0	absence NN B-noun.act	of IN 0	a DT 0	role NN B-noun.attribute	of IN 0	CYP2D6 NNP B-noun.person	in IN 0	zaleplon NN B-noun.communication	s PRP 0	metabolism NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d132.s18	Cyclosporine NNP B-noun.person	, , 0	Administration NNP B-noun.person	of IN 0	nonsteroial_anti JJ B-adj.all	- : 0	inflammatory_drugs NNS B-noun.person	concomitantly RB B-adv.all	with IN 0	cyclosporine NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	an DT 0	increase NN B-noun.act	in IN 0	cyclosporine NN 0	- : 0	induced VBN B-verb.creation	toxicity NN B-noun.attribute	, , 0	possibly RB 0	due JJ 0	to TO 0	decreased VBN B-verb.change	synthesis NN B-noun.cognition	of IN 0	renal JJ B-noun.phenomenon	prostacyclin NN I-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d558.s5	If IN 0	a DT 0	patient NN B-noun.person	requires VBZ B-verb.body	TIKOSYN NNP B-noun.group	and CC 0	anti NNS B-noun.person	- : 0	ulcer NN B-noun.person	therapy NN B-noun.person	, , 0	it PRP 0	is VBZ 0	suggested VBN B-verb.communication	that IN 0	omeprazole NN B-noun.person	, , 0	ranitidine NN B-noun.person	, , 0	or CC 0	antacids NNS B-noun.substance	( ( 0	aluminum NN B-noun.person	and CC 0	magnesium_hydroxides NNS B-noun.group	) ) 0	be VB 0	used VBN B-verb.consumption	as IN 0	alternatives NNS B-noun.person	to TO 0	cimetidine VB B-verb.social	, , 0	as IN 0	these DT 0	agents NNS B-noun.person	have VBP B-verb.social	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	TIKOSYN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d440.s12	The DT 0	incidence NN B-noun.relation	of IN 0	upper JJ B-adj.all	gastrointestinal JJ B-adj.pert	events NNS B-noun.state	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	taking VBG 0	aspirin NN B-noun.attribute	or CC 0	NSAIDs NNP B-noun.person	was VBD B-verb.stative	similar JJ B-adj.all	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	ibandronate JJ I-verb.social	2.5 CD 0	mg NN B-noun.quantity	daily RB B-adv.all	( ( 0	21.7 CD 0	% NN 0	) ) 0	and CC 0	150 CD 0	mg NNS B-noun.quantity	once RB B-adv.all	monthly JJ B-adv.all	( ( 0	22.0 CD 0	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d179.s14	- : 0	Etretinate NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Tegison NNP B-noun.person	) ) 0	or CC 0	. . 0
DDI-DrugBank.d400.s5	This DT 0	interaction NN B-noun.act	should MD 0	be VB 0	given VBN B-verb.possession	consideration NN B-noun.attribute	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	NSAIDs NNP B-noun.person	concomitantly RB B-adv.all	with IN 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d240.s1	It PRP 0	may MD 0	also RB 0	interact VB B-verb.contact	with IN 0	amantadine JJ B-adj.all	or CC 0	other JJ B-adj.all	anticholinergic_drugs NNS B-noun.object	or CC 0	MAOIs NNP B-noun.location	, , 0	which WDT 0	may MD 0	intensify VB B-verb.cognition	the DT 0	anticholinergic JJ B-adj.pert	action NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d97.s57	Antiarrhythmics NNS B-noun.person	, , 0	bepridil NN B-noun.person	, , 0	lidocaine NN B-noun.person	( ( 0	systemic JJ 0	) ) 0	and CC 0	quinidine NN B-noun.location	. . 0
DDI-DrugBank.d241.s3	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	FLOLAN NNP B-noun.group	was VBD 0	used VBN B-verb.consumption	with IN 0	digoxin NN B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	anticoagulants NNS B-noun.person	, , 0	oral JJ B-adj.all	vasodilators NNS B-noun.person	, , 0	and CC 0	supplemental JJ B-adj.all	oxygen NN B-noun.person	. . 0	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	substudy NN B-noun.artifact	in IN 0	patients NNS B-noun.person	with IN 0	congestive JJ B-adj.all	heart NN B-noun.person	failure NN B-noun.person	receiving VBG B-verb.change	furosemide NN B-noun.artifact	or CC 0	digoxin NN B-noun.substance	in IN 0	whom WP 0	therapy PRP 0	with IN 0	FLOLAN NNP B-noun.group	was VBD 0	initiated VBN B-verb.creation	, , 0	apparent JJ B-adj.all	oral JJ B-adj.all	clearance NN B-noun.phenomenon	values NNS B-noun.attribute	for IN 0	furosemide NN B-noun.attribute	( ( 0	n UH 0	= $ 0	23 CD B-adj.all	) ) 0	and CC 0	digoxin NN B-noun.person	( ( 0	n UH 0	= $ 0	30 CD B-adj.all	) ) 0	were VBD 0	decreased VBN B-verb.change	by IN 0	13 CD B-adj.all	% NN 0	and CC 0	15 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	on IN 0	the DT 0	second JJ B-adj.all	day NN 0	of IN 0	therapy NN B-noun.act	and CC 0	had VBD 0	returned VBN B-verb.communication	to TO 0	baseline NN B-verb.cognition	values NNS B-noun.attribute	by IN 0	day NN 0	87 CD 0	. . 0	. . 0
DDI-DrugBank.d122.s0	Nephrotoxicity NN B-noun.motive	has VBZ 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	cephalosporins NNS B-noun.person	with IN 0	aminoglycoside_antibiotics NNS B-noun.person	or CC 0	potent JJ B-adj.all	diuretics NNS B-noun.person	such JJ 0	as IN 0	furosemide NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d466.s3	In IN 0	2 CD B-adj.all	separate JJ B-adj.all	studies NNS B-noun.communication	, , 0	fexofenadine_hydrochloride JJ 0	120 CD 0	mg NN B-noun.quantity	twice RB B-adv.all	daily RB B-adv.all	( ( 0	240 CD 0	mg IN 0	total JJ B-adj.all	daily JJ B-noun.event	dose NN 0	) ) 0	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	either DT 0	erythromycin NN B-noun.communication	500 CD 0	mg IN 0	every DT 0	8 CD B-adj.all	hours NNS B-noun.time	or CC 0	ketoconazole NN B-noun.communication	400 CD 0	mg NN B-noun.quantity	once RB B-adv.all	daily RB B-adv.all	under IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	conditions NNS I-noun.state	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	n=24 UH 0	, , 0	each DT 0	study NN B-noun.artifact	) ) 0	. . 0	. . 0
DDI-DrugBank.d124.s30	Coadministration NN B-noun.person	with IN 0	compounds NNS B-noun.person	that WDT 0	are VBP B-verb.stative	potent JJ B-adj.all	inducers NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	( ( 0	eg UH 0	, , 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	dexamethasone NN B-noun.person	, , 0	carbamazepine NN 0	) ) 0	may MD 0	result VB B-verb.stative	in IN 0	decreased VBN B-verb.change	plasma NN B-noun.substance	levels NNS B-noun.state	of IN 0	saquinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d85.s10	Probenecid JJ 0	given VBN 0	concurrently RB B-adv.all	increases VBZ B-verb.change	naproxen JJ B-adj.all	anion NN 0	plasma NN B-noun.substance	levels NNS B-noun.state	and CC 0	extends VBZ B-verb.stative	its PRP$ 0	plasma NN B-noun.substance	half NN B-noun.food	- : 0	life NN B-noun.person	significantly RB B-adv.all	. . 0	. . 0
DDI-MedLine.d99.s8	Plasma NNP B-noun.person	was VBD 0	analyzed VBN B-verb.cognition	for IN 0	tolbutamide NN 0	, , 0	and CC 0	urine NN B-noun.person	was VBD 0	analyzed VBN B-verb.cognition	for IN 0	tolbutamide NN 0	and CC 0	its PRP$ 0	two CD 0	metabolites NNS B-noun.food	, , 0	4-hydroxytolbutamide JJ 0	and CC 0	carboxytolbutamide NN 0	by IN 0	means NNS B-noun.person	of IN 0	HPLC NNP B-noun.group	. . 0	. . 0
DDI-MedLine.d73.s1	The DT 0	neurochemical JJ B-adj.all	and CC 0	functional JJ B-adj.all	consequences NNS B-noun.event	following VBG 0	MPTP NNP B-noun.group	administration NN B-noun.time	to TO 0	the DT 0	rat NN B-noun.person	were VBD 0	evaluated VBN B-verb.communication	and CC 0	compared VBN B-verb.cognition	to TO 0	similar JJ B-adj.all	effects NNS B-noun.phenomenon	following VBG B-verb.stative	methamphetamine JJ B-adj.all	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d284.s1	When WRB 0	paroxetine NN B-noun.person	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP2D6 NNP B-noun.person	, , 0	was VBD B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	BROVANA NNP B-noun.group	at IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.state	, , 0	exposure NN B-noun.person	to TO 0	either DT 0	drug NN B-noun.person	was VBD 0	not RB B-adv.all	altered VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d440.s7	Among IN 0	these DT 0	patients NNS B-noun.person	, , 0	the DT 0	incidence NN B-noun.event	of IN 0	upper JJ B-adj.all	gastrointestinal JJ B-adj.pert	adverse JJ B-noun.object	experiences NNS I-noun.object	in IN 0	the DT 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	Ibandronate NNP B-noun.communication	150 CD 0	mg NNS B-noun.quantity	once RB B-adv.all	monthly RB I-adv.all	was VBD B-verb.stative	similar JJ B-adj.all	to TO 0	that DT 0	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	Ibandronate NNP B-noun.person	2.5 CD 0	mg NNS B-noun.quantity	once RB B-adv.all	daily RB I-adv.all	. . 0	. . 0
DDI-MedLine.d114.s8	In IN 0	addition NN 0	, , 0	we PRP 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	RR NNP 0	is VBZ B-verb.stative	a DT 0	useful JJ B-adj.all	pharmacological JJ B-adj.all	tool NN B-noun.act	with IN 0	which WDT 0	to TO 0	examine VB B-verb.communication	the DT 0	InsP(3)-mediated JJ B-adj.all	responses NNS B-noun.act	of IN 0	megakaryocytes NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d529.s7	Beta SYM 0	- : 0	adrenergic_Blocking_Agents NNS B-noun.person	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	flurbiprofen NN B-noun.animal	on IN 0	blood NN B-noun.act	pressure NN B-noun.act	response NN B-noun.act	to TO 0	propranolol VB B-verb.communication	and CC 0	atenolol NN B-noun.person	was VBD 0	evaluated VBN B-verb.change	in IN 0	men NNS B-noun.person	with IN 0	mild JJ B-adj.all	uncomplicated JJ B-adj.all	hypertension NN B-noun.person	( ( 0	n UH 0	= $ 0	10 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d458.s30	Also RB B-adv.all	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	differences NNS B-noun.cognition	in IN 0	adverse JJ B-adj.all	events NNS B-noun.event	when WRB 0	loratadine NN B-noun.person	was VBD 0	administered VBN B-verb.possession	with IN 0	or CC 0	without IN 0	ketoconazole NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d549.s4	Intravenous JJ B-adj.all	infusion NN B-noun.cognition	of IN 0	iloprost NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d154.s3	Chronic NNP B-adj.pert	administration NN B-noun.time	of IN 0	phenobarbital NN B-noun.artifact	, , 0	a DT 0	known VBN B-adj.all	enzyme NN B-noun.person	inducer NN I-noun.person	, , 0	may MD 0	be VB 0	associated VBN B-verb.cognition	with IN 0	a DT 0	decrease NN B-noun.event	in IN 0	the DT 0	plasma NN B-noun.plant	half NN B-noun.quantity	- : 0	life NN B-noun.time	of IN 0	fenoprofen NN B-noun.person	. . 0	. . 0
DDI-MedLine.d134.s2	An DT 0	intravenous JJ B-adj.all	injection NN B-noun.event	of IN 0	perchlorate NN B-noun.person	given VBN B-verb.possession	later RB B-adv.all	also RB B-adv.all	produces VBZ B-verb.creation	a DT 0	complete JJ B-adj.all	and CC 0	immediately RB B-adv.all	beginning VBG B-verb.change	depletion NN B-noun.process	of IN 0	pertechnetate NN B-noun.person	already RB B-adv.all	accumulated VBN B-verb.change	in IN 0	the DT 0	thyroid NN B-noun.body	, , 0	within IN 0	a DT 0	period NN B-noun.time	of IN 0	195 CD 0	min NN 0	after IN 0	99m SYM 0	- : 0	TcO-4-injection NN 0	with IN 0	a DT 0	corresponding JJ B-adj.all	increase NN B-noun.event	in IN 0	blood NN B-noun.location	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d99.s12	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	drugs NNS B-noun.artifact	that WDT 0	can MD 0	inhibit VB B-verb.possession	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d239.s2	The DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Natrecor NNP B-noun.location	with IN 0	IV NNP 0	vasodilators NNS 0	such JJ 0	as IN 0	nitroglycerin NN B-noun.person	, , 0	nitroprusside NN B-noun.person	, , 0	milrinone NN 0	, , 0	or CC 0	IV $ 0	ACE_inhibitors NNS 0	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.consumption	( ( 0	these DT 0	drugs NNS B-noun.artifact	were VBD B-verb.stative	not RB B-adv.all	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	Natrecor NNP B-noun.person	in IN 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	) ) 0	. . 0	. . 0
DDI-DrugBank.d212.s25	The DT 0	effect NN B-noun.cognition	of IN 0	Keppra NNP B-noun.person	_ ( 0	on IN 0	probenecid NN B-noun.person	was VBD B-verb.stative	not RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d307.s11	Antiepileptic_drugs NNS B-noun.artifact	, , 0	Potential JJ B-noun.person	interactions NNS I-noun.person	between IN 0	Trileptal NNP B-noun.person	and CC 0	other JJ 0	AEDs NNP B-noun.person	were VBD 0	assessed VBN B-verb.communication	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d41.s0	Cholestyramine NN B-noun.person	and CC 0	Charcoal NNP B-noun.location	Administration NNP I-noun.location	of IN 0	cholestyramine NN B-noun.act	or CC 0	activated_charcoal JJ B-adj.all	in IN 0	patients NNS B-noun.person	( ( 0	n=13 NN 0	) ) 0	and CC 0	volunteers NNS B-noun.person	( ( 0	n=96 NNP 0	) ) 0	resulted VBD B-verb.stative	in IN 0	a DT 0	rapid JJ B-adj.all	and CC 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	plasma NN B-noun.substance	M1 : 0	( ( 0	the DT 0	active JJ B-adj.all	metabolite NN B-noun.attribute	of IN 0	leflunomide NN B-noun.artifact	) ) 0	concentration NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d143.s54	Dextromethorphan NNP B-noun.person	is VBZ B-verb.stative	a DT 0	substrate NN B-noun.person	for IN 0	both DT 0	CYP2D6 NNP B-noun.group	and CC I-noun.group	CYP3A4 NNP I-noun.group	. . 0	. . 0
DDI-DrugBank.d236.s0	Acidifying_agents NNS B-noun.artifact	, , 0	Gastrointestinal_acidifying_agents NNS B-noun.person	( ( 0	guanethidine NN 0	, , 0	reserpine NN B-noun.person	, , 0	glutamic_acid_HCl NNP B-noun.person	, , 0	ascorbic_acid JJ 0	, , 0	fruit NN B-noun.artifact	juices NNS I-noun.artifact	, , 0	etc FW 0	. . 0	) ) 0	lower JJR B-adj.all	absorption NN B-noun.communication	of IN 0	amphetamines NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d132.s28	Naproxen NNP B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	diflunisal NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d121.s1	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	doubled VBD B-verb.contact	the DT 0	AUC NNP B-noun.group	for IN 0	cefprozil NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d549.s1	However RB 0	, , 0	iloprost RB 0	has VBZ B-verb.possession	the DT 0	potential NN B-noun.person	to TO 0	increase VB B-verb.change	the DT 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	vasodilators NNS B-noun.person	and CC 0	antihypertensive_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d45.s4	In IN 0	rheumatoid JJ B-adj.all	arthritis NN B-noun.state	, , 0	concomitant JJ B-adj.all	medications NNS B-noun.communication	besides IN 0	MTX NNP B-noun.group	were VBD B-verb.stative	nonsteroidal_anti JJ B-adj.all	- : 0	inflammatory_agents NNS B-noun.person	, , 0	folic_acid JJ 0	, , 0	corticosteroids NNS B-noun.person	and/or CC 0	narcotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s6	Diflunisal NNP B-noun.person	decreased VBD B-verb.communication	the DT 0	hyperuricemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	hydrochlorothiazide NN 0	. . 0	. . 0
DDI-DrugBank.d308.s1	Therefore RB 0	when WRB 0	central_nervous_system_depressants NNS B-noun.location	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	hydroxyzine PDT 0	their PRP$ 0	dosage NN B-noun.communication	should MD 0	be VB 0	reduced VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d395.s7	Digoxin NNP B-noun.person	, , 0	Enoxacin NNP B-noun.person	may MD 0	raise VB B-verb.emotion	serum NN I-verb.emotion	digoxin NN B-noun.state	levels NNS B-noun.state	in IN 0	some DT 0	individuals NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d97.s8	Among IN 0	the DT 0	risk NN B-noun.plant	factors NNS B-noun.person	studied VBD B-verb.cognition	, , 0	two CD 0	appear VBP 0	to TO 0	increase VB B-verb.change	the DT 0	risk NN 0	of IN 0	ARE NNP 0	, , 0	the DT 0	prescription NN B-noun.person	of IN 0	thiabendazole NN 0	to TO 0	treat VB B-verb.body	strongyloidiasis NN I-verb.body	during IN 0	the DT 0	melarsoprol NN B-noun.act	cure NN B-noun.act	and CC 0	the DT 0	bad JJ B-adj.all	general JJ B-noun.state	clinical JJ I-noun.state	conditions NNS B-noun.cognition	of IN 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d43.s3	The DT 0	effects NNS B-noun.phenomenon	of IN 0	allopurinol NN B-noun.animal	on IN 0	didanosine NN B-noun.person	pharmacokinetics NNS B-noun.person	in IN 0	subjects NNS B-noun.person	with IN 0	normal JJ B-adj.all	renal JJ B-adj.all	function NN B-noun.act	are VBP B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d469.s3	certain JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	especially RB B-adv.all	the DT 0	aminoglycosides NNS B-noun.artifact	and CC 0	polymyxins NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d222.s2	Since IN 0	barbiturates NNS B-noun.person	are VBP 0	potentiated VBN B-verb.communication	by IN 0	the DT 0	anticholinesterases NNS B-noun.attribute	, , 0	they PRP 0	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	convulsions NNS B-noun.food	. . 0	. . 0
DDI-MedLine.d21.s12	In IN 0	the DT 0	second JJ B-adj.all	experiment NN B-noun.communication	, , 0	non RB 0	- : 0	diabetic NN B-noun.person	and CC 0	streptozotocin NN B-noun.person	- : 0	induced VBN B-verb.creation	diabetic JJ B-adj.all	rats NNS B-noun.person	were VBD 0	fasted VBN B-verb.creation	, , 0	and CC 0	the DT 0	same JJ B-adj.all	procedures NNS B-noun.person	were VBD 0	followed VBN B-verb.stative	for IN 0	estimation NN B-noun.act	of IN 0	glucose JJ B-adj.all	tolerance NN B-noun.communication	30 CD B-adj.all	min NN B-noun.communication	after IN 0	glucose DT 0	overload NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d327.s0	There EX 0	have VBP 0	been VBN 0	isolated VBN B-verb.change	reports NNS B-noun.artifact	of IN 0	patients NNS B-noun.person	experiencing VBG B-verb.communication	increases NNS B-noun.event	in IN 0	their PRP$ 0	prothrombin NN B-noun.possession	times NNS B-noun.event	when WRB 0	etidronate NN B-noun.person	was VBD 0	added VBN B-verb.change	to TO 0	warfarin VB B-verb.consumption	therapy NN I-verb.consumption	. . 0	. . 0
DDI-DrugBank.d68.s3	Coadministration NN B-noun.person	of IN 0	digoxin NN B-noun.person	did VBD 0	not RB B-adv.all	have VB 0	effects NNS B-noun.phenomenon	on IN 0	either CC 0	the DT 0	safety NN B-noun.artifact	or CC 0	efficacy NN B-noun.phenomenon	of IN 0	ibutilide NN B-noun.food	in IN 0	the DT 0	clinical JJ B-adj.all	trials NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d165.s28	Tinnitus NNP B-noun.person	and CC 0	decreased VBD B-verb.change	hearing NN I-verb.change	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	patients NNS B-noun.person	concomitantly RB B-adv.all	receiving VBG B-verb.communication	Itraconazole NNP B-noun.person	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-MedLine.d74.s6	Arginine NN B-noun.person	, , 0	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	glucose NN B-noun.attribute	or CC 0	theophylline NN 0	, , 0	caused VBD B-verb.creation	excessive JJ B-adj.all	glucagon NN B-noun.artifact	release NN I-noun.artifact	in IN 0	the DT 0	diabetics NNS B-noun.person	and CC 0	undetectable JJ B-adj.all	insulin NN B-noun.substance	release NN B-noun.state	in IN 0	either DT 0	diabetics NNS B-noun.person	or CC 0	normals NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d561.s10	Other JJ 0	No DT 0	clinically RB B-adv.all	important JJ B-adj.all	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	occurred VBD B-verb.cognition	when WRB 0	Lotensin NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	hydrochlorothiazide NN 0	, , 0	chlorthalidone NN 0	, , 0	furosemide RB 0	, , 0	digoxin NN B-noun.person	, , 0	propranolol NN B-noun.person	, , 0	atenolol NN B-noun.person	, , 0	naproxen NN B-noun.person	, , 0	or CC 0	cimetidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d30.s3	Ketoconazole NNP B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	conversion NN B-noun.cognition	of IN 0	losartan NN B-noun.animal	to TO 0	the DT 0	active JJ B-adj.all	metabolite NN B-noun.food	after IN 0	intravenous JJ B-adj.all	administration NN B-noun.time	of IN 0	losartan NN B-noun.food	, , 0	and CC 0	erythromycin NN B-noun.person	had VBD 0	no DT 0	clinically RB B-adv.all	significant JJ B-adj.all	effect NN B-noun.cognition	after IN 0	oral JJ B-adj.all	administration NN B-noun.time	. . 0	. . 0
DDI-MedLine.d133.s2	METHODS NNS B-noun.attribute	, , 0	From IN 0	the DT 0	beginning NN B-noun.cognition	of IN 0	the DT 0	experiment NN B-noun.person	, , 0	rats NNS B-noun.person	were VBD 0	given VBN B-verb.possession	10 CD B-adj.all	weekly RB B-adv.all	subcutaneous JJ B-adj.all	injections NNS B-noun.event	of IN 0	AOM NNP 0	( ( 0	7.4 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.attribute	) ) 0	and CC 0	subcutaneous JJ B-adj.all	injections NNS B-noun.event	of IN 0	bombesin NN B-noun.substance	( ( 0	40 CD B-adj.all	microg NN B-noun.quantity	/ ( 0	kg IN 0	body NN 0	weight NN B-noun.attribute	) ) 0	every DT 0	other JJ 0	day NN 0	, , 0	and CC 0	from IN 0	week NN B-noun.time	16 CD 0	, , 0	intraperitoneal JJ B-adj.all	injections NNS B-noun.act	of IN 0	verapamil NN B-noun.animal	( ( 0	10 CD B-adj.all	or CC 0	20 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.attribute	) ) 0	every DT 0	other JJ 0	day NN 0	until IN 0	the DT 0	end NN 0	fo IN 0	the DT 0	experiment NN B-noun.person	in IN 0	week NN B-noun.time	45 CD 0	. . 0	. . 0
